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Foreword
In the constant struggle for natural resources, all life has to defend itself against other life that 
threatens to encroach on its domain – or perish. Microbial parasites (viruses, bacteria, fungi,
protozoa, worms) were among the earliest life forms on our planet and will continue to 
endanger the health and survival of their involuntary hosts. One such type of parasite, 
Mycoplasma, a class of bacteria that are able to enter and survive in association with 
eukaryotic cells, has literally infiltrated this work and became – true to their nature – an 
unintended topic hosted in this thesis. 
All living organisms, by virtue of the successful survival of their ancestors, have in 
some way adapted to the evolutionary pressures of disease-causing agents. Every kind of 
multicellular organism, in which different cell types cooperate to fulfill specialized functions, 
has some type of immunity, i.e. the capacity to stay free from biological invasion and
infection. Vertebrates, including the humankind, evolved to develop sophisticated defense 
systems composed of distinct molecules and highly specialized cell types which together 
recognize dangerous biological structures and initiate counter-measures to rid their bodies of 
such undesired presence.
In order to effectively fight off disease-causing microorganisms (‘pathogens’), the cells 
of the immune system (for short, ‘immune cells’) must be able to distinguish, in anthropologic 
terms, ‘harmful’ from ‘harmless’ so as not to attack the body’s own parts. In other words,
immune cells tolerate ‘self’ while retaining the ability to detect and destroy ‘foreign’ or 
‘non-self’. It is therefore practical to begin with a description of the defense system that 
makes the important distinction between ‘self’ and ‘non-self’ in Homo sapiens, which may be 
viewed as exemplary for other mammals. The human immune system will be explained in 
more detail in the introduction of this thesis.
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When the immune system fails to make these essential distinctions, diseases occur. 
‘Non-foreign’ but dangerous cells are not controlled and as a result cancer will develop. 
Normal ‘self’ cells are mistakenly attacked and autoimmune disease may manifest. Both 
conditions can be life-threatening and both can, in many cases, be treated by replacing the 
defective cells with those from a healthy person and establishing a new, functional immune 
system. The procedure by which this is made possible, allogeneic stem cell transplantation, is
the superordinate topic of this thesis. 
The issue of compatibility between ‘self’ and ‘non-self’ is of importance in the 
transplantation of cells, tissues or whole organs from a donor to a sick person; the patient’s 
immune cells will recognize incompatible cells as foreign and reject them. Conversely, when 
immune cells enter a defense-less body (due to disease or artificially rendered ‘immune 
compromised’) via a transplanted graft, their natural function in the foreign environment of 
the host organism is to inactivate and destroy unknown ‘non-self’ cells. In this way, 
transferred donor immune cells which attack the recipient of the graft give rise to the so-called 
graft-versus-host disease, a man-made immune disorder necessitated by stem cell 
transplantation as the only available treatment option for many patients suffering from severe 
malignancies, but frequently fatal in itself. 
My intention with the writing of this thesis was, apart from the obvious objective to 
satisfy the demands for the doctoral dissertation set by the faculty, to give a summary of the 
basic underlying principles of bone marrow transplantation, graft-versus-host disease and 
mesenchymal stromal cell therapy as the main subjects of my doctoral research, and to 
provide a comprehensive starting point for new PhD candidates who are about to embark on 
this exciting field of science. 


1 
Introduction
Chapter I. Generation of blood and immune cells in the human body
Before laying out the main principles of immunity and going into the basic mechanisms of 
immune recognition in health and disease, it is instructive to illustrate how immune cells are 
generated in the human body and to describe briefly what their principal functions are. 
The immune system is an integral component of the hematopoietic system. Hemato-
poiesis, the generation of red blood cells, platelets and leukocytes, is initiated in prenatal life 
in blood islands of the yolk sack, and later in the fetal anlage of the liver, spleen and lymph 
nodes. After birth, hematopoiesis occurs mainly in the bone marrow (BM). It has been known 
since the 1950s that mammalian blood cells derive from the spleen and marrow, but it was a 
major scientific breakthrough when Till, McCulloch and colleagues were able to demonstrate
some 50 years ago that a single clonal BM cell (then termed the ‘colony-forming unit spleen’, 
CFU-S) could give rise to all cells of the murine blood system [reviewed by Weissman and 
Shizuru 2008]. Abramson et al. later formally confirmed the proposed existence of the so-
called ‘hemacytoblast’ [Abramson 1977], which was renamed to ‘hematopoietic stem cell’ 
(HSC), as the founder cell of all blood cells (Figure 1). The biological process by which 
daughter cells with different properties are produced through self-replication of stem cells has 
been termed ‘asymmetric cell division’. It is believed that one daughter cell becomes an 
identical copy of the original cell during cell division and thereby, serves to replenish the cell 
pool (‘self-renewal’). Conversely, the other daughter cell will undergo biological changes 
during further cell divisions in a process termed ‘differentiation’ and become the progenitor 
for a family of cell offspring, eventually giving rise to all mature (terminally differentiated) 
cells of the blood system. 
Stroma consists of various cell types, including vascular endothelial cells, reticular cells 
and mesenchymal stromal cells (MSC), which create the physical niches for stem and 
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progenitor cells. HSC quiescence, self-renewal and differentiation is controlled and main-
tained through the expression of intercellular messenger molecules (cytokines), cell-adhesion 
molecules and hematopoietic growth factors by stromal resident cells [Ehninger and Trumpp 
2011]. In response to such signals, HSC reside in, migrate from and return to their hemato-
poietic niches in the BM [Bhattacharya 2006] and are thus able to repopulate the blood system 
in the same organism or a different one (‘functional reconstitution’). Migratory primitive 
blood progenitor cells are normally found at very low numbers in the circulation. 
I.1 Mature blood cells derive from a common progenitor in the bone marrow
The multipotent HSC gives rise to early hematopoietic progenitor cells. Hematopoiesis 
is separated into two main lineages of blood cells, i.e. the lymphoid and the myeloid lineage. 
Accordingly, two progenitor cell types represent the origins of these branches, the common 
lymphoid and the common myeloid progenitor cell, respectively (cf. Figure 1).
 
 
Figure 1 | Hematopoiesis  
A schematic drawing of the classical model of hematopoiesis, the generation of the blood system, 
in the human body. All mature blood cells derive from a multipotent progenitor cell, the HSC.  
Published under the Creative Commons license by Häggström (2009) on public domain http://cs.wikipedia.org/  
 
3 
Myeloid cells and their progeny (erythrocytes, granulocytes, megakaryocytes, mono-
cytes, and macrophages) are produced in the BM and in the peripheral blood (PB) [Janeway 
2005]. The myeloid stem branches off into the granulocyte and monocyte lineages. Granulo-
cytes are polymorphonuclear cells commonly divided into basophils, eosinophils, and neutro-
phils. These are known to kill bacteria and worm parasites either by direct cell lysis through 
antimicrobial compounds called granules, which are stored in subcellular compartments and 
can be secreted upon activation, or by engulfing and ingesting the target cells altogether
(phagocytosis). 
Macrophages and myeloid dendritic cells are the descendants of blood-borne, circula-
ting monocytes. Macrophages are present in peripheral tissues where they take up invading 
microorganisms and small particles in vesicles (endocytosis) and alert other parts of the 
immune system, leading to an influx of neutrophils and other effector cells. Tissue-resident 
dendritic cells have the ability to leave the site of infection and transport the internalized 
pathogen to nearby lymphoid tissues where they activate other immune cells to become 
involved in the ongoing immune response. Dendritic cells have a marked morphology which 
is believed to maximize the cell surface area where antigens are presented to other immune 
cells (cf. Chapter II) [Janeway 2005].
Together, these components have critical roles in direct defense mechanisms of the 
immune system. In addition to their functions in generating and supporting inflammatory 
processes, they have the ability to initiate ‘adaptive’ immune responses (cf. Chapter II) against 
persistent infections [Parham 2005].
Lymphocytes are the cells of the lymphoid lineage of white blood cells. Lymphocytes 
comprise T cells, B cells and natural killer (NK) cells, which have critical functions in the 
body’s recognition of and defense against infections and disease.
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NK cells play a central role in the primary immune surveillance against virus-infected 
and other aberrant or neoplastic (tumor) cells. Like other components of the ‘innate’ immune 
system (cf. Chapter II), NK cells broadly recognize typical, conserved structural components 
of pathogens and react immediately by contact-dependent lysis of the target cell (e.g. through
degranulation, i.e. the secretion of cell wall-perforating proteins such as perforin). They are 
generally assumed to be non-specific and short-lived, but recently, characteristics of these 
cells have been discovered [Sun 2009; Paust 2010] that can be interpreted as the ability to 
adapt to previous encounters of the infection (‘immunological memory’): This quality was 
hitherto considered as an exclusive feature of ‘adaptive’ immune cells (explained in more 
detail in Chapter II).
T and B cells of the lymphoid lineage form the main constituents of the so-called 
adaptive immune system. They can be long-lived and respond relatively slowly to primary 
infections, using highly specific immune recognition mechanisms. T cells have primarily cell-
killing or cell-activating functions. B cells are lymphocytes which are specialized to produce, 
assisted by T cells, large amounts of soluble defense molecules (immunoglobulins, Ig) against 
infections. T cells and B cells arise and mature in the primary (central) lymphoid tissues, i.e.
the thymus and the BM, respectively, hence their names. After completed maturation, these 
cells circulate in the bloodstream and the lymphatic system. They pass through and accumu-
late in high numbers in the secondary (peripheral) lymphoid tissues (SLT) where they may 
become activated by antigen-presenting cells (APC) (cf. Chapter II).
Dendritic cells have their origins both in the lymphoid and the myeloid lineage and are 
separated into different subtypes (e.g. plasmacytoid and myeloid dendritic cells) [Ziegler-
Heitbrock 2010].
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I.2 The plasticity of blood cell differentiation and development makes a
modification of the classical model of hematopoiesis necessary
The presented dichotomic scheme of hematopoiesis can assist our understanding of the 
process by illustrating sequential developmental events which lead to the formation of 
terminally differentiated, fully mature and functional blood cells. However, the model of 
myeloid versus lymphoid lineage commitment is overly simplistic as it suggests that blood 
cells develop in a strictly linear fashion. The model does not account for the diversity of 
seemingly ‘committed’ cell types to transgress into other distinct lineages under different 
physiological conditions [Buza-Vidas 2007; Doulatov 2010; Kawamoto 2010]. For example, 
T cell progenitors, although categorized as lymphoid cells, retain considerable myeloid 
potential [Wada 2008; Bell and Bhandoola 2008]; likewise, NK cells as well as macrophages 
and dendritic cells may derive either from the myeloid or the lymphoid branch [Doulatov 
2010; Grzywacz 2011]. These studies demonstrated the capacity of ‘trans-differentiation’ at 
certain developmental stages and challenge the current concept of rigid unidirectionality in 
hematopoiesis. Thus, the complexity and plasticity of hematopoietic cell development is 
likely underappreciated for the time being.
Chapter II. The two arms of the immune system
II.1 Innate immune cells use germline encoded receptors for recognition
of common pathogenic structures, adaptive immune cells express 
recombined receptors which are highly specific for their antigens
The term ‘innate’ summarizes the inherent nature of immune cell types and humoral 
components (e.g. complement molecules that tag and lyse pathogens by attachment to their 
plasma membrane in a process termed ‘opsonization’) of this category to detect and react to 
common pathogenic features promptly and broadly, and without further adaptation to the 
particular infection at hand. Their mode of action is unchanged in recurring immune 
responses. Innate immune cells are activated upon binding of exogenous biological structures 
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such as bacterial flagellin, lipopolysaccharide (LPS), DNA or RNA to germline encoded 
receptors termed Toll-like receptors (TLR) [Medzhitov 2001].
Adaptive immunity, on the other hand, has the capacity to form its immune response 
specifically to the respective pathogen, and gets help from the innate immune system to fight 
an infection. When becoming activated and engaged in an immune response, only a small 
number of T and B cells have the appropriate specificity to participate in fighting the parti-
cular infectious agent. These cells will expand and adapt their response in its course. The 
processes of activation, expansion and adaptation of the responsive T and B cell clones 
require longer time (several days) than the immediately ensuing innate immune responses 
(several minutes to hours) [Janeway 2005]. By adaptation to a specific infectious agent,
adaptive immune cells are able to achieve long-lasting protection against renewed challenges 
of the same pathogen. This capacity to ‘remember’ is facilitated by a small pool of modified, 
long-lived cells which persist in the individual after an infection has been successfully 
eliminated and are capable of improved clearance of secondary infections, i.e. they exhibit 
immunological memory. Conversely, the adaptive immune system remains ‘naïve’ to 
pathogens it has never previously encountered.
II.2 T cells and B cells rearrange genes to generate highly specific receptors 
for foreign antigen detection
Mature T and B cells express specialized receptors on their cell surface. B cells express
a membrane-bound Ig molecule (also called the B cell receptor, BCR) consisting of two heavy 
and two light chains. T cells display the T cell receptor (TCR) comprised of 	
protein chain on their cell surface together with several signaling molecules in the TCR:CD3
complex. B cells, when activated, differentiate to become so-called plasma cells which secrete 
high copy numbers of their surface Ig as soluble molecules (antibodies). Individual T cells 
and B cells, respectively, express TCR and BCR of a certain type which have unique binding 
specificity for a particular biological structure (the antigen). The form of the receptor is 
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determined during T cell and B cell development in a random process of rearrangement of 
genes which make up the receptor subcomponents (‘somatic rearrangement’). Junctional 
diversity during rearrangement of gene segments and somatic hypermutation can further 
extend the diversity of the array of BCR specificities and enhance their fine-tuning to a 
particular antigen [Janeway 2005].
The binding site of one particular receptor type forms an inverted negative pattern 
which closely matches the shape of its cognate antigen and thereby, defines the receptor 
specificity. Together, the sum of structurally related but highly specific receptor molecules 
can bind to a virtually infinite range of possible, and potentially harmful, biological structures. 
This creates the diversity of cell clones with distinct ligand-binding affinities within the 
adaptive immune system.
Adaptive immunity is not restricted to pathogen defense, however, but can detect any 
foreign entity in the body, at least in theory. This concept is illustrated by allergies, mani-
festations of immunological hyperreactivity to substances that are hardly dangerous per se,
but cause complications for the affected person [Janeway 2005].
How does the adaptive immune system, which lacks innate receptors designed for the 
recognition of common pathogen-associated molecular patterns, make the distinction between 
harmless and potentially hazardous agents and decide whether they should be ignored or 
eliminated? How does the healthy body with its competent immune system avoid attacking its 
own cells? Why does it not tolerate other human cells or tissues as is often witnessed after the 
transplantation of organs? The presentation of a group of highly variable proteins which 
indicate the identity of a cell and convey the presence of infections to the immune defense 
system addresses these questions in the following chapter. 
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II.3 The major histocompatibility complex determines the ‘immunological 
identity’ of an individual
Every cell of the human body (and likewise of any other vertebrate organism) carries a 
set of signature molecules that identifies it as normal, i.e. it is marked as ‘self’. These cell 
surface proteins are encoded within a special gene region, the major histocompatibility 
complex (MHC). Tissues with a certain MHC expression pattern are not compatible (because 
they are ‘non-self’) with another individual of a different MHC makeup. Thus, the MHC 
determines the ‘biological identity’ of a given individual, which is of importance not least in 
clinical transplantation. 
The MHC forms a large genomic segment of contiguous genes which are coinherited as 
haplotypes (genes located next to each other on the same chromosome). Some MHC genes 
have the largest number of alleles (i.e. different versions of a gene present in the genetic pool 
of the population) that are known [Kelley 2005b]. This high degree of genetic polymorphism 
(cf. subchapter III.6, p.26ff.) renders a set of MHC proteins expressed in a given individual 
highly distinct within the population. Exceptions to this are pairs of identical twins who share 
the same genes, including the MHC, between them, and syngeneic individuals of inbred 
Figure 2 | Comparison of the major histocompatibility complexes on human chromosome 6 
(HLA, bottom), mouse chromosome 17 (H-2, top) and rat chromosome 12 (RT1, center), p.8-9  
The subregions of the MHC are decoded by color (red, class I; velvet, extended class I; blue, class 
II; yellow, extended class II; green, class III, contains e.g. complement, HSP70 and TNF genes). 
Individual genes are schematically shown as boxes in telomer-centromer orientation (from left to 
right, not drawn to scale). Rat and mouse carry the classical class I genes RT1-A and H-2K, re-
spectively, at the centromeric end of their MHC, in contrast to the telomeric position of HLA-A, -B 
and -C in human.  
Adapted with permission from Springer: Kelley, Walter & Trowsdale (2005), Immunogenetics 56 
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animal strains such as the laboratory rats used in experiments in this work. The human, rat 
(Rattus norvegicus) and mouse (Mus musculus) MHC gene regions are schematically depicted 
in Figure 2.
In humans, MHC genes have been termed human leukocyte antigens (HLA). The rat 
and mouse MHC regions are denoted RT1 and H-2, respectively [Kelley 2005b]. The HLA, 
RT1 and H-2 complexes share some overall similarities (cf. Figure 2). Three major gene 
clusters divide the MHC into class I (MHC-I), class II (MHC-II) and class III (MHC-III)
regions, where the MHC-I and -II molecules are directly involved in antigen presentation.
MHC-III genes often have functions related to the immune response. In humans, HLA-A, -B
and -C are the MHC-I molecules and HLA-DR, -DQ, and -DP the MHC-II molecules which 
are constitutively expressed by APC. The rat has its MHC-I region physically divided into
‘classical’ (RT1-A, located at the centromere end of the complex) and ‘non-classical’ (RT1-
CE/M/N, at the telomere end) genes. The class II genes are denoted RT1-B/D in the rat 
genome.
On the protein level, MHC molecules are plasma membrane-anchored glycoproteins 
that consist of two associated polypeptides. MHC-I molecules are made up of one large 
protein (the heavy chain) composed of three Ig-
    	-microglobulin 
(encoded by a single gene outside the MHC). MHC-II molecules are composed of two gene 
  -  	-chain, that combine to form a heterodimeric protein on the cell 
membrane [Janeway 2005].
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II.4 MHC molecules signal infections to the immune system
The essential immunological function of HLA proteins is to bind short peptides and 
present them on the cell surface. Peptides can be the degradation products of endogenous 
cellular proteins or external pathogenic elements, e.g. from viral or bacterial infections. A cell 
can thereby display a representative sample of its internal content on a selection of MHC-I
molecules distributed on its surface. MHC-II molecules are distinct in that they are loaded 
with and present peptides derived from the extracellular space and are expressed only on 
certain cell types (see below).
Viral and some bacterial infections have an intracellular life cycle and often target 
certain cell types. MHC-I loading with cytosolic peptides takes place in the endoplasmatic 
reticulum of the cell. After peptide loading, the MHC-I protein is transferred to the outer cell 
membrane where it can serve as a ligand for T cells expressing the corresponding TCR for the
specific MHC-I:peptide complex. In this way, viral and bacterial peptides, just as other 
intracellular breakdown products, are exposed to detection by the immune system on the 
infected cell. Virtually all nucleated cells of the body, with the exception of red blood cells, 
express MHC-I molecules on their cell surface [Janeway 2005].
Elimination of exogenous bacteria and other parasites involves various immune defense 
mechanisms. The innate immune system has the ability to detect and neutralize pathogens in 
the extracellular space. Whole pathogens, their cell fragments or soluble products (e.g. bac-
terial toxins) are taken up by phagocytosis directly or, opsonized with complement or anti-
body, through specific surface receptors on phagocytes. The pathogens and their products are 
then internally degraded within the endosomal compartments of the phagocytic cell. Endo-
somes fuse with intracellular compartments where available membrane-bound MHC-II
molecules can bind degraded pathogenic leftovers in the form of short peptides. The 
assembled MHC-II:peptide complex is transported to the cell surface where it may be
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recognized by T cells. APC have the ability to take up, process and load antigens from the 
extracellular space onto MHC-I molecules by an unknown mechanism, thus making these 
peptides available also in the MHC-I presentation pathway [Janeway 2005]. This prosess is 
termed ‘cross-presentation’.
B cells, dendritic cells, macrophages and microglia in the brain, which are all involved 
in immune responses against extracellular pathogens, constitutively express MHC-II on their 
cell surface. Thymic epithelial cells which are required for negative selection of autoreactive 
T cell clones may also express MHC-II [Janeway 2005].
Self-reactive T cells which can bind to peptides derived from normal endogenous 
protein (self-antigen) in the context of MHC molecules are normally not present in the 
peripheral T cell pool as these cells are removed early during T cell development in the 
thymus [Klein 2009]. Immature T cells which have a high binding affinity for self-antigen 
presented on thymic epithelial cells undergo controlled cell death by induced apoptosis. The
rigorous negative selection of autoreactive T cell clones is a critical safeguard to ensure 
immunological self-tolerance, and failure to dispose of these cells during maturation can
result in autoimmune disease [Anderson 2002].
T cells require a coreceptor for TCR binding of the MHC molecule. T cells which 
recognize foreign antigen presented in the context of MHC-I molecules are ‘cytotoxic’ T (TC)
cells; they express the CD8 coreceptor [Norment 1988]. T cells which engage the CD4 
coreceptor for MHC-II:peptide complex binding [Doyle and Strominger 1987] are called 
‘helper’ T (TH) cells.
To activate a naïve T cell, an additional costimulatory signal is required and provided 
by a separate receptor-ligand interaction, e.g. the CD28 receptor on T cells and its ligands 
CD80 and CD86; or CD40 ligand and CD40 on APC. In the absence of a costimulatory 
signal, non-responsiveness (anergy) may be induced in the responding T cell. 
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Activation of CD4-expressing (CD4+) T cells by APC mostly takes place in SLT, 
typically the draining lymph node nearest to the site of infection. CD4+ TH cells respond to 
activation with proliferation, expansion and differentiation to effector T (TE) cells, which 
typically secrete proinflammatory cytokines, such as interferon  and tumor necrosis 
 and chemotactic cytokines (chemokines) to attract other leukocytes. Activated 
helper cells may further mediate the recruitment of innate immune cells such as neutrophils 
and macrophages; the activation of APC effecting upregulation of MHC expression and 
thereby increased presentation of antigen; and the proliferation and differentiation of B cells 
into antibody-producing plasma cells. In this way, TH cells help counteract persisting infec-
tions which are not effectively cleared by the innate immune system.
CD4+ T cells also play a role in the activation of CD8+ T cells. As mentioned above, 
APC can present extracellular antigens in the context of MHC-I which are recognized by TC
cells. A CD4+ TH cell which contacts the same APC via TCR:MHC-II interaction can help to 
activate the CD8+ TC cell. TC cells expressing the apposite TCR for the specific peptide 
antigen on display can thereby become involved in the ongoing immune response. 
TC cells may become activated directly by MHC-I presentation of viral antigen on den-
dritic cells, leading to lysis of infected target cells. TCR and coreceptor engagement on the 
TC cell results in an intracellular signaling cascade that activates degranulation or alternative 
killing pathways (e.g. through CD95/CD95 ligand binding). A well-appreciated strategy used 
by intracellular pathogens to evade TC cell responses is to effect downregulation of MHC-I
surface expression.
II.5 Various subtypes of leukocytes are defined by their cell phenotype and
‘innate’ or ‘adaptive’ functionality 
We have seen that T cells can be divided into functionally different subtypes by use of 
phenotypic markers (mostly surface proteins expressed on certain types of cells), e.g. mature 
T cells which express either CD4 or CD8 molecules together with the rearranged TCR on the 
13 
cell surface. These two T cell subsets are characterized by their typical patterns of cytokine
production, cytotoxic activity and stimulation of other cells. Other cell types besides the 
already mentioned CD4 TH cells and CD8 TC cells cells have been defined according to their 
distinct features and phenotypes. Some of these cell types will become important in later 
chapters of the thesis and are therefore briefly introduced. 
The expression of surface proteins on naïve CD4 and CD8 T cells is altered upon
antigen binding; activated T cells upregulate CD44 and downregulate CD62L on the cell 
surface. A fraction of the cells which are selected and proliferate during an immune response
do not undergo apoptosis after its completion and persist in the circulation as ‘memory’ 
T cells. T cells with antigen-recall properties are the ‘central memory’ T cells (typically 
expressing CD44+CCR7+CD62hi) located in SLT and ‘effector memory’ T cells (CD44+
CCR7CD62lo) present in the periphery.
TH cells are traditionally divided into two main subtypes, TH1 and TH2 cells, which 
differ in their cytokine requirements and secretion patterns, as well as the type of adaptive
immune response they promote [Krenger and Ferrara 1996]. More recently, a new subtype of 
TH cell (which can be either CD4+ or CD8+), referred to as the TH17 cell, has been defined by 
its characteristic secretion of interleukin (IL)17, IL21 and IL22 when stimulated with trans-
forming growth factor (TGF)	 and IL6. This cell type is thought to have important roles in 
immune regulation and pathological conditions, including infectious and autoimmune 
diseases [Weaver 2007].
‘Regulatory’ T (TR) cells have the capacity to suppress immune cell activation. Thymic-
derived TR cells, which express CD4 and CD25 surface markers and the transcription factor 
FoxP3, are thought to have ‘natural’ suppressive capacity [Hori 2003] without the 
requirement for priming of this property. Notably, peripheral CD4+ T cells can be induced to 
! !"# $ %	  &' stimulation and assume regulatory functions (‘inducible’ 
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TR cells) [Chen 2003]. TR cells can inhibit TE cells and APC through cell contact or secretion 
of antiinflammatory cytokines, e.g. IL10. The lack of TR cells can cause autoimmune disease 
[Sakaguchi 1995; reviewed by Sakaguchi 2008; Buckner 2010]. Recent studies have shown 
that TR cells may differentiate into IL17-producing CD4+ T cells in vivo [Yang 2008; Koenen 
2008], shifting the balance further towards autoreactivity. Novel functional subtypes of 
regulatory cells within the T cell population have been described recently [Buckner 2010].
NKT cells display a T lymphocyte-like phenotype with surface expression of CD3 and 
TCR together with NK cell receptors. Some NKT cells display semi-invariant TCR molecules
with a limited repertoire that binds the non-classical MHC-I ligand CD1 [Berzins 2011]. NKT 
cells are considered as innate immune cells which mediate crucial immunomodulatory 
properties in different disease settings [Berzins 2011].
NK cells have been associated with the innate immune defense (see the following 
subchapter). However, according to recent reports, NK cells display certain properties of 
plasticity and flexibiliy, such as education for self-tolerance, adaptation to the cell-molecular 
environment and immunological memory [Vivier 2011].
The rigid distinction between adaptive and innate immune responses is becoming more 
difficult to uphold as both arms of the immune system are found to be closely regulated and 
interdependent; phenotypically defined cell types may combine dichotomic functions that 
were historically strictly classified as either innate or adaptive characteristics.
II.6 Natural killer cells are large granular lymphocytes that can reject infected, 
transformed and transplanted allogeneic hematopoietic cells
NK cells are large granular lymphocytes that make use of a range of receptor types to 
distinguish normal from aberrant cells. Unlike the TCR and BCR, NK cell receptors (NKR) 
do not undergo somatic rearrangement, but are encoded in the germline. The natural killer 
gene complex (NKC; Figure 3) and leukocyte receptor complex (LRC) gene regions encode 
several families of NKR. Most defined NKR have specificities for MHC class I molecules,
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such as human classical HLA-A, -B, -C, and non-classical HLA-E, -G, or the non-classical 
class I molecules RT1-C/E in the rat. Some receptors can bind to other MHC-related ligands,
such as MIC-A and -B. NK cells can thereby monitor target cells for the presence of surface 
MHC-I and stress-induced ligands.
Among the receptors utilized by human NK cells are the killer cell Ig-like receptors 
(KIR) located in the LRC [Yokoyama and Riley 2008]. Rodents have evolved a number of 
C-type lectin-like genes within the NKC, the Ly49 family, which fulfill similar functions 
[Yokoyama and Plougastel 2003]. Both gene families comprise receptors with inhibitory and 
activating functions that regulate NK activity. 
Inhibitory receptors contact MHC-I alleles expressed on normal cells and thereby arrest 
NK cell effector functions (i.e. release of cytotoxic perforin/granzyme and cytokines). Target 
cells which do not express MHC-I ligands have a ‘missing self’ phenotype and are therefore 
susceptible to NK cell-mediated lysis due to the failure to inhibit NK cell activation [Kärre 
1986]. In this way, downregulation of MHC-I expression as an immune evasion strategy 
against recognition by TC cells is counteracted by NK cell surveillance.
Activating NKR may recognize stress-induced ligands such as MIC-A and MIC-B
through the NKG2D receptor [Bauer 1999], or MHC-like viral decoy molecules such as m157 
Figure 3 | Comparison of the natural killer complexes on human chromosome 12 (bottom), 
mouse chromosome 6 (top) and rat chromosome 4 (center)  
Colors decode the different lectin gene families on the NKC (gray indicates genes that are not 
considered NK receptors, white are pseudogenes). Individual genes are schematically shown as 
boxes (circles indicate the centromere/ telomere ends, left to right, not drawn to scale). There are 
several Ly49 genes (red) in the rodent NKC. Their number is dependent on the haplotype and 
varies between different strains. There is one human Ly49 gene (pseudogene). Similar to human, 
only one Ly49 gene has been found in baboon, orang-utan, dog, cat, cow and pig (not shown). 
Adapted with permission from Elsevier: Kelley, Walter & Trowsdale (2005), PLoS Genetics 1  
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encoded by murine cytomegalovirus which is recognized by Ly49H [Smith 2002]. Ligand 
binding of an activating receptor does not necessarily result in killing of the target cell as the 
stimulatory signal must compete with simulaneous inhibitory signals triggered on the same 
NK cell. How activating and inhibitory signals are integrated to balance NK activity is not 
fully understood. This model is further complicated by observations that several receptors can 
bind to more than one ligand (including allogeneic and xenogenic proteins) and that different 
NKR, both activating and inhibitory, may share the same ligand [Naper 2005; Kveberg 2011].
NK cells have the ability to reject transplanted hematopoietic cells depending on the 
MHC-constitution of the donor. Recipient NK cells tolerate injections of genetically identical 
hematopoietic cells, but destroy allogeneic donor cells which either express allogeneic MHC 
ligands that engage activating receptors or lack appropriate autologous MHC ligands to 
inhibitory receptors [Vaage 1994; Ruggeri 2006]. The role of NK cells in allogeneic hemato-
poietic cell transplantation (HCT), a potent therapeutic procedure for leukemias and other 
hematological diseases, is becoming more important as the toxicity of this treatment, 
including T cell alloreactivity, is increasingly well controlled [Velardi 2009].
Chapter III. Hematopoietic stem cell transplantation 
HCT is a clinical treatment modality for a variety of malignant diseases such as leukemias 
(myeloid and lymphoblastic leukemias in acute and chronic forms) and non-malignant 
diseases such as congenital or acquired hematopoietic disorders (aplastic anemia, myelodys-
plastic syndrome), immunodeficiency syndromes as well as autoimmune diseases [Storb 
2003]. The hematopoietic system of the patient can be replaced by grafted HSC from a
healthy allogeneic (i.e. genetically different) donor with the prospect of permanent cure of the 
underlying disease. 
HSC are obtained by aspiration of BM or alternatively, by apheresis of PB after the 
mobilization of HSC from the BM through administration of granulocyte colony-stimulating 
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factor (G-CSF). Umbilical cord blood (UCB) is an alternative source of HSC at childbirth and 
can be stored for the long term by cryopreservation. UCB units are becoming more commonly 
used for the treatment of both malignant and non-malignant diseases [Brunstein and Laughlin 
2010] due to a lower risk of adverse immune reactions compared with adult BM grafts 
[Malgieri 2010].
The MHC is the dominant genetic region that governs mutual tolerance between donor
and host. Matching of MHC-I and -II alleles increases the likelihood of successful engraft-
ment of HSC drastically (cf. subchapter III.5). However, even in the case of full compatibility 
of MHC alleles, other polymorphic genes may translate to alloantigens that can be recognized 
by T cells. These are collectively described as ‘minor histocompatibility (H) antigens’. Major 
and minor H antigens may likewise invoke host-versus-graft, graft-versus-host (GvH) and 
graft-versus-leukemia (GvL) effects and thus, determine the risk of rejection, recurrence of 
the original disease (relapse) and graft-versus-host disease (GvHD) (described in subchapter 
III.2).
Qualified donors are either family members (parents, siblings, identical twins) or 
unrelated volunteers who have variable degrees of MHC compatibility with the patient.
Children share one set of MHC genes with each of their parents by inheritance, they are 
‘haploidentical’. Among siblings, there is a statistical probability of 25 % that two have 
inherited the same maternal and paternal MHC haplotypes and are thus MHC-identical. 
The use of a related or matched unrelated donor (MUD) with a genetic composition that 
is (in part) different from the HCT recipient raises some important considerations: Firstly, the 
graft may not be accepted by the host. Secondly, donor-derived immune cells may be 
activated by immunologic disparities in the host. Thirdly, the host malignancy must be 
completely eradicated or at least permanently suppressed by the transplanted cells.
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III.1 Allogeneic HCT is an established therapy for diseases of the blood and 
immune system
In the past year, more than 25,000 allogeneic HCT were performed worldwide, and the 
total annual number of clinical procedures are predicted to rise in the future [Savani 2011].
This treatment modality is currently performed in patients with relatively severe and advanced 
diseases for whom few alternative therapeutic options are available.
Allogeneic HCT requires the conditioning of the patient prior to transplantation, either 
by ionizing radiation (radiotherapy) or pharmacological conditioning (chemotherapy), or both
in combination, to deplete hematopoietic host cells. This is important mainly for three 
reasons: Firstly, to eradicate the malignant cells. Secondly, to destroy competent host immune 
cells and thereby facilitate the entry of transplanted cells, i.e. to avoid host-versus-graft 
reactions and graft rejection. Thirdly, to make available HSC niches in the host BM allowing
sustained engraftment by donor progenitor cells. Thus, by successful establishment of donor 
hematopoiesis, the transplanted patient will develop a new, stable hematopoietic system and 
permanent immune protection. Whether the host’s hematopoietic system will be completely 
replaced by donor cells (full donor chimerism), or whether mutually tolerant host and donor 
blood cells will coexist over time (mixed chimerism), can vary between protocols and 
depends on the type and dose of pretransplant immunosuppression, the genetic constitution of 
both recipient and donor, the source and composition of the donor graft and unknown factors. 
At present, a major complication in allogeneic HCT is GvHD, an immunological 
condition which is caused by the uncontrolled reactivity of donor leukocytes against host 
tissues. Allogeneic donor T cells are transferred via the hematopoietic graft and become 
activated by histological disparities encountered in the foreign environment of the trans-
planted patient (cf. subchapter III.2). The host is immunocompromised due to pretransplant 
conditioning and thus unable to mount an effective immune response against the influx of 
competent donor T cells. In its severe form, GvHD is associated with a high prevalence of 
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transplant-related mortality (TRM) and morbidity, resulting in poor prospects of survival of 
the affected patients.
The main causes of TRM besides GvHD are graft rejection, infections and tumor 
relapse [Gibbons and Sykes 2008]. The breakdown of the immune defense in immuno-
compromised and immunodeficient patients against otherwise harmless opportunistic 
microorganisms or reactivation of latent viral infections is an impressive, if disastrous, 
demonstration of the efficient protection provided by a normally functioning immune system. 
HCT has made it possible to subject patients to high doses of ionizing radiation or 
chemotherapy to eliminate leukemic cells (myeloablative treatment) which would otherwise 
be lethal [Appelbaum 2001]. Sublethal (non-ablative) doses of conditioning represent a
feasible alternative to obtain engraftment while reducing TRM. With either alternative, the 
complete clearance of malignant cells can be achieved by the transfer of competent donor 
immune cells with graft-versus-tumor (GvT) reactivity, i.e. GvH reactivity directed against 
host tumor cells. Although a strong GvT response is required to avoid relapse by killing
residual tumor that has escaped the initial cytotoxic treatment, the presence of T cells with 
GvH-reactivity in the graft is potentially dangerous for the aforementioned reasons. 
The toxicities associated with allogeneic HCT may lead to life-threatening 
complications which can outbalance the potentially curative effects of engraftment, BM 
reconstitution and beneficial antitumor responses. The strong association of GvH and GvT
effects [Appelbaum 2001] mediated by transplanted donor T cells raises the questions
whether these two phenomena are separable, and whether GvHD can be avoided without 
compromising prolonged cure of the underlying disease.
III.2 Graft-versus-host disease is a transplant-related multiorgan system 
disorder with complex pathophysiology
The physiological events which manifest in the systemic immune syndrome recognized 
as acute GvHD are relatively well understood (the chronic form of this disease however 
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remains more elusive, cf. subchapter III.3). The principle pathology of GvHD can be divided 
into sequential stages of disease development (explained below and schematically described 
in Figure 4).
IMMUNE PRIMING. Patients undergo chemotherapy or radiotherapy, or both, before allogeneic 
HCT. The conditioning regimen causes acute and extensive tissue damage as well as the 
release of proinflammatory cytokines (e.g. IL1, IL6, T   other endogenous 
danger signals [Ferrara and Reddy 2006]. Infections and the underlying disease can also 
contribute to the ongoing inflammation in the patient. This initial ‘cytokine storm’ [Ferrara 
1993] leads to sensitization and activation of tissue-resident APC, resulting in the 
upregulation of surface MHC and costimulatory molecules as well as increased sequestration
of chemokines. LPS, a degradation product of the bacterial cell wall which acts as a potent 
stimulator of immune functions, may also be released from the gut as a result of intestinal 
damage.
T CELL ACTIVATION AND STIMULATION. Activated APC migrate to SLT, e.g. the spleen, 
lymph nodes or Peyer’s Patches, in the inflamed environment of the host. They effect the 
recruitment of immune cells, including transplanted donor T cells, from the blood stream to 
SLT. Those donor T cells which possess a TCR specific for a host-derived antigen presented 
on the APC are primed. The ability of APC to process and present both intra- and extra-
cellular antigens opens different possibilities of alloreactive donor T cell activation, e.g.
through the presentation of host-derived antigens by MHC-I and MHC-II molecules on donor 
APC established in the HCT recipient. Experimental studies in mice have shown that GvHD 
may be initiated by donor CD8+ T cells that are activated by host APC [Shlomchik 1999] as 
well as donor CD4+ T cells that are activated by either host or donor BM-derived APC 
[Anderson 2005].
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ALLOREACTIVE T CELL EXPANSION. In the initiation phase of GvHD, activated CD4+ and 
CD8+ T cells proliferate and differentiate to become alloreactive effector cells which can 
cause GvHD. Inflammatory cytokines further contribute through bystander effects resulting in 
unspecific stimulation of TE cells [Teshima 2002].
TRAFFICKING. Subsequently, activated donor T cells go from SLT into circulation and 
migrate to peripheral tissues in response to chemokine attraction and the enhanced expression 
of adhesion molecules (integrins and selectins) on endothelial cells in the vasculature 
[Wysocki 2005]. TH cells are thought to have less cytotoxic activity, but effect the recruitment 
of immune cells, including neutrophils, monocytes, NK cells, B cells and TC cells, to sites of 
ongoing inflammation and immune activation by the secretion of stimulatory cytokines (e.g.
&()

centrations of these cytokines further enhance antigen 
presentation as well as cytokine and chemokine secretion by APC, thereby amplifying the 
activation and recruitment of effector immune cells.
Figure 4 | Schematic model 
defining the main pathological 
stages of GvHD development  
(a) Prior to HCT, the conditioning 
regimen causes damage of host 
tissue and substantial secretion of 
proinflammatory cytokines in the 
patient. (b) Donor T cells entering 
the inflammatory milieu of the 
patient are activated by alloanti-
gens presented on host or donor 
APC. (c) Activated donor T cells 
expand, produce inflammatory 
cytokines and chemokines and (d) 
recruit innate immune cells (e.g. 
monocytes, NK cells, granulocytes) 
and other T cells. In the final (e) 
effector stage, activated immune 
cells as well as cytokines mediate 
the destruction of host tissues, 
leading to the elimination of tumor 
cells (the GVT effect) and causing 
multiple organ GvHD. 
Reprinted with permission from Annual 
Reviews: Welniak et al. (2007), ARI 25 
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TISSUE INFLAMMATION AND DESTRUCTION. TC cells and NK cells are the main effector cell
types responsible for tissue destruction through cytotoxicity in the final phase of GvHD.
Moreover, soluble inflammatory proteins contribute to host tissue damage either directly or 
indirectly by stimulating nearby effector cells.  	 
	 	 	 major effector 
molecules which directly mediate damage and necrosis of target tissues causing advanced-
stage GvHD pathology [Krenger 1997; Ferrara and Krenger 1998; Brown 2002]. Bacterial 
products such as LPS may cause additional damage of mucosa and skin in late stages of 
GvHD as they induce inflammatory pathways through TLR signaling in various innate 
immune cells, e.g. NK cells, monocytes and macrophages [Ferrara 2009].
III.3 Severe GvHD results in extensive tissue damage, systemic immune failure 
and possible death of the patient
Acute and chronic GvHD are viewed as two related but different disease syndromes 
which are distinguished primarily based on the time of disease onset (earlier or later than 100 
days, respectively, after transplant) and the clinical disease phenotype. The primary sites of 
graft-versus-host reactions (GvHR) in acute GvHD are the mucosa of skin, liver and the 
gastrointestinal tract [Ferrara and Reddy 2006]. Lymphoid organs can also be involved, e.g.
thymus and spleen, while the lungs are a target organ especially in chronic GvHD [Yanik and 
Cooke 2006]. Recently, Shono et al. have identified 
the BM as a target organ of GvHD [Shono 2010],
showing that MHC-mismatched, alloreactive donor 
T cells can disrupt the hematopoietic niches of host 
HSC [Shono 2010]. These findings offer a plausible 
explanation for recognized GvHD-related symptoms 
such as suppression of hematopoiesis and delayed 
immune reconstitution. 
Box 1 | Symptoms of acute GvHD  
 
Skin 
 maculopapular skin rash 
Upper gastrointestinal tract 
 nausea, anorexia, or both 
 positive histological findings 
Lower gastrointestinal tract 
 watery diarrhea 
 severe abdominal pain 
 bloody diarrhea or ileus 
Liver 
 cholestatic hyperbilirubinaemi 
 
Adapted with permission from Elsevier. 
Ferrara et al. (2009), Lancet 373 
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A range of clinical symptoms typical of either 
form of GvHD has been defined [Ferrara 2009] (Box 
1 and Box 2). Transplant recipients may present with 
heterogeneous syndromes at variable time points and 
suffer from GvHD of variable degrees of severity.
Ongoing alloreactivity and cytotoxicity against host 
epithelial tissues and hematopoietic cells result in a 
state of chronic inflammation, target organ damage 
and a defective immune system of the patient. The 
necessity to deliver immunosuppressive drugs 
contributes to the weakened functionality of the host 
defense and as a consequence, opportunistic 
infections are frequent causes of complications and 
death of GvHD patients.
III.4 Clinical assessment of GvHD 
There is a need for objective criteria to 
clinically assess and grade GvHD in patients to aid a 
more precise diagnosis and a more reliable prediction
of the risk of treatment including the odds of survival. 
Despite ongoing research efforts in this area (cf.
subchapter III.6), diagnosis of the disease is mainly 
based on clinical observations and distinct 
pathologies of target organs.
Glucksberg and colleagues defined a set of 
criteria based on defined clinical evaluations of the 
Box 2 | Symptoms of chronic GvHD  
 
Skin 
 dyspigmentation  
 new-onset alopecia  
 poikiloderma 
 lichen planus-like eruptions  
 sclerotic features 
Nails 
 nail dystrophy or loss 
Mouth 
 xerostomia 
 ulcers 
 lichen-type features 
 restrictions of mouth opening 
from sclerosis 
Eyes 
 dry eyes 
 sicca syndrome 
 cicatricial conjunctivitis 
Muscles, Fascia, Joints 
 fasciitis 
 myositis 
 joint stiff ness from contractures 
Female Genitalia 
 vaginal sclerosis 
 ulcerations 
Gastrointestinal Tract 
 anorexia, weight loss 
 oesophageal web or strictures 
Liver 
 jaundice 
 transaminitis 
Lungs 
 restrictive or obstructive defects 
on pulmonary function tests 
 bronchiolitis obliterans 
 pleural effusions 
Kidneys 
 nephrotic syndrome (rare) 
Heart 
 pericarditis 
Marrow 
 thrombocytopenia 
 anaemia 
 neutropenia 
 
Adapted with permission from Elsevier. 
Ferrara et al. (2009), Lancet 373 
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main target organs of acute GvHD (skin, liver and the gastrointestinal tract) as well as 
subjective assessment of patient performance [Glucksberg 1974]. The clinical parameters are 
categorized in escalating stages of severity as outlined in Table 1. Patients are assigned grades 
from I to IV (mild to severe) according to the pattern of observed clinical symptoms as out-
lined in Table 2. This general grading system is a useful tool for the practical management of 
GvHD and is widely used by hematologists and HCT specialists. 
Table 2 | Grading of GvHD severity after Glucksberg et al.  
grade 
 
degree of organ involvement 
I 
 
 
+ to ++ skin rash; no gut involvement; no liver involvement; no decrease in clinical 
performance; 
II 
 
 
+ to +++ skin rash; + gut involvement or + liver involvement (or both); mild decrease in 
clinical performance; 
III 
 
 
++ to +++ skin rash; ++ to +++ gut involvement or ++ to +++ liver involvement (or 
both); marked decrease in clinical performance; 
IV 
 
 
similar to grade III with ++ to ++++ organ involvement and extreme decrease in clinical 
performance; 
Reprinted with permission from The New England Journal of Medicine: Thomas et al. (1975), NEJM 292 
Table 1 | Clinical stages of acute GvHD symptoms after Glucksberg et al.  
stage 
 
skin liver intestinal tract 
+ 
 
 
macropopular rash 
< 25 % of body surface 
bilirubin 
2-3 mg per 100 mL 
> 500 mL diarrhea 
per day 
++ 
 
 
macropopular rash 
25-50 % of body surface 
bilirubin 
3-6 mg per 100 mL 
> 1000 mL diarrhoea 
per day 
+++ 
 
 
generalized erythroderma bilirubin 
6-15 mg per 100 mL 
> 1500 mL diarrhoea 
per day 
++++ 
 
 
 
generalized erythroderma 
with bullous formation and 
desquamation  
bilirubin 
> 15 mg per 100 mL 
severe abdominal pain with 
or without ileus 
Reprinted with permission from The New England Journal of Medicine: Thomas et al. (1975), NEJM 292  
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Clinical assessment may be complemented with histopathological evaluation of biopsies
from GvHD target organs. We have applied the grading scheme for cutaneous GvHD intro-
duced by Lerner and colleagues [Lerner 1974] as outlined in Table 3 to measure GvHR of the 
skin in our studies. 
III.5 The MHC is the primary determinant for the outcome of allogeneic HCT 
Matching the donor’s with the recipient’s HLA-I and -II genes is an essential pre-
requisite for successful HCT [Lee 2007]. Allele-matching of HLA-A, -B, -C, -DRB1 (‘8/8 
match’) and -DQB1 (‘10/10 match’) significantly reduces the risk of treatment failure
[Petersdorf 2001; Petersdorf 2007]. However, GvHD may occur despite full HLA 
compatibility, for example after transplantation between HLA-identical siblings due to 
disparities in minor H antigens [Dickinson 2008]. In the case of unrelated donors, MHC
mismatches (permitted or undetected) and the high number of minor H antigen differences 
result in an increased incidence of GvHD [Petersdorf 2007]. Furthermore, the majority of 
genes encoded in the MHC do not encode for HLA proteins (cf. Figure 2), but polypeptides 
that function as ‘non-HLA’ minor H antigens which also contribute to the risk of GvHD.
Table 3 | Grading of cutaneous GvHD after Lerner et al. 
 
grade 
 
symptoms 
0 normal  
I vacuolization of epidermal basal cells 
II diffuse vacuolization of basal cells with dyskeratotic bodies 
III subepidermal cleft formation 
IV complete epidermal separation 
Adapted with permission from The British Medical Journal (open access): Sviland and Dickinson (1999), JCP 52  
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III.6 Gene polymorphisms can influence susceptibility to GvHD and serve as 
biomarkers for disease diagnosis
Robust risk estimates of GvHD incidence and severity would allow clinicians to 
intervene at the stage of donor selection, patient preconditioning and immunosuppressive 
treatment in the course of transplantation. Despite the abundance of genetic disparities 
between most allogeneic HCT recipients and their donors, indicators which can be used as 
unequivocal markers of the disease or reliable predictors of treatment outcome have yet to be 
identified [Ferrara 2009; Paczesny 2009b].
Gene polymorphisms, i.e. divergent DNA sequences of allelic gene variants, e.g. single 
nucleotide base pairs and microsatellites, between individuals may affect gene expression,
translate to alloantigens and predispose to or protect from disease. Several non-HLA genes 
with immunological roles, e.g. genes encoding for cytokines (including IL1 receptor 
antagonist &* &+ &'/    e.g. CCL8) and receptor molecules 
(NOD/CARD15, estrogen and vitamin D receptors), display polymorphic phenotypes and 
have been implicated as predictors of risk of GvHD [Dickinson 2008; Paczesny 2009a; 
Dickinson 2010].
For example, while polymorphisms   0 0   are linked to 
increased risk of acute GvHD [Holler 1995; Middleton 1998] 
 antagonist 
IL10 can protect patients who produce relatively high amounts of this cytokine [Holler 2000].
1
0       clinical treatment of GvHD at present (cf. subchapter III.9,
Targeted pharmacological intervention)    cytokine which has critical 
importance in GvHD pathology (cf. subchapter III.2), exerting immune cell activation and 
upregulation of MHC gene expression on target cells among other roles. Recipient poly-
morphisms of this gene have been associated with acute GvHD after HLA-identical sibling 
HCT [Cavet 2001])  0  
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the blood plasma during acute GvHD could be exploited for better disease diagnosis [Hu 
1999; Levine 2008].
The recipient’s gene for IL6 can predispose for GvHD in the acute or chronic form
[Cavet 2001; Socie 2001]. Middleton and coworkers found that family donors with a variable 
number tandem repeat in the IL1RN gene, coding for a IL1 family cytokine, are less likely to 
cause acute GvHD in HCT recipients [Cullup 2001].
Polymorphisms in genes encoding for innate immune receptors have also been identi-
fied as risk factors in experimental animal studies, e.g. TLR9 in chronic GvHD [She 2007].
Mutations in the NOD2/CARD15 gene (which encodes a protein sensor of the bacterial cell 
wall component muramyl-dipeptide expressed in the cytoplasm of intestinal epithelial cells, 
monocytes and macrophages) could predict GvHD incidence and TRM in recipients of MHC-
matched related and unrelated donor BM transplants [Holler 2004; Holler 2008].
Heat-shock proteins (HSP) are encoded by a class of highly conserved genes which 
maintain fundamental functions in the protection of the cell against exogenous and endo-
genous stresses (heat, irradiation, inflammation, et c.) [reviewed by Srivastava 2002]. Such 
stress-inducible intracellular chaperones, e.g. the human HSP70 family of genes located in the 
MHC-III region, are implicated as regulatory molecules in adaptive and innate immune 
responses owing to their ability to bind antigenic peptides and make them available for cross-
presentation by APC [Srivastava 2002]. Regulation of GvHD by polymorphic HSP is 
therefore plausible. Evidence for such an association are anti-HSP70 antibodies present in the 
blood serum and overexpression of HSP70 in SLT of rats with GvHD [Goral 1995; Goral 
1998]. Serum antibodies towards HSP70 and HSP90 were also found increased at an early 
stage following PB-mobilized HCT in patients with acute GvHD, but not in GvHD-free 
patients [Goral 2002].
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More recently, Paczesny and coworkers have studied HCT patient plasma by high-
throughput screening using antibodies and isolated 8 candidate proteins which were 
associated with the incidence of acquiring acute GvHD [Paczesny 2009c]. Subsequent 
evaluation of these indicators resulted in a panel of four soluble blood serum molecules, 
namely IL2 receptor &5 1 and hepatocyte growth factor, which had superior 
predictive power over similar risk factor assessments [Paczesny 2009c].
In addition to genetic risk factors, clinical parameters such as age and gender of both
donor and patient, history of previous infections, time from diagnosis until transplant and the 
type of transplant used, among others, may influence the likelihood of developing acute or 
chronic GvHD and predict posttransplant survival [Gratwohl 1998].
III.7 In vitro models of GvHD 
The wish to gain a better understanding of the etiopathology of GvHD and to improve 
the clinical management of this disease has driven research in developing adequate laboratory
methods and animal models. The mixed lymphocyte reaction (MLR), where donor and 
recipient lymphocytes from the PB of patients or autopsied lymphoid tissues from laboratory 
animals are coincubated in standard cell culture, is a feasible method to elicit GvHR in vitro.
Allogeneic donor lymphocytes serve as responder cells, which are sensitized during several 
days of coculture with recipient lymphocytes that have been irradiated in order to inhibit 
mitosis and serve as stimulator cells. The proliferative response can be assayed as a measure
of T cell activation and expansion. 
Other laboratory techniques have been designed to prospectively quantify GvHR for 
predictive GvHD risk measurement, e.g. limiting dilution assays to determine the frequencies 
of alloreactive TC and TH lymphocyte precursors in vitro [Kaminski 1989; Theobald 1992].
These models, however, either lacked the sensitivity to predict GvHR reliably or were too 
impractical to find their way into routine testing.
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The skin explant assay is a model which can predict GvHR with high sensitivity and 
specificity in vitro. The method was originally described by Berkman et al. and was pro-
spectively tested for the prediction of GvHD incidence and severity in a donor/patient cohort 
by Vogelsang et al. [reviewed by Sviland and Dickinson 1999]. The skin explant assay had a 
reported correlation of 80-90 % with clinical outcome and was superior to other in vitro 
models for this purpose [Dickinson 1998; Sviland and Dickinson 1999; Dickinson 2001; 
Hromadnikova 2001]. The assay is performed ex vivo in medium culture and comprises a 
primary MLR to activate T cells from the marrow donor against recipient lymphocytes,
followed by a secondary reaction of the primed T cells against a skin biopsy from the same 
patient and subsequent histological evaluation. The skin explant closely resembles the 
histopathology of cutaneous GvHD and allows the study of pathophysiological processes 
related to GvHR [Dickinson 2002]. Thus, histological grading of the skin explant represents a 
standardized method to evaluate the risk for selected donor-recipient combinations before 
transplantation. As a scoring table the scheme for pathological grading of GvHD-affected skin 
(Table 3) may be used.
III.8 In vivo models of GvHD
Experimental work using animal models of HCT, first and foremost in mice and dogs 
(Canis lupus), has contributed substantially to the current knowledge of the etiopathogenesis 
of GvHD [Welniak 2007; Socie and Blazar 2009]. Animal models have also been 
instrumental for discovering and testing a variety of therapeutic options for their feasibility 
and efficacy [Socie and Blazar 2009; Ferrara 2009].
Preclinical models can, for example, yield important insights into the effects and 
toxicities of prophylactic or therapeutic pharmacological treatments and may help elucidate 
clinically relevant questions, e.g. the factors determining a patient’s unresponsiveness to these 
medications. It has to be taken into account, however, that medical treatment of animals may 
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deviate significantly from the effects and pharmacodynamics observed in humans [Socie and 
Blazar 2009]. The limitations to the interpretability of research performed in animal models 
are dealt with in more detail in the General Discussion.
Dog models of allogeneic BM transplantation (BMT) have provided insights into 
important aspects of transplantation and GvHD prevention in clinical practice (cf. subchapter 
III.9). Non-myeloablative conditioning using reduced intensities to decrease toxicity and 
morbidity in patients; pharmacological immunosuppression regimens posttransplant; ex vivo 
depletion of T cells from the graft by polyclonal antilymphocyte and antithymocyte globulins 
for prevention of GvHD; and delayed donor lymphocyte transfusions to induce GvT effects 
and conversion of mixed to complete donor chimerism are examples of protocols that were 
developed or improved in canine models [Storb and Thomas 1985; Storb 2003; Socie and 
Blazar 2009].
The mouse has been the species of choice in biomedical research historically and con-
tinues to dominate experimental studies of acute and chronic GvHD to date. Recipient mice 
are usually conditioned for transplantation with a lethal irradiation regimen. Animal models 
which are based on preconditioning by chemotherapy are rare [Sadeghi 2008; Socie and 
Blazar 2009]. In further contrast to humans, the BM graft is conventionally supplemented 
with spleen or lymph node cells to invoke GvHD in the experimental setting. 
An array of murine models designed for mismatch of the MHC, minor H antigens, or 
both, are available today [Schroeder and DiPersio 2011]. Fully incompatible strain 
combinations regarding both the MHC and the genetic background, e.g. [C57/BL6 (H-2b) ;
Balb/C (H-2d)], are often used. Parent-to-F1 HCT models are employed for haploidentical 
transplantations. Experimental protocols using non-myeloablative preconditioning are 
particularly interesting to mimic low-dose conditioning regimens for patients [Schroeder and 
DiPersio 2011].
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In the context of MHC mismatches, differences in minor H antigens are of minor 
importance in the pathogenesis of GvHD. In MHC-matched models, on the other hand, the 
contributions of minor H antigens to GvHR can be studied. In order to target individual 
antigens more specifically, transgenic mouse models which express a single recombinant 
TCR with defined antigen-specificity are also available. 
Transplantation of human cells into mice is made possible by xenogenic transplant
models to study ‘humanized’ GvHD in vivo, albeit in immunodeficient individuals of a 
different species. Recombination activating gene 2- &(  -deficient and 
non-obese diabetic, severe combined-immunodeficient mice can be used for this purpose. For 
a comprehensive summary of often used experimental mouse models of acute and chronic 
GvHD, the reader is referred to a recent review [Schroeder and DiPersio 2011].
III.9 State-of-the-art prevention and treatment of GvHD
The available and novel therapeutic approaches for the treatment of GvHD are too 
diverse for detailed discussion in this thesis. The main lines of treatment presently in clinical 
use are here briefly mentioned. Their individual advantages and complications are discussed.
Where applicable, insights into the efficacies of selected strategies of GvHD prevention and 
therapy through clinical trials are updated. They include therapeutic approaches which will be 
dealt with in the following categories: Adaptation of conditioning regimens, Alteration of the 
graft composition, Targeted pharmacological intervention and Cell-mediated therapy. Inter-
vention can be attempted prior to transfer of the disease-causing agent (donor immune cells) 
or at different stages of disease progression (host APC activation; donor T cell activation, 
differentiation and trafficking; effector cell-mediated cytotoxicity). 
Generally, positive effects of preventive and therapeutic treatments are often out-
weighed by adverse effects, such as an increased risk of graft failure, increased frequency of 
disease relapse and secondary lymphoproliferative disorders, severe side effects of immuno-
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suppressive drugs or loss of protection against opportunistic infections. Achieving long-
lasting tumor protection through a beneficial GvT effect without triggering the detrimental 
alloimmunity manifested in GvHD, while establishing full immune reconstitution and 
maintaining host tolerance to the graft, renders the clinical management of this disease a 
formidable challenge at present. 
Adaptation of conditioning regimens
RADIATION, CHEMOTHERAPY AND PROPHYLAXIS. Patients awaiting allogeneic HCT receive 
chemotherapy or total body irradiation or both, to kill hematopoietic cells and render the host 
receptive for the donor graft. Calcineurin inhibitors (cyclosporine, tacrolimus, et c.) target T 
cells and prevent their activation. Other metabolic inhibitors (methotrexate, mycophenolate 
mofetil, et c.) are often applied in combination with calcineurin inhibitors to further dampen 
the host immune response. The corticosteroids used in pretransplant prophylaxis are often 
administered for continued immunosuppression after HCT or acutely for treatment of sympto-
matic GvHD. The agents may be applied either systemically, topically (skin GvHD) or by 
inhalation (lung GvHD). First-line treatment of acute GvHD with steroids results in complete 
or partial remission (resolution of symptoms) in approximately half the patients [MacMillan 
2002]. For those who do not respond and develop steroid-refractory (resistant) GvHD, a
number of second-line treatment options are available (see below).
ANTIBODIES. Mono- and polyclonal antibodies (e.g. antithymocyte and antilymphocyte 
globulins) may be used to prevent GvHD by depleting donor T cells in vivo. As with other 
treatments targeting T cells directly (such as calcineurin inhibitors), however, GvHD
prevention and alleviation is compromised by the loss of beneficial antitumor effects as GvH 
and GvT reactivities are equally affected, resulting in an increased risk of tumor relapse.
REDUCED INTENSITY CONDITIONING (RIC). Lethal doses of irradiation and chemotherapy can 
be used to deplete host cells in conjunction with subsequent transfer of BM stem cells that 
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rescue the patient [Appelbaum 2001]. However, these treatment regimens are highly toxic and 
cause severe detrimental effects in the patient. The use of reduced or minimum intensity 
conditioning with lower toxicity was designed to deminish, if not avoid, tissue damage and 
treatment-related complications, but is associated with increased rates of leukemic relapse and 
bacterial infections [Appelbaum 2010].
Alteration of the graft composition
T-CELL DEPLETION (TCD). TCD of the stem cell graft is a non-pharmacological strategy to 
avoid GvHD, which is especially useful in donor-patient combinations that have partial MHC
mismatches, because they activate higher numbers of alloreactive T cells [Kolb 2008].
Depletion is performed ex vivo prior to transplantation by use of immunological (T cell-
specific antibodies in combination with complement-mediated lysis, immunotoxins, magnetic 
beads) or physical methods (agglutination, density gradient fractionation) [Ho and Soiffer 
2001]. Since the broad removal of donor T cells results in the loss of beneficial GvT activity, 
TCD results in higher rates of tumor relapse as well as increased risk of graft rejection, 
delayed immune reconstitution, viral reactivation and, possibly, infection [Ho and Soiffer 
2001]. Stronger tumor prophylaxis or prolonged and additional immunosuppressive regimens
may therefore be required and can be complemented with additional transfusions of donor 
lymphocytes (see Cell-mediated therapy, p.34) posttransplant to confer GvT-reactivity and 
avoid transplant-related complications. 
GRAFT ENRICHMENT. To overcome the obstacle of engraftment failure that is associated with 
RIC and TCD, graft enrichment of CD34+ HSC and infusion of a large number (‘megadose’) 
of BM stem cells are performed with success [Bachar-Lustig 1995; Ringdén 2003].
Targeted pharmacological intervention
CYTOKINE MODULATION. Cytokine modulation through pharmacological intervention has 
become a subject of GvHD $)$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of GvHD, from initiation to the late effector phase (cf. subchapter III.2) has been recognized. 
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GvHD in the clinical setting [Levine 2008]. However, attempts to enhance or neutralize 
cytokines with putative anti- or proinflammatory activity in vivo may have unintended effects. 
The systemic administration of immunosuppressive cytokines (e.g. IL4, IL10) has produced 
obscure results in experimental and clinical studies [Murphy and Blazar 1999]. Paradoxically, 
cytokines generally considered as proinflammatory/immunostimulatory (e.g. &(&'5
can dampen alloreactivity and improve GvHD. For instance, blocking the IL2 signal by calci-
neurin inhibitors may not only induce T cell anergy, but also adversely influence the main-
tenance of TR cells [Zeiser 2006], which may in turn lead to problems regarding long-term 
tolerance and GvHD prevention. Infusion of recombinant IL2 was shown to alleviate, rather 
than exacerbate, GvHD [Wang 1995] by increasing the number of TR cells in patients [Zorn 
2006]. In fact, inducing GvHD patients’ TR cells by IL2 administration is now being tested in 
a clinical phase II trial [http://clinicaltrials.gov/ct2/show/NCT00539695]. 
G-CSF administration, which is often used to accelerate neutrophil engraftment after 
total body irradiation and BMT, initiated a complex immune cascade involving the 
stimulation of host APC and led to increased GvHD in a mouse model [Morris 2009].
Therefore, the deliberate manipulation of complex signaling pathways by administration 
of cytokines, chemokines or their antagonists can have unexpected effects in ways that may 
not be apparent, but are potentially dangerous.
Cell-mediated therapy
DONOR LYMPHOCYTE INFUSION (DLI). DLI is applicable for the prevention or treatment of 
relapse of hematological malignancies and is often combined with chemotherapy or other 
immunosuppression [reviewed by Kolb 2008]. Donor lymphocyte grafts contain CD4 T cells,
CD8 T cells and NK cells with GvT potential. DLI has been especially successful in patients 
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with chronic myelogenic leukemia. The risks of this treatment are GvHD and 
myelosuppression [Kolb 2008]. The optimal timing and dose of DLI in the treatment of the 
different malignancies are not known [Tomblyn and Lazarus 2008].
ADOPTIVE IMMUNOTHERAPY WITH ALLOREACTIVE T CELLS. Allelic mutations can translate 
to altered protein structures which may serve as epitopes for allogeneic T cells when the 
corresponding peptide is presented in the context of HLA, thus forming a minor H antigen. 
Alloreactive donor T cells with specificity for such antigens can be exploited for the treatment 
of residual, refractory or relapsing tumors [reviewed by Bleakley and Riddell 2011]. T cell 
clones which react with tumor-derived antigens can be used to prevent or treat leukemia 
[Dudley 2002]. By the same token, therapeutic infusions of ex vivo-expanded T cells which 
specifically target common human pathogens (e.g. Epstein-Barr virus, herpes simplex virus 
and cytomegalovirus) can provide persistent posttransplant immunity against infection and 
viral reactivation [Riddell 1992; Bleakley and Riddell 2011].
Adoptive immunotherapy is particularly promising when T cell clones are selected
which can augment GvL effects directed against minor H antigens that are only expressed on 
recipient hematopoietic cells, including leukemia, but leave non-hematopoietic cells intact 
[Dickinson 2002; Bleakley and Riddell 2011]. Widely expressed antigens, on the other hand, 
bear the risk of triggering GvHR [Dickinson 2002]. T cell clones with specificity for recipient 
minor H antigens have been successfully isolated from GvHD patients, enriched by ex vivo
expansion and applied to prevent leukemic relapse [Goulmy 1996; Falkenburg 1999; Mutis 
1999]. The first phase I clinical trial to use such an approach showed that adoptive transfer of 
minor H antigen-specific donor TC cells augmented the GvL effect and led to complete 
remission in several patients who experienced leukemic relapse after HLA-matched 
allogeneic HCT [Warren 2010]. Expression of the respective alloantigen on lung epithelia 
caused pulmonary toxicity in some patients, illustrating the potential danger of this method if 
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tissue-specific expression patterns of the target antigens are not meticulously mapped. 
Furthermore, infused antitumor T cells must persist in the host in order to provide durable 
protection from tumor relapse.
REGULATORY T CELLS. Refined strategies which aim to selectively remove GvH-reactive 
populations from the graft or add back T cells with suppressor function have also been 
developed. In a clinical pilot study, ex vivo-expanded TR cells from UCB units were adminis-
tered to a cohort of patients who received partially HLA-matched double UCB transplants 
[Brunstein 2011]. Infusions were tolerated with no intervention-related toxicity, and adverse 
effects of the treatment regarding early mortality, risk of infection or relapse were not 
observed. The incidence of acute GvHD was statistically lower in this patient group relative to 
comparable historical controls. Future clinical trials will elucidate whether adoptive TR cell 
transfer is a feasible and effective therapy, and whether GvHD prevention can be achieved 
without compromising immune protection from neoplastic relapse, formation of secondary 
tumors and infections [Riley 2009].
In general, the production of sufficient amounts of the desired T cell subset requires ex
vivo expansion to achieve satisfactory purity and desirable potency. This approach is currently 
too labor- and cost-intensive for its general application, especially if the effector cell unit has 
to be tailored to individual donor-patient pairs [Riley 2009].
GVH-REACTIVE NK CELLS. Although putting the patient at a higher risk of GvHD, partial 
HLA-mismatch of the HSC donor may hold an advantage for the treatment of leukemias in 
HCT [Velardi 2009]. Transplantation of donor NK cells that are alloreactive against patient 
hematopoietic and leukemic cells which lack cognate MHC ligands to inhibitory receptors
reduces the rate of rejection and relapse [Ruggeri 2002]. Importantly, donor-versus-host 
reactive NK cells do not cause, but protect against GvHD due to cytotoxicity against host 
37 
APC [Ruggeri 2002]. Thus, the selection of donors with KIR:HLA mismatches may be 
beneficial for recipients of haploidentical HCT. 
EXTRACORPOREAL PHOTOPHERESIS (ECP). ECP represents an adjunct therapy for severe 
steroid-resistant GvHD. The procedure comprises apheresis of PB followed by loading with 
8-methoxypsoralen, a DNA-intercalating agent, to sensitize blood cells to ultraviolet radiation 
and subsequently induce apoptosis of PB mononuclear cells ex vivo. Reinfusion of psoralen 
and ultraviolet A-treated patient PB led to complete resolution of steroid-refractory or steroid-
dependent GvHD in phase I and II studies [Greinix 2000; Messina 2003; Foss 2005; Greinix 
2006; Couriel 2006; Flowers 2008] and was particularly efficient in patients suffering from 
acute or chronic GvHD with skin involvement. Significantly better long-term survival rates
were recorded. ECP is generally tolerated well without significant side effects [Knobler 
2009]. Complete or partial response to the ECP regimen may allow an earlier reduction or the 
discontinuation of corticosteroid treatment, thereby improving patient morbidity and 
mortality. Inhibition of antigen presentation on dendritic cells, increase in the number of 
donor TR cells and reduction of alloreactive donor effector cells in experimental GvHD 
treatment have been implicated, but much of the underlying immunological mechanisms of 
this approach remains unknown [Knobler 2009].
MESENCHYMAL STROMAL CELLS. Transfusion of MSC has emerged as a new treatment 
modality for GvHD after their immunosuppressive potential has been realized (cf. subchapter 
IV.3). The demonstrated efficacy and safety of single or repeated MSC infusions in early 
studies [Le Blanc 2004; Ringdén 2006] gave promise to the development of this therapy in 
subsequent clinical trials [Le Blanc 2008].
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Chapter IV. Mesenchymal Stromal Cells
IV.1 Mesenchymal stromal cells are a heterogeneous population of early 
progenitor cells in the stroma of various organs 
MSC are non-hematopoietic progenitor cells with multilineage differentiation potential. 
Friedenstein et al. were the first to identify and define explanted clonal progenitor cells from 
the BM that produced fibroblast-like progeny in monolayer cultures (then termed ‘colony-
forming unit fibroblast’, CFU-F) and retained differentiation potential for bone, cartilage and 
adipose cells [Friedenstein 1968]. Heterotopic transplantation of BM stromal cells generated
ectopic skeletal and fibrous tissue in vivo [Friedenstein 1968; Friedenstein 1974].
MSC from several species have been characterized, but were most thoroughly studied in 
humans and mice. An illustrative protocol of isolation, enrichment and single colony-derived 
generation of rat MSC lines is given in a video article by Zhang and Chan [Zhang and Chan 
2010]. MSC have been iso-
lated from the BM and other 
adult organs [Pittenger 1999; 
Zuk 2001; da Silva Meirelles 
2006; Beltrami 2007; Covas 
2008] as well as the female 
reproductive system [Erices 
2000; in 't Anker 2003; in 't 
Anker 2004; Patki 2010] and 
fetal tissues [Campagnoli 
2001; in 't Anker 2003]. Of 
these, adipose tissue, amniotic 
fluid and UCB have lately 
 
Figure 5 | Differentiation potential of BM-derived MSC  
BM-resident MSC have the ability self-renew and differentiate into 
several cell types (e.g. bone, cartilage, fat cells) of the mesodermal 
lineage. The reported ability to transdifferentiate also along other 
germline lineages (ectodermal and endodermal) in vivo is currently 
controversial. 
Reprinted with permission from Nature Publishing Group: Uccelli et al. 
(2008), NRI 8  
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gained importance as practically available sources of 
MSC for clinical use [Malgieri 2010] (cf. subchapter 
IV.4).
The MSC population contains only few self-
renewing progenitor cells with multipotency for the 
mesodermal lineage [Bianco 2008], including stroma, 
bone, cartilage and fat cells [Horwitz 2005] (Figure 5).
Transdifferentiation of MSC into cells of non-meso-
dermal lineages, e.g. epithelial cells, hepatocytes or 
neurons, has been reported by single studies [Oswald 2004; Arthur 2008; Snykers 2009]. To
date, the developmental ontogeny and the in vivo identity of the bona fide mesenchymal stem 
cell remains unknown, mainly due to the current lack of specific biomolecular markers and 
appropriate in vivo assays for true ‘stemness’ of this cell type [da Silva Meirelles 2008; 
Nombela-Arrieta 2011].
Different protocols of isolation and ex vivo expansion have led to descriptions of MSC 
from different organ sources which vary with respect to their phenotype and differentiation 
potential [Nombela-Arrieta 2011]. At present, a characterization of MSC ought to fulfill
certain minimal requirements regarding their morphology, differentiation potential and 
surface expression phenotype set by The International Society for Cellular Therapy [Dominici 
2006] (Box 3). 
IV.2 Stromal cells control cell maintenance and function in various tissues 
Stromal cells create a suitable microenvironment for the growth, maturation and 
survival of other cells and thereby, maintain their correct function in the respective organ. 
MSC support hematopoiesis in the BM through cytokine cues and cell contact-dependent 
mechanisms [Méndez-Ferrer 2010]. The constitutive expression of adhesion molecules 
Box 3 | MSC minimal criteria 
 
 MSC adhere to plastic surfaces 
under standard in vitro culture 
conditions. 
 MSC have the capacity to 
differentiate into adipocytes, 
chondrocytes and osteocytes. 
 MSC express CD73, CD90 and 
CD105 markers, but not the 
hematopoietic markers CD11b, 
CD14, CD19, CD34 and CD45 or 
surface MHC-II molecules. 
 
Adapted from informa healthcare: 
Dominici et al. (2006), Cytotherapy 8  
40 
including integrins [Stagg 2007] is consistent with the ability of MSC to interact with 
hematopoietic progenitors in HSC niches [reviewed by Ehninger and Trumpp 2011]. It has 
been suggested that the heterogeneous MSC population comprises different cell types with 
distinct in vivo functions, i.e. they either support HSC survival and hematopoiesis or homing 
and maintenance of memory immune cells [Tokoyoda 2010].
IV.3 MSC regulate immune responses
MSC exhibit low densities of MHC-I molecules and do not express MHC-II molecules 
on the cell surface unless exposed to inflammatory stimuli [Le Blanc 2003; Le Blanc and 
Pittenger 2005]. They also lack costimulatory molecules such as CD40, CD80 and CD86
[Uccelli 2006]. This has led to speculations that MSC are ‘immune privileged’, i.e. MHC-
disparate MSC are not recognized by the immune system, but this hypothesis is presently 
controversial. MSC survived in allogeneic hosts and mediated immunomodulatory effects
such as acceptance of allogeneic skin grafts [Bartholomew 2002; Le Blanc and Pittenger 
2005]. MSC were also shown to be inert to TC cell recognition and lysis [Rasmusson 2007].
Other studies demonstrated that MSC are in rejected in allogeneic recipients [Eliopoulos 
2005; Nauta 2006b]. The ability of MSC to elicit immune responses (immunogenicity), or 
lack thereof, is important for their use in clinical therapy (cf. subchapter IV.4) as this will 
determine the rejection of or tolerance towards non-autologous MSC upon transfer in vivo.
In past years, a wealth of studies has reported on the modulation of immune responses
by MSC. These cells were shown to inhibit T cell proliferation, cytokine secretion and 
cytotoxicity [Krampera 2003; Le Blanc 2003; Maitra 2004; Meisel 2004; Aggarwal and 
Pittenger 2005; Groh 2005; Chabannes 2007; Sato 2007; Nasef 2008; Ren 2008; Ren 2009; 
Gieseke 2010], induce apoptosis in activated T cells [Plumas 2005], inhibit TH17 cell 
differentiation [Tatara 2010; Duffy 2011] and induce TR cell expansion [Nasef 2008; 
Ghannam 2010a; Mougiakakos 2011], inhibit B cell proliferation and differentiation [Glennie 
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2005; Corcione 2006], inhibit NK cell 
proliferation, cytokine secretion and 
cytotoxicity [Sotiropoulou 2006; Spaggiari 
2006], inhibit dendritic cell maturation 
[Beyth 2005; Jiang 2005; Nauta 2006a; 
Djouad 2007], inhibit TNF  by 
macrophages [Ortiz 2007] and protect
neutrophils from apoptosis [Raffaghello 
2008]. Different explanations for their 
immunosuppressive properties have been
offered, some postulating the need for cell 
contact while others implicated different 
soluble factors and signaling molecules 
[reviewed by Uccelli 2006; Ghannam 2010b]. Inhibitory mechanisms include the secretion of 
cytokines (e.g. IL6, &'/ %	) and other messenger molecules (e.g. prostaglandin E2), 
enzymatic production of small bioactive compounds (e.g. nitric oxide, carbon monoxide, L-
kynurenine) as well as carbohydrate substrates (lectins) [Di Nicola 2002; Meisel 2004; 
Aggarwal and Pittenger 2005; Chabannes 2007; Sato 2007; Ren 2008; Gieseke 2010; 
Mougiakakos 2011].
It is noteworthy that MSC utilize a range of different molecular pathways, which may 
be overlapping and redundant to some degree, to suppress immune responses and modulate 
the functions of target cells. Variations in the modus operandi of human and rodent MSC 
have been described [Ren 2009].
Figure 6 | Suppression of immune cells by MSC  
MSC use different molecular signals and path-
ways (e.g. IL6, PGE2, IDO, NO HLA-G) to inhibit 
the proliferation and functions of neutrophilic 
granulocytes, T cells, B cells, NK cells and dendri-
tic cells, or to induce TR cells to exert immuno-
suppression. 
Reprinted with permission from BioMed Central  
(open access): Ghannam et al. (2010), SCR&T 1 
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IV.4 MSC have therapeutic potential for GvHD and autoimmune diseases
The property to replace damaged cells and form new tissues in vivo has earned MSC a
long-standing interest in regenerative medicine. MSC transplantation is now being tested for 
injury repair and replacement strategies of different tissues, e.g. cartilage, bone, cardiac 
muscle, brain and spinal cord, et c. [http://clinicaltrials.gov/]. More recently, their potential as 
inhibitors of immune responses has made this cell type a promising candidate for cell-based 
treatments of alloimmune (GvHD) and autoimmune (diabetes mellitus type 1, multiple 
sclerosis, ulcerative colitis, Crohn’s disease, oral lichen planus, systemic lupus erythema-
tosus) diseases [Uccelli and Prockop 2010; Dazzi and Krampera 2011; Kebriaei and Robinson 
2011; Tolar 2011].
The first report of temporary efficacy of MSC came from a pediatric patient with 
severe, refractory liver and gut GvHD [Le Blanc 2004]. A subsequent phase I clinical trial 
[Ringdén 2006] demonstrated the feasibility and safety of MSC adoptive therapy, where most 
patients responded favorably to the treatment. A non-randomized multicenter trial [Le Blanc 
2008] measured an initial response rate of 70 % with improved TRM and longer overall 
survival at 2 years post transplant, compared with non-responders. Injections of ex vivo-
expanded MSC were tolerated without side effects and the allotype (HLA-matched and 
haploidentical donors were used) was not important [Le Blanc 2008]. A number of non-
randomized trials [Fang 2007; Müller 2008; von Bonin 2008; Kebriaei 2009; Prasad 2010]
also showed positive effects of MSC therapy compared with historical patient data, and 
recorded no significant adverse effects. These findings, although lacking the proper controls, 
were promising and led to a sponsored, randomized phase III clinical trial [Martin 2010],
where 244 patients received repeated infusions of commercially produced MSC (Prochymal®)
from unrelated donors or placebo for four weeks. The results from this study were disappoin-
ting [Allison M 2009] as the primary endpoint of durable complete response at 28 days post
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treatment initiation was not reached. Response rates for visceral (liver and gastrointestinal) 
GvHD at 100 days were significantly improved, but a positive effect in cutaneous GvHD was 
not detected [Martin 2010].
Multipotent adult progenitor cells (MAPC) represent an alternative cell type with 
greater proliferative and multilineage potential than ‘conventional’ MSC [Jiang 2002] and 
proven immunosuppressive capacity in vivo [Highfill 2009]. A human MAPC product is 
commercially available (MultiStem®) and currently the object of a clinical proof-of-safety 
study for GvHD prevention [http://clinicaltrials.gov/ct2/show/NCT00677859].
MSC-based therapy has entered trials for chronic GvHD as well [reviewed by Kebriaei 
and Robinson 2011; Tolar 2011] with reports of favorable responses in a number of patients 
[Ringdén 2006; Müller 2008; Lucchini 2010; Weng 2010; Zhou 2010]. The pilot study 
conducted by Zhou et al. showed significant alleviation of sclerodermal chronic GvHD in all 
four patients after repeated intra-BM injections of MSC [Zhou 2010]. Transient beneficial 
effects upon single application of MSC as salvage treatment for severe, resistant chronic 
GvHD were noted in four out of eleven pediatric patients by Lucchini et al. [Lucchini 2010].
Of particular concern regarding this treatment modality is the possible inhibition of 
beneficial GvL effects by transplanted MSC [Tolar 2011]. One randomized trial reported a 
decrease in GvHD incidence with a concurrent increase in leukemia relapse in patients who 
received MSC injections [Ning 2008]. It is presently disputed whether MSC promote or 
protect against tumor growth in vivo [Klopp 2011]. Future studies should address putative 
adverse effects, such as transfer of infectious agents, attenuation of GvL effects, enhanced 
neoplastic relapse and carcinogenesis in the presence of MSC or malignant transformation of 
the transplanted MSC per se [Tolar 2011].
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Chapter V. Mycoplasma infection
V.1 Mycoplasma occur as cell-associated or intracellular pathogens in a wide 
range of species
Mycoplasma is a genus of bacteria under the taxonomic order Mycoplasmatales in the 
class of Mollicutes [Tree of Life web project 2006] and comprise the smallest known uni-
cellular organisms regarding both physical size (300-800 nm in diameter) and genome size 
(M. genitalium, 580,070 base pairs). Their cell surface is composed of a single plasma 
membrane and lacks a cell wall. 
Mycoplasma evolution has led to an obligate parasitic or commensal lifestyle in a wide 
host of species, including fungi, plants and animals. In mammals, most Mycoplasma species 
infect the respiratory tract (M. pneumoniae, et c.) where they cause coughing and respiratory 
impairment, whereas a number of species have their natural habitat in mucous surfaces of the 
genitourinary tract (M. genitalium, et c.) and less frequently, in the eyes, joints or mammary 
glands [Razin 1998].
Mycoplasmas are adapted to the protective environment of their natural host cell and 
live either attached to the outer cell surface (cytadherence) or inside the cell lumen (intra-
cellular residence) [Razin 1998]. However, they may retain the ability to cross tissue and 
species boundaries and adjust to new host environments [Razin 1998]. The majority of 
Mycoplasma species cause no symptoms or only mild or chronic forms of infection, but rarely 
kill their hosts [Razin 1998]. However, mycoplasmal diseases do occur, and the pathogenicity 
of infection ranges from pneumonia to autoimmune manifestations by non-specific immune 
activation of their host organisms. Furthermore, mycoplasmas are suspected to be a factor in 
carcinogenesis [Namiki 2009].
V.2 Mycoplasma infections successfully evade the immune system
Mycoplasma infection can, besides causing specific antimycoplasmal immune 
responses, either stimulate or suppress the host immune defense non-specifically by 
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influencing the behavior of immune cells in vitro and in vivo [reviewed by Razin 1998].
Activation of immunity may result in macrophage and complement activation, increased 
proliferation and cytotoxicity of effector cells, induction of surface receptor expression and
secretion of inflammatory cytokines (e.g. &+ as well as non-specific polyclonal 
T cell and B cell activation [Razin 1998]. For example, it is known that M. hyorhinis or cell 
products derived from this organism are able to induce the secretion of several pro-
inflammatory cytokines by monocytes, and may activate the proliferation and maturation of 
B cells [Proust 1985; Kostyal 1995]. Different molecular components may be responsible for 
the stimulation of, respectively, mitosis and cytokine production by the same species of 
Mycoplasma [Razin 1998]. On the other hand, infection with M. hyorhinis can also result in 
the mitotic and functional suppression of B and T cells [Teh 1988; Zinöcker 2011b].
Mechanisms of immune suppression by mycoplasma encompass the induction of anergy,
substrate depletion and production of cytokines (e.g. IL10 and IL13) or compounds with 
cytocidal effects (e.g. nitric oxide) [Razin 1998]. Such effects can be initiated by both viable 
and inactive mycoplasma cells as well as isolated cell membrane components and soluble 
factors. Mycoplasmas are furthermore able to actively escape immune recognition by 
antigenic variation of lipid membrane molecules [Razin 1998].
Thus, the ability to inhibit and modify immune responses and inflammatory processes 
provides a distinct advantage to these highly adapted parasites in the evasion of the host 
immune system. Efficient vaccination strategies against mycoplasmal diseases have proven 
difficult to develop [Nicholas 2002]. The need to control this disease in human and veterinary 
medicine warrants further investigation to better understand the complex aspects of myco-
plasma infection.
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V.3 Mycoplasma are ubiquitous cell culture contaminants in laboratory 
science
The arrival of cell culture in laboratories around the world has created new artificial 
habitats for mollicutes. A small number of species account for more than 90 % of the detected 
contaminations: M. orale, M. hyorhinis, M. arginini, M. fermentans, M. hominis and Achole-
plasma laidlawii [Drexler and Uphoff 2002]. The microorganisms found in contaminated cell 
cultures stem from cross-infection by previously contaminated cell lines, culture media, 
reagents and additives (e.g. bovine serum) or from the human operator [Drexler 2002].
Contamination with mycoplasmas may have a variety of biological effects on 
eukaryotic and hybridoma cells [Drexler and Uphoff 2002]. However, they do not always 
cause obvious functional or phenotypical alterations in the original cell lines and are therfore 
often not detected. Consequently, mycoplasma contaminantion generates substantial losses 
and increases the costs of managing and monitoring cell culture. Moreover, they may lead to 
experimental artifacts and misinterpretations of research results [Proust 1985; Ruuth 1985; 
Sinigaglia and Talmadge 1985; Merkenschlager 1988]. It is therefore critical to prevent and 
avoid mycoplasma contamination in the experimental setup. 
Among the different detection protocols which have been proposed [Drexler and Uphoff 
2002], mycoplasma-specific PCR remains the most reliable and widely used method today. 
To eradicate infections from cell cultures, antimicrobial substances such as tetracyclin and 
quinolone compounds are commonly used, but may be toxic to the target cells under treatment
[Drexler and Uphoff 2002]. Antibiotics which block cell-wall synthesis, such as penicillin, do
not obstruct mycoplasma growth and are therefore non-efficient. Effective and robust 
techniques for the detection and elimination of mycoplasma infections are nowadays 
commercially available. 
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V.4 Mycoplasma as a bacterial model of the ‘minimal cell’
The complete genome sequence of M. genitalium, the smallest gene complement of a 
non-viral living organism known to date, has been published [Fraser 1995]. The recent 
artificial generation of a unicellular organism (M. laboratorium) that is capable of self-
replication was achieved by the assembly of a synthetic genome based on the sequence of 
M. mycoides and transplanted into a DNA-purged M. capricolum cell [Gibson 2010].
The idea that M. genitalium, because of its small genome and low total number of 
genes, embodies the minimal (or ‘close-to’ minimal) requirements of a self-replicating cell is 
currently being explored to identify genes that are essential for the maintenance of cell-
cycling functions under defined conditions. This research should allow investigators to gain 
insight also into other important molecular functions of the cell, e.g. the modulation or 
avoidance of immune responses, which are sustained by these organisms and could prove 
important for the development of effective vaccines against them.
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Aims of the thesis
This work was initiated with an early researcher grant in the research training network 
“TRANS-NET” under the Sixth Framework Programme (Marie Curie Actions) of the 
European Commission. Our collaborative efforts were focused on the “[I]dentification of 
genomic and biological markers as [predictive, diagnostic and therapeutic] tools for use in 
allogeneic stem cell transplantation” [“TRANS-NET” Technical Annex 2004], with the over-
all aim to translate our research results into better accessibility, safety and efficacy of this 
important but hazardous medical procedure. The subordinate milestone of our workpackage 
(‘Models of GvHD’) was to develop the skin explant assay in the rat model to study GvHD 
and GvL responses; this work was carried out in cooperation with our research partners at the 
University of Newcastle-upon-Tyne and Georg-August-Universität Göttingen. 
In a parallel collaborative project, we aimed to test and develop MSC therapy against 
GvHD in the rat model, together with Gunnar Kvalheim at the Norwegian Radium Hospital.
In summary, the overall research objectives of this thesis were:
1. to characterize molecular and cellular interactions behind the pathogenic mechanisms of 
GvHR;
2. to develop enhanced diagnostic tools for GvHD in the rat, in particular, to develop the skin 
explant assay for this species and compare it with the hallmarks of human GvHD;
3. to investigate the roles of MHC genes as well as genes encoding for receptors of the innate 
immune system on stem cell engraftment, immune reconstitution and GvH responses; 
4. to test and improve MSC therapy of GvHD in the experimental allogeneic HCT rat model; 
5. to elucidate the molecular mechanisms by which MSC suppress T cell alloreactivity.
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Summary of Results
Paper I
Kinetics of lymphocyte development after allogeneic bone marrow transplantation: 
Markers of acute graft-versus-host disease.
This study provides a characterization of the experimental GvHD model which was the 
subject of investigation throughout this doctoral thesis. We tried to identify reliable markers 
related to acute GvHD in the rat model, with the long-term goal to translate these findings to 
clinical allogeneic HCT. To this aim, we applied a twofold approach, where we monitored 
the frequency of donor- and host-derived leukocyte populations following BMT and during 
acute GvHD, and at the same time studied the histopathology of selected organs known to be 
involved in the physiopathological development of the disease.
In this model, recipient BN rats received myeloablative irradiation before transplantation of 
fully mismatched T cell-depleted BM from donor PVG.7B rats. Severe acute GvHD was 
induced in the test group by a delayed injection of donor lymphocytes that was lethal in all 
recipients within 2 to 6 weeks after DLI. GvHD presented with rapid weight loss, apathy,
hunching, ruffled fur and hair loss, skin flaking and occasional skin lesions. Histological 
changes were mainly restricted to the skin. Lymph nodes and spleen showed a marked 
destruction of the normal architecture, while the gut, liver and lung appeared unaffected. 
Host reconstitution with donor NK cells ensued rapidly and completely, and the DLI 
established stable and full donor chimerism of T cells. We noted a significant decrease in 
Ly49s3+ NK cells and CD62L+ T cells as well as an extensive loss of CD4+CD25hiFoxP3+ TR
cells in the PB of animals at the onset of GvHD, in marked contrast to controls. We suggest 
that these cell populations may serve as accessible cellular markers of acute GvHD.
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Paper II
Correlation of Hsp70-1 and Hsp70-2 gene expression with the degree of graft-versus-
host reaction in a rat skin explant model.
Paper III
Expression profiling of major histocompatibility complex genes in skin explant assays 
reveals new candidates for controlling risk of graft-versus-host disease.
In these two papers, we developed an in vitro model for cutaneous GvHD in the rat in 
analogy to the human skin explant assay in a collaborative project. We employed the rat skin 
explant assay to study the pathology of (Paper II) and regulation of gene expression (Paper II
and Paper III) in GvHR with the aim to identify genes involved in GvHD pathophysiology.
We focused on the MHC and the NKC as the gene regions of prime importance in allogeneic 
transplantation. The use of inbred, genetically well-defined rat strains with disparity either in 
the MHC, the non-MHC genetic background, or both, allowed us to study the importance of 
major and minor H antigens in GvHR. 
Rat skin explants displayed similar pathology as has been described previously in the human. 
The grade of observed GvHR was in correlation with the degree of genetic mismatch (no 
mismatch < minor < major < minor plus major). Hsp70 genes -1 and -2, but not -3, all located 
within the MHC class III region, were differentially regulated in GvHR. More elaborate 
studies of the gene expression profiles in skin GvHR using a custom-designed oligonucleo-
tide microarray revealed the significant and strong regulation of 25 MHC, 6 NKC, and 168 
genes encoded in other genomic regions. We observed similar regulation patterns of a panel 
of selected MHC and NKC genes in skin lesions from rats with GvHD and of their human 
homologues in skin samples from GvHD patients. Several of the identified genes, including
HLA-DMB, C2, AIF1, SPR1, UBD, and OLR1, show polymorphisms and are therefore valid 
candidates for genetic risk assessment of GvHD in recipients of allogeneic HCT.
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Paper IV
Rat bone marrow-derived mesenchymal stromal cells suppress T cell stimulation in 
vitro through nitric oxide production
Several molecular pathways by which MSC inhibit lymphocyte activation, expansion and 
effector functions have been described in the literature. The appropriate physiological 
conditions and the exact mode of action of MSC inhibition, however, are still not fully 
understood, in particular for MSC derived from various tissues and from other species than 
mouse and human. Herein, we demonstrate that MSC generated from rat BM utilized 
inducible nitric oxide synthase (iNOS) to inhibit T cell stimulation in vitro. MSC were 
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induced or allogeneic mixed lymphocyte cultures to express iNOS, leading to the release of 
high levels of nitric oxide and suppression of T cell proliferation. Furthermore, MSC blocked 
the secretion of proinflammatory cytokines in activated lymphocyte cultures, a function that 
appeared to be regulated via an iNOS-independent mechanism.
Paper V
Mycoplasma contamination revisited: Mesenchymal stromal cells harboring 
Mycoplasma hyorhinis potently inhibit lymphocyte proliferation in vitro
Our investigation of the suppressive effects of MSC on activated lymphocytes was turned 
topsy-turvy by the unintended infection of primary rat marrow stromal cell lines with the 
common contaminant M. hyorhinis. Because we observed a pronounced inhibitory effect by 
both MSC and cell-free MSC-conditioned culture medium in mitogen-activated and mixed 
lymphocyte cultures, we became interested in mapping a putative effect of the infectious 
agent in this context. We ascertained that mycoplasma infection increased the suppression of 
both mitogenic and alloantigen-induced T cell proliferation in cocultures with MSC
dramatically. Also, cytokine production by T cells was altered in the presence of infected 
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MSC. Therefore, M. hyorhinis infection had a strong effect on T cell activation assays, 
highlighting the importance of controlling and monitoring cell cultures for this contaminant. 
Paper VI
Mesenchymal stromal cells fail to alleviate graft-versus-host disease in rats transplanted 
with major histocompatibility complex-mismatched bone marrow
MSC have immunomodulatory potential which can be exploited in the clinic, e.g. to inhibit 
undesirable auto- or alloimmunity by T cells in vivo. We wanted to test the hypothesis that rat 
BM-derived MSC have a beneficial, suppressive effect on T cell alloreactivity in
experimental GvHD, as has been shown both in animal models and in the clinical treatment 
of GvHD previously. We employed two different donor-recipient combinations of rat strains 
differing in the degree of genetic compatibility, with full major and minor H mismatch in one 
setup, and mismatch of the MHC class II and non-classical MHC class I subregions in the 
other setup. We applied an experimental protocol of three infusions of donor-syngeneic MSC 
doses starting at the time point of allogeneic donor lymphocyte transfusion and repeated in 
weekly intervals. This treatment showed a beneficial effect on acute GvHD in 3 out of 10 rats 
in the partially mismatched transplantation setting, however, improved overall survival was 
not statistically significant.
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General Discussion 
Animal HCT models
Minor H antigens contribute to the genesis of GvHD as HCT between HLA-identical siblings
less frequently result in GvHD compared to HLA-MUD [Welniak 2007]. The most severe 
forms of the disease are seen in recipients of HLA-non-identical transplants from 
haploidentical family or imperfectly HLA-MUD. Nevertheless, such transplantation scenarios
may have certain advantages with respect to the treatment of leukemias because of the 
presence of donor-versus-host-reactive NK cell populations which mediate beneficial GvL 
effects without GvHD [Velardi 2009]. Fully mismatched donors are not considered for 
transplantation, because even if the risk of rejection can be successfully managed, the risk of 
GvHD is exceedingly high. TCD of the graft lowers the risk of acquiring GvHD substantially. 
Potent conditioning regimens combined with high cell numbers in the graft are necessary in 
order to achieve stable long-term engraftment. 
Our group has developed rat BMT models to study the consequences of MHC disparity 
on engraftment, GvL effects and GvHR [Engh 2001; Nestvold 2008]. The experimental 
models we applied were based on a simulated transplantation scenario where, after myelo-
ablative radiotherapy and successful engraftment of high-dose, TCD BMT, an additional DLI 
is administered to counteract relapse of the malignant disease, but resulted in severe acute 
GvHD [Nestvold 2008]. The experimental protocol of allogeneic HCT with partial MHC-
mismatch [PVG.1U (RT1u) ;PVG.R23 (RT1r23)] between donor and host rat strains (Paper 
VI) was designed to resemble the clinical setting of HLA-mismatched BMT more closely than 
the fully mismatched [PVG.7B (RT1c) ;1RT1n)] model.
The HCT protocol described in depth in Paper I resulted in GvHD-typical symptoms
mainly confined to the skin and lymphoid organs, while the liver and gastrointestinal tract 
were not significantly affected. Thus, the results from this model are valid primarily with 
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respect to cutaneous GvHD, and interpretations regarding other GvHD target sites are more 
limited. Furthermore, we have established and included the in-vitro skin explant assay in our 
investigations (cf. Paper II and Paper III).
Laboratory animals give us the opportunity to do functional studies which are not 
ethical and not feasible in humans. Rodent strains are systematically bred, genetically 
homogeneous and biologically well characterized. This facilitates the study of effects of 
defined genes and gene regions, characterization of the physiological functions of proteins 
and mapping associations with observable pathological phenotypes. In addition, genetic 
engineering represents a viable scientific tool which has been historically restricted to the 
mouse and has of late become possible also in the rat [reviewed by Huang 2011].
Conditioning regimens vary in the extent of leukemia eradication and tissue damage 
between patients [Appelbaum 2010] and therefore, influence both the GvHD phenotype and 
the risk of relapse and consequently, have a substantial impact on transplantation outcome.
Patients usually undergo pretransplant chemotherapy which may or may not be combined 
with irradiation, whereas rodent models typically receive only irradiation before trans-
plantation [Schroeder and DiPersio 2011]. As a consequence, the initial stage of GvHD 
induction in experimental hosts may not be similar to patients.
Experimental animal models of HCT, such as those employed in our own studies, allow
the omission of immunosuppressive treatment with corticosteroids or other T cell-targeted 
pharmaceuticals to study GvHD de novo on the molecular and cellular level. This is an
advantage both in determining the individual contributions of selected cell populations and 
subpopulations and in dissecting the immunological interactions between donor and host 
biology. 
The fact that immune cell types show not only species-specific but also tissue-
dependent variations regarding phenotype, antigen expression, relative frequencies, stages and 
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kinetics of development, regulatory mechanisms, migratory properties, et c. in homeostasis as 
well as after transplantation, has important implications for the selection and design of appro-
priate experimental models. For instance, conventional experimental protocols of rodent HCT 
models apply a transfusion of BM cells supplemented with whole spleen or lymph node cell 
suspensions which contain the GvH-reactive donor T cell populations. In human recipients of 
HCT, on the other hand, GvHD is caused by passenger donor T lymphocytes from the 
marrow, peripheral or UCB graft.
Moreover, age, average lifespan, circadian cycles, microbiological environment 
(housing under specific pathogen-free conditions restricts the natural exposure to microbes 
and pathogens), spatial conditions and nutrition (limited motion and unlimited access to food
favor obesity) are only some of the factors which make up the plethora of biological varia-
tions between laboratory animals and human individuals and complicate the translation of 
research findings from small and large animal models to the human species.
Notwithstanding such considerations which apply to the use of animal models in 
general, the disease pathology that we observed both in rats which undergo experimental 
acute GvHD and in the rat skin explant model was very similar to the typical histopathology 
of cutaneous GvHD in patients (Paper II). The rat model seems to share the pathological 
phenotype of clinical GvHR of the skin and therefore, ought to be useful for translational 
studies. The concordance of the markers identified in gene expression profiling studies 
between human and rat samples (Paper III) is indicative of common underlying mechanisms 
in skin GvHD between these two species. 
Markers of GvHD
Biological markers which are unambiguously and robustly associated with GvHD could 
significantly improve the accuracy of diagnosis and influence the choice of treatment alter-
natives for allogeneic HCT patients. Gene association studies can be performed in human 
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volunteers to discover genetic determinants of GvHD, but are impeded by the non-random 
coupling (i.e. genetic linkage) of alleles on a given haplotype, resulting in the distribution of 
allele combinations which deviate from stochastic frequencies (the phenomenon is known as 
‘linkage disequilibrium’). Effect correlations with certain genetic loci can thus lead to the 
identification of false associations.
Gene expression profiling studies can be used to sidestep this methodological restric-
tion. The DNA microarray technique has the potential to discover novel gene associations, but 
depends on complementary methods to confirm the generated hypotheses. Ideally, such
findings should be confirmed by demonstrating the functional relevance of the gene 
association in question.
We identified a number of molecular and cellular markers associated with experimental 
acute GvHD and discussed their putative use in prospective disease diagnosis [Novota 2008; 
Novota 2011; Zinöcker 2011a]. L-Selectin (CD62L) is a cell adhesion molecule expressed on 
naïve T cells that enables their homing to SLT. TE cells gain access to peripheral tissues after 
losing this marker upon activation. CD62L= T cells did not induce GvHD in allogeneic hosts
[Anderson 2003]. The reduction in CD62L-expressing T cells associated with GvHD (Paper 
I) may be explained by activation-dependent downregulation of surface CD62L on allo-
reactive T cells and migration to peripheral sites of allostimulation and inflammation, e.g.
GvHD-affected skin.
TR cells also require L-Selectin to alleviate GvHD upon adoptive transfer [Taylor 2004; 
Ermann 2005] in order to inhibit the activation of alloreactive T cells in lymph nodes and 
spleen, i.e. at the site of allopriming. In accordance with other studies performed in 
experimental GvHD model systems as well as GvHD patient cohorts [Miura 2004; Zorn 2005; 
Rieger 2006; Matthews 2009], we identified a specific lack of TR cells in the PB. Again, this 
could be due to recruitment of these cells as part of the CD4+CD25hiCD62L+ T cell population
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from the blood, possibly to suppress T cell activation and expansion in SLT or other 
peripheral tissues. Alternatively, the reconstitution, expansion or induction of TR cells might 
be deficient in allotransplanted hosts.
NKT cells of the host can induce the expansion of donor TR cells and thereby protect 
against GvHD [Pillai 2009]. Donor NKT cells may also regulate GvHD [Zeng 1999; Pillai 
2007; Kohrt 2010]. In our experiments (Paper I and unpublished observations), donor 
NKT cells were reconstituted at negligible numbers in myeloablated recipients after 
allogeneic HCT. Host NKT cells were not present in the blood of transplanted rats suffering 
from GvHD. Peripheral TR cell frequencies may have been influenced by the lack of NKT 
cells of both donor and host origin, but we did not address this hypothesis experimentally.
In a report by Magenau et al., TR cell frequency in the PB of patients had prognostic
value in acute GvHD [Magenau 2010]. More recently, however, Waldmann and colleagues
have illustrated in a set of gene expression experiments the importance of using syngeneic 
controls in comparative animal models to confirm or exclude the validity of biomarkers 
unequivocally in the context of transplantation [Cobbold 2011]. Including syngeneic donors, 
i.e. identical twins, as control groups could also improve GvHD biomarker studies in patient 
cohorts. This finding may to some extent explain why the multitude of biomarkers implicated 
in preclinical models of various diseases rarely translates to clinically useful diagnostic tools.
Importantly, the study by Cobbold et al. also found that TR-associated genes were 
similarly expressed in both rejected and tolerated allogeneic skin grafts as well as syngeneic 
transplants [Cobbold 2011], thus arguing against the validity of TR cells as a cellular 
biomarker of transplantation tolerance.
For our biomarker studies of GvHD, we applied both healthy and syngeneic skin as 
controls for comparison with allogeneic skin explants (cf. Paper II and Paper III). Controls
receiving syngeneic donor cell transfusions may have strengthened the validity of cellular 
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markers discovered in allogeneic transplantation experiments (Paper I), and the lack of such a 
control group is a weakness of this study.
HSP of several gene families have the capacity to channel peptides into MHC:antigen 
presentation pathways [Srivastava 2002]. Due to their functional roles in antigen presentation 
and thereby, in the activation of T cells, HSP may be directly involved in the pathophysio-
logical processes of GvHD. Indeed, several studies support the role of HSP70 in GvHD (cf. 
subchapter III.5 of the Introduction). In line with previous findings that HSP70 genes were 
highly expressed in human allogeneic skin explants [Jarvis 2003], we found a close 
correlation of expression levels of stress-inducible HSP70-1 and HSP70-2 with increasing
grades of GvHR, presented in Paper II of this thesis. In line with these results, Olr1, a gene 
encoding for a HSP70:peptide complex-binding receptor on APC, was upregulated in both rat 
and human allogeneic skin explants (Paper III).
The MHC is the primary genetic determinant for the outcome of allogeneic HCT. This 
region contains genes that do not encode for MHC-I/-II molecules but may predispose for 
GvHD and thus, could be useful as diagnostic biomarkers (cf. subchapter III.6, p.26ff.). The 
NKC in the rat encodes receptor proteins that have proven or putative ability to bind MHC 
ligands and thereby, may inhibit or activate NK cell cytotoxic GvH and GvL effects after 
MHC-mismatched HCT (cf. subchapter III.9, p.36ff.). 
We designed a customized microarray chip which covered these two regions of the rat 
genome and included non-MHC/non-NKC genes for reference and data normalization. The 
oligonucleotide microarray contained specific probes for 224 MHC genes, 43 NKC genes as 
well as 6342 non-MHC/non-NKC genes (Paper III). Of these, 4.9 % MHC genes and 14.0 %
NKC genes were significantly regulated in GvHR, compared with 2.6 % of genes located 
outside these genomic regions. Thus, predictive genes were more frequent in the NKC and 
MHC than in the rest of the genome. A number of the GvHR-associated MHC genes that were 
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identified have known functions in the processing and presentation of antigen to T cells, are 
involved in cell signaling and cell adhesion or are related to apoptosis. Several classical (RT1-
A) and non-classical (RT1-CE/N/M) class I MHC genes were significantly upregulated and 
may function as ligands for Ly49 and other receptors expressed on NK cells [Naper 2002a; 
Naper 2002b; Naper 2005 and unpublished observations by our group]. Six of the NKC genes 
which were also upregulated in skin GvHR were inhibitory receptors of the Ly49 gene family. 
The majority of MHC and NKC gene associations were confirmed by quantitative real-
time PCR. We also showed an overall concordance of the gene expression patterns in the skin 
explant assay and skin biopsies of GvH-diseased rats. Exceptions were the genes encoding for 
the Ly49si1 and Ly49i9 receptors which were not completely consistent in skin GvHD
samples. Putative ligands of these receptors have not been isolated, and their exact functions 
are therefore not known. Moreover, the peripheral Ly49s3+ NK cell subset was associated
with GvHD development (Paper I), which could be due to receptor downregulation in the BN 
host, or alternatively, preferential recruitment from the circulation to other sites during GvHD. 
However, other NKR markers, including the DAR13 antibody which also binds Ly49s3,
tested on PB cells did not confirm this association. The microarray analysis showed no 
significant change in Ly49s3 expression in skin GvHR. The possible infiltration of NK cells 
in GvHD skin or regulation of NKR expression in vivo may not be authentically reflected in 
GvHR occurring in the simplified skin explant assay. Thus, it is not straightforward to 
interpret the findings regarding the expression of Ly49 receptors in rat skin GvHR and GvHD.
We validated the gene associations identified in rat skin explant assays also in human 
skin explants. This analysis revealed a high overall concordance with the human homologues
tested (e.g. TAP1, C2, AIF1, UBD, OLR1; these genes were upregulated both in human and 
rat skin explants) and indicates that GvHR are similarly regulated in humans and rats. For a 
number of these genes polymorphic human homologues exist (e.g. HLA-DMB, C2, AIF1,
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SPR1, OLR1) making them interesting candidates for predictive biomarkers in the clinical 
setting. These findings could potentially improve the prognostic value of grading GvHR in the 
skin explant or GvHD in patients for better prediction of transplantation outcomes in the 
future.
The expression profile of cutaneous GvHD has previously been assessed in a mouse 
model of minor H antigen-mismatched HCT [Sugerman 2004]. Several of the gene associ-
ations identified (e.g. upregulation of MHC-I genes, Tap1, Psmb8) overlapped and the general 
gene expression patterns compared well with our study in the rat. The significance of other 
genes with known involvement in GvHD pathological processes (e.g. TNF, IFNHSP70 
genes), however, was not confirmed by our experiments. The possibility that important 
candidate genes with true disease associations are missed by this type of study should be 
underlined here.
Recent studies compared the gene expression profiles of PB cells from patients with 
acute and chronic GvHD, respectively, to transplant recipients who did not develop GvHD 
[Buzzeo 2008; Poloni 2011]. They found that proinflammatory cytokines (e.g. 
superfamily genes) were upregulated in GvHD. Baron et al. tested whether the gene 
expression profile of PB T cells from the donor could predict the risk of acute and chronic 
GvHD prior to transplantation [Baron 2007]. They showed that gene expression patterns in 
donor T lymphocytes were relatively stable over time and were predictive of GvHD. The 
dangerous ‘strong alloresponder’ trait was under multigenic control. Therefore, the use of 
genetic signatures might help to select ‘low alloresponders’ as donors and allow tailoring of 
immunosuppressive regimens for HCT recipients who are at risk of GvHD or rejection [Baron 
2007].
Extending the numbers of genes used in diagnostic tests could lead to more specific and 
more sensitive prediction of GvHD incidence, onset and progression [Baron 2007; Paczesny 
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2009c]. Therefore, rather than relying on single biomarkers, the analysis of a composite set of 
disease-associated genes or global gene expression patterns of the recipient, the donor, or both
in combination, might result in clinically more relevant diagnostic tools in the future [Baron 
2007; Cobbold 2011].
MSC pathways of immunosuppression
MSC have an important role in the regulation of immune responses. They exert immuno-
suppressive effects on different cell types involved in the immune defense and employ 
several, possibly overlapping, pathways to facilitate this (cf. Introduction, subchapter IV.3). 
Observations that infusions of MSC dampened allo- and autoimmune reactions in vivo under 
clinical as well as experimental conditions [reviewed by Le Blanc and Pittenger 2005; Uccelli 
and Prockop 2010; Dazzi and Krampera 2011; Kebriaei and Robinson 2011; Tolar 2011]
substantiated these findings. It is worthwhile to further explore how these cells serve their 
physiological roles in the complex immune response network of different species.
We described a molecular pathway which was critical for the inhibitory properties of rat 
MSC. Mouse and rat MSC express iNOS, an enzyme which catalyzes the conversion of 
L-arginine to nitric oxide, in response to lymphokine activation signals and in turn, suppress 
lymphocyte stimulation with respect to cell proliferation and cytokine secretion [Oh 2007; 
Sato 2007; Ren 2008; Ren 2009; and Paper IV of this thesis] this inhibitory pathway with 
macrophages [Niedbala 2006]. However, the possibility that rat MSC suppress T cell 
proliferation through, e.g., heme oxygenase-1 [Chabannes 2007] and other molecular 
pathways should not be dismissed. Notably, human MSC utilize distinct inhibitory 
mechanisms, e.g. secretion of indoleamine 2,3-dioxygenase and prostaglandin E2, but not 
iNOS [Ren 2009], to suppress T cells.
Our own results suggest that even closely related species such as the mouse and rat may
display mechanistic divergence in the regulation of molecular targets (different cytokine 
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stimuli induced iNOS expression in mouse and rat MSC) that have the same function 
(suppression of T cell activation). 
MSC therapy
MSC transfusion as a therapy against acute and chronic GvHD has produced beneficial effects 
[Le Blanc 2004; Ringdén 2006; Le Blanc 2008; Weng 2010; Zhou 2010] especially in
patients with severe and rapidly progressing, steroid-resistant GvHD, although results from a 
recent randomized clinical trial raised doubts on the effectiveness of this treatment [Martin 
2010]. The study reported an improvement of intestinal and liver GvHD, but MSC therapy 
lacked efficiency in the cutaneous GvHD patient cohort [Martin 2010]. One may therefore 
speculate that MSC are more competent to attenuate hepatic and intestinal GvHD than 
cutaneous GvHD.
In our hands, repeated infusions of MSC did not rescue lethally irradiated, transplanted 
rats from severe acute GvHD following partially or fully MHC-mismatched DLI and death 
due to rapid wasting and weight loss (Paper V and Paper VI). MSC therapy applied in similar
preclinical animal models have produced conflicting results, with some protocols that cured 
GvHD successfully [Yanez 2006; Tisato 2007; Polchert 2008; Joo 2010] while other studies 
failed to show beneficial effects [Sudres 2006; Badillo 2008; Prigozhina 2008; Mielcarek 
2011].
Several factors may explain why MSC immunosuppression was not effective in HCT 
models. It is possible that GvH-reactivity after fully or partially MHC-mismatched allogeneic 
HCT and DLI was too strong to be controlled by MSC in vivo. MSC infusions may have 
beneficial effects in a less challenging allogeneic setting, e.g. in a model of minor H-mis-
matched HCT, or in haploidentical HCT where rat MAPC were recently shown to alleviate 
GvHD [Kovacsovics-Bankowski 2009].
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Furthermore, the source of MSC, optimal cell passage, transfusion dose, time points of 
intervention, as well as the route of administration (e.g. systemic, site-directed or local) may 
all be crucial factors in transplantation protocols [Wang 2011]. The lack of standardized 
culture conditions for the production of MSC ex vivo represents another parameter which may 
contribute to variations in outcome. The aforementioned aspects may require optimization 
depending on the type of underlying disease and other practical considerations for the future 
use of MSC as a potent therapy. 
SOURCE OF MSC. MSC are routinely isolated from BM aspirates for clinical administration, 
although a variety of fetal and adult tissue types have become more readily available as 
alternative sources (cf. Chapter IV). In our studies, we applied a protocol of in vitro cell 
adhesion and expansion to generate BM-derived MSC lines [Lennon and Caplan 2006].
Tissue-dependent variability regarding the in vivo efficacy of MSC immunosuppression is 
currently elusive.
TIMING AND DOSAGE OF MSC INFUSIONS. The timing and dosage of single or repeated MSC 
injections vary considerably between different studies, as standardized treatment protocols 
remain to be established. The MSC transfusion protocols applied in our own experiments
were designed to directly intervene at three main stages of GvHD development: prior to donor 
T cell activation (concurrent with the DLI); after the onset of donor T cell expansion and 
migration to peripheral sites of GvHR; and acutely during the late effector stage of GvHD.
IN VITRO CULTURE CONDITIONS. Changes in MSC biology induced through prolonged in 
vitro culture offers another explanation for lack of in vivo effectiveness. The possible 
influences of in vitro culture (e.g. culture medium composition, atmospheric constitution, 
plating density, number of passages, et c.) under artificial laboratory conditions are incom-
pletely understood. This obstacle is difficult to overcome methodologically, because
expansion of MSC ex vivo is a prerequisite to obtain sufficient cell numbers for therapeutic 
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use. It seems preferable to generate MSC under conditions resembling their natural niche as
closely as possible, however, this goal is hardly achievable at present even in complex three-
dimensional culture.
Bovine serum components (fetal calf serum is commonly used as a physiological source 
of growth factors) incorporated during in vitro culture can lead to immune reactions directed 
against serum-derived antigens in vivo [Horwitz 2002; Spees 2004] and bear the risk of 
transfer of infectious agents. Newer protocols substitute xenogenic serum with growth factors 
derived from human platelet lysate as a medium supplement for clinical grade MSC 
expansion [von Bonin 2008] to circumvent these problems. The possibility of immune 
recognition of transfused MSC in vivo following bovine serum-supplemented culture cannot 
be ruled out in our studies, even though we did not register T cell activation or proliferation 
responses to syngeneic or allogeneic MSC in vitro. Replacement of fetal bovine with rat 
serum might improve our culture protocols in order to exclude this possibility.
IMMUNOGENICITY OF MSC. Transfused MSC might be recognized and extinguished by the 
recipient’s immune system if the MSC donor is allogeneic to the host or the HSC donor. 
Large-scale production of HLA-disparate MSC for clinical application is nonetheless
desirable for reasons of convenience (e.g. long-term storage). Third-party MSC were safely 
applied in several clinical trials where these cells were equally effective as were HLA-
identical MSC [Ringdén 2006; Le Blanc 2008].
The topic of MSC immunogenicity is disputed (cf. Chapter IV). Early reports have 
shown that MSC express low levels of MHC-I molecules and lack MHC-II as well as co-
stimulatory molecules on the cell surface [Le Blanc 2003]. MSC evaded immune recognition 
even when MHC-I and -II expression was upregulated in an inflammatory milieu [Le Blanc 
and Pittenger 2005]. El Haddad et al. demonstrated that murine MSC employ specific serine 
protease inhibitors to evade host immune responses through inactivation of granzyme B by TC
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cells [El Haddad 2011]. Other studies have demonstrated, however, that allogeneic MSC were 
rejected by NK cells in vitro [Spaggiari 2006] and by T cells in vivo [Eliopoulos 2005; Nauta 
2006b].
Patients who suffer from GvHD are under immunosuppressive treatment, which makes 
the rejection of allogeneic cells less likely [Nauta 2006b]. In our BMT experiments, we tested 
donor-syngeneic (i.e. fully histocompatible with the donor graft) MSC in high intensity
radiation-conditioned recipient rats which showed rapid donor hematopoietic reconstitution 
and full donor chimerism, thereby minimizing the risk of allorejection in the host-versus-graft 
direction.
IN VIVO MIGRATION OF MSC. The route of administration may play a crucial role in MSC 
trafficking and homing to anatomical locations of ongoing GvHR. This may ultimately 
determine the effectiveness or failure of the treatment if colocalization is required for the 
efficient suppression of alloreactive immune cells [Sato 2007; Ren 2008]. Support for the 
importance of homing to the site of T cell priming in vivo came from a murine model showing 
a reduction of GvHD symptoms when MAPC were administered intrasplenically, but not after 
systemic injection [Highfill 2009].
Furthermore, Rombouts et al. showed that in vitro passage can negatively affect MSC 
homing ability to the BM and spleen in syngeneic hosts [Rombouts and Ploemacher 2003].
Failure to migrate to sites of GvHR may explain why repeated MSC injections did not cure
diseased rats in our models (Paper VI).
Trapping of MSC in the capillaries of visceral organs, e.g. lungs, liver and spleen, after 
systemic administration is known from animal studies [Sudres 2006; Schrepfer 2007]. We and 
others have found that transplanted animals are at risk of potentially fatal pulmonary 
embolisms after intravenous injection and aggregation of MSC in the lungs [Schrepfer 2007; 
Prigozhina 2008; Zinöcker 2011b]. In addition, we observed by in vivo imaging that 
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transgenic MSC expressing enhanced green fluorescence protein accumulated in large 
numbers in the lungs shortly (within minutes) after injection, but were detectable neither at 
this site nor in other organs after several days in vivo and post mortem (unpublished 
observations). We were unable to ascertain whether MSC migrate further after the initial 
aggregation in the pulmonary vasculature. It has been shown that MSC are indeed able to
migrate to sites of tissue injury after systemic injection in various animal experimental 
contexts [reviewed by Chamberlain 2007].
LICENSING OF MSC. Lately, it has been proposed that MSC require a ‘license’ to become 
fully competent immunosuppressor cells by activation through certain physiological signals 
[Dazzi and Krampera 2011]. Priming of MSC by incubation with IFN [Polchert 2008] or a 
TLR ligand [Waterman 2010] improved the inhibitory potential of mouse and human MSC 
both in vivo and in vitro. >IFN and the TLR4 agonist 
LPS induced iNOS expression and production of nitric oxide by rat MSC in vitro, resulting in 
potent inhibition of proliferation of stimulated T cells (cf. Paper IV).
Mycoplasma immune modulation
The vertebrate immune system has developed ways by which it is able to discover and fight 
infections, and microorganisms have likewise adapted to these strategies. The capacity of 
Mycoplasma ssp. to either suppress or stimulate immune functions [Razin 1998] is intriguing
and could, at least in part, explain how these bacteria are able to evade immune recognition.
In our hands, M. hyorhinis infection multiplied and spread quickly in lymphocyte 
cultures, starting at low numbers below the detection threshold of PCR to high titers (cf.
Paper V). Mycoplasma completely blocked the proliferation of T lymphocytes in the presence 
of potent mitogenic or allogeneic stimuli and caused increased cell death in infected cultures.
We made use of the intracellular fluorescent dye CFSE to confirm mycoplasma-
dependent inhibition of the lymphocyte stimulation assays. We could exclude the possibility 
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that M. hyorhinis degraded CFSE, in analogy to its ability to cleave thymidine substrates 
[Sinigaglia and Talmadge 1985; Merkenschlager 1988]: suppressed, non-proliferating 
lymphocytes that did not divide showed full CFSE fluorescence intensity in mycoplasma-
infected cell cultures in our assays.
It is theoretically conceivable that live, non-adherent mycoplasma were present in the 
transferred MSC solution, and that they infected and suppressed lymphocyte cultures 
independently of the cell vector. Experiments that could verify the presence of precisely one 
contaminated cell per well (possibly by radiolabeling of MSC prior to incubation or expansion 
of the cell clone following readout) might help to validate the observed ‘single cell’ effect.
Because mycoplasma infection potently suppressed allostimulated lymphocytes in vitro,
one might expect a strong immunosuppressive effect of infected MSC also in GvHD animals.
On the other hand, we do not know whether mycoplasma infection had the opposite effect in 
vivo and stimulated, rather than suppressed, alloreactive donor cells. We did not observe a 
beneficial effect of mycoplasma-infected MSC on GvHD mortality and morbidity in vivo 
(Paper V). Mycoplasma-free MSC were also ineffective as GvHD therapy in the same 
experimental setting (Paper VI). Thus, M. hyorhinis infection did not improve the inhibitory 
potency of MSC in vivo as we have seen in vitro. On the contrary, it is possible that intra-
cellular mycoplasma marked infected MSC for elimination and elicited an immune response 
in transplanted and immune reconstituted hosts.
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Conclusions
1. In a rat model of fully mismatched BMT [PVG.7B (RT1c) ; 1  RT1n)], acute GvHD 
symptoms were mainly confined to the skin and correlated with pathological findings. 
Also, the frequencies of TR cells and CD62L+ T cells in the PB were decreased in acute 
GvHD and thus could potentially serve as accessible diagnostic biomarkers.
2. Rat skin explants exhibited GvHR with similar histopathology as is known from human 
skin explants and was observed also in rat skin GvHD. The assay may be used comple-
mentary with the human skin explant assay as a model of skin GvHD to study disease-
related tissue pathology and underlying mechanisms of GvHR. Furthermore, the rat skin 
explant assay is an alternative to the use of live animals.
3. The degree of mismatch of MHC and non-MHC genes predicted the average grade of 
GvHR in rat skin explants. The rat skin explant assay was a valuable research tool for gene 
association studies and helped identify a number of genes that were differentially regulated 
in GvHR. Hspa1b and Hspa1a genes, respectively, encoding for HSP70-1 and HSP70-2 of 
the rat, were significantly upregulated in allogeneic rat skin explants and correlated with 
the grade of GvHR. A number of genes of the MHC and NKC were significantly up- or 
downregulated in allogeneic skin explants compared to both syngeneic skin explants and
healthy skin, and their expression patterns were in line with GvHD-affected rat skin. 
Comparative studies in human skin explants were largely in agreement with the observed 
expression patterns of homologous genes. In addition, a significant proportion of the non-
MHC/non-NKC genes tested was also differentially regulated. Therefore, gene expression 
profiling performed on rat skin explants identified putative biomarkers which may become 
useful for clinical GvHD diagnosis and prognosis.
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4. MSC lines generated from rat BM expressed iNOS in response to soluble inflammatory 
       $ 0- or alloantigen-activated lympho-
cytes. iNOS expression resulted in an increased output of nitric oxide and the efficient 
suppression of T cell proliferation in lymphocyte cocultures with MSC. Furthermore, MSC 
inhibited the expression of proinflammatory cytokines by lymphocytes in the presence of 
mitogen by an iNOS-independent mechanism.
5. MSC had potent immunosuppressive potential in vitro, but failed to alleviate acute GvHD 
after fully or partially MHC-mismatched experimental BMT.
6. M. hyorhinis rapidly infected lymphocyte cultures in vitro and efficiently blocked both 
mitogen- and alloantigen-induced T cell proliferation independently of its cell vector. Also, 
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 secretion.
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Abstract
Background: The major histocompatibility complex (MHC) is the most important genomic region that contributes to the
risk of graft versus host disease (GVHD) after haematopoietic stem cell transplantation. Matching of MHC class I and II genes
is essential for the success of transplantation. However, the MHC contains additional genes that also contribute to the risk of
developing acute GVHD. It is difficult to identify these genes by genetic association studies alone due to linkage
disequilibrium in this region. Therefore, we aimed to identify MHC genes and other genes involved in the pathophysiology
of GVHD by mRNA expression profiling.
Methodology/Principal Findings: To reduce the complexity of the task, we used genetically well-defined rat inbred strains
and a rat skin explant assay, an in-vitro-model of the graft versus host reaction (GVHR), to analyze the expression of MHC,
natural killer complex (NKC), and other genes in cutaneous GVHR. We observed a statistically significant and strong up or
down regulation of 11 MHC, 6 NKC, and 168 genes encoded in other genomic regions, i.e. 4.9%, 14.0%, and 2.6% of the
tested genes respectively. The regulation of 7 selected MHC and 3 NKC genes was confirmed by quantitative real-time PCR
and in independent skin explant assays. In addition, similar regulations of most of the selected genes were observed in
GVHD-affected skin lesions of transplanted rats and in human skin explant assays.
Conclusions/Significance: We identified rat and human MHC and NKC genes that are regulated during GVHR in skin explant
assays and could therefore serve as biomarkers for GVHD. Several of the respective human genes, including HLA-DMB, C2,
AIF1, SPR1, UBD, and OLR1, are polymorphic. These candidates may therefore contribute to the genetic risk of GVHD in
patients.
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Introduction
Haematopoietic stem cell transplantation (HSCT) is currently
the only potentially curative treatment for many malignant and
non-malignant haematological diseases. However, the overall
survival rate after transplantation is still only 40% to 60% due
to severe posttransplant complications [1], which include graft
versus host disease (GVHD), relapse, and infection. Human
leukocyte antigen (HLA) matching is essential to reduce the risk of
graft rejection and GVHD [2]. However, non-HLA genes also
impact on transplant outcome [3] and acute GVHD can be fatal
even in patients receiving transplants from HLA-identical matched
sibling donors (MSD). The cumulative incidence of grade II to IV
GVHD was 35% in a recent study evaluating 1960 MSD
transplants [4]. MSDs are currently available for about one third
of the patients and, therefore, alternative donors are needed.
HLA-matched unrelated donors (MUD) are more readily accepted
than cord blood or mismatched related donors.
The level of HLA matching used for selection of MUDs has
changed over time and usually includes now HLA-A, B, C, and
DRB1 loci (8/8 match). In some studies matching has been
extended to the HLA-DQB1 locus (10/10 match). A large recent
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study has compared MSD and 8/8 matched MUD transplants in a
homogenous cohort of patients with chronic myeloid leukemia and
found a 2.44 times higher risk of grade II to IV acute GVHD in 8/
8 matched MUD compared to MSD transplants [5]. In another
study, the incidence of grade II to IV acute GVHD was still higher
in 10/10 matched MUD compared to MSD transplants [6]. The
higher risk of GVHD after MUD compared to MSD transplants
could be due to a higher degree of similarity in non-HLA genes for
siblings, who share 50% of their genome with the respective
recipient. However, also the HLA region itself could contribute to
this difference since it harbors, in addition to the classical HLA
class I and II genes, more than 200 other genes [7], many with
immunological functions. In accordance with this hypothesis,
mismatching of microsatellite markers in HLA class I, class II, and
class III regions was associated with an increased risk of death in
10/10 matched MUD transplants [8]. The HLA complex, as is the
whole human genome, is organized into segments of closely linked
genetic variants that are inherited as haplotypes on the same DNA
strand [9]. HLA haplotypes can be defined by HLA class I and II
alleles and they are in strong linkage disequilibrium with defined
genetic variants of non-class I/non-class II genes within the
haplotype blocks within this region [10,11]. However, a given
HLA allele can occur in the context of different HLA haplotypes
in MUDs. Interestingly, HLA haplotype mismatching in 10/10
matched MUD transplants was associated with an increased risk of
severe acute GVHD [12]. This finding demonstrates that the HLA
complex encodes in addition to HLA-A, B, C, DRB1, and DQB1
further unidentified genes that contribute significantly to the risk of
developing acute GVHD. In case of disparity between donor and
recipient alleles these genes may function as minor histocompat-
ibility antigens. Alternatively, specific allelic variants may also
increase the risk of GVHD, e.g., TNFA, a gene located within the
class III region of the MHC encoding the pro-inflammatory
cytokine tumor necrosis factor alpha (TNF-a.) Several TNFA
polymorphisms have been associated with an increased risk of
GVHD and some of them are associated with increased TNF-a
levels [13]. The strong linkage disequilibrium within the HLA
complex makes it very difficult to identify further non-class I/non-
class II HLA genes involved in the pathophysiology of GVHD by
genetic association studies alone.
HLA gene expression profiling may be an alternative strategy to
identify HLA genes that are involved in the pathophysiology of
GVHD. We assumed that at least some non-class I/non-class II
HLA genes that contribute to the risk of GVHD change their
expression levels during disease progression. However, the genetic
variation between clinical samples complicates the situation
because allelic variation of gene expression could interfere with
expression change in the pathophysiological process. Therefore,
we decided to analyze a rat model of GVHD making use of
genetically well-defined inbred strains. Importantly, the non-class
I/non-class II genes of human (HLA) and rat (RT1) MHCs are
highly conserved [14,15,16]. However, the size and organization
of MHC class I encoding regions are considerably variable and the
rat possesses a significant number of MHC class Ib genes for which
no human homologues exist [15]. At least some of these genes
have already been proven to encode ligands for inhibitory or
activating natural killer (NK) receptors [17,18]. In the rat, in
contrast to human, NK receptors of the Ly49 killer cell lectin-like
receptor type predominate over killer cell Ig-like receptor genes
[19]. Therefore, we also included the natural killer complex
(NKC) in the expression profiling which harbors the Ly49 genes
and additional natural cytotoxicity receptor genes.
To reduce the complexity of the experimental approach, we
used an in-vitro-model of the graft versus host reaction (GVHR) –
the skin explant assay. This assay has been shown to be a sensitive
predictor of GVHD in patients [20]. It was also used to study the
pathophysiology of GVHR [21]. Recently, we developed a rat skin
explant assay [22]. This standardized in-vitro-model allows the
study of gene expression during GVHR in a setting that is not
influenced by undefined genetic differences between tissue samples
which is unavoidable in human studies. In the present study we
used this model to analyze the MHC and NKC gene expression
profiles of GVHR.
Results
GVHR in rat skin explant assays
To obtain skin explant samples for an expression profiling
experiment, we used BN rats (RT1n) as recipients and PVG rats
(RT1c) as donors. This combination is mismatched for minor and
major histocompatibility antigens, which gives rise to GVHR
grades I to IV [22]. PVG splenocytes were stimulated for 7 days in
a mixed lymphocyte reaction (MLR) with irradiated BN
splenocytes. Syngeneic co-cultures (BN plus irradiated BN
splenocytes) were performed as control experiments. The
stimulation index indicated a specific proliferation of PVG
lymphocytes in response to irradiated BN lymphocytes in contrast
to syngeneic cultures of BN lymphocytes (p,0.0001, U test; n = 12
responder animals per strain, data not shown). After 7 days the
PVG and BN lymphocytes were harvested, added to fresh BN skin
samples from 12 individual animals and cultured for 3 further
days. For further controls, additional BN skin samples from the
same animals were cultured in medium only. On day 3 the skin
samples were harvested and snap frozen for RNA preparation.
Parallel samples were fixed and assayed for histological evidence of
GVHR (Fig. 1). Co-culture of BN skin explants with pre-
stimulated allogeneic PVG lymphocytes resulted in higher grade
GVHR than co-culture with BN lymphocytes (p = 0.0336; U test).
As in a previous experimental series [22], the syngeneic
lymphocyte co-culture more frequently resulted in GVHR-like
pathology of grade II or higher than culture of the skin explants in
medium only.
Figure 1. Induction of a GVHR in BN rat skin explants exposed
to PVG lymphocytes. A summary of the histological GVHR grading of
BN skin samples cultured in medium alone, together with syngeneic BN
lymphocytes, and together with pre-stimulated allogeneic PVG
lymphocytes (n = 12 in each group) is given. The samples represented
by closed circles were used for both gene expression profiling and qRT-
PCR experiments, whereas the other samples were only used for gene
expression profiling. The pair-wise comparison (U test) indicated a
significant difference between skin explant cultures with BN and PVG
lymphocytes.
doi:10.1371/journal.pone.0016582.g001
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Expression profiling of GVHR in rat skin explants
RNA was prepared from the 24 BN skin explants exposed either
to syngeneic (BN; n= 12) or to allogeneic (PVG, n= 12)
lymphocytes and used for MHC gene expression profiling. We
designed a custom microarray which contained specific probes for
the 224 MHC genes. For this purpose the annotated sequence of
the MHC of the BN strain was used [16]. For 88 of these genes,
i.e. 39.3%, we had to design custom probes. A list of the MHC
genes in the chromosomal order with all results obtained in the
expression profiling experiment is given in the Table S1a. For 42
of the 224 MHC genes, a probe on the array indicated a
significant regulation (p,0.05) in the allogeneic skin explant assays
(n = 12) compared to the syngeneic controls (n = 12) (Table S1b).
Eleven of these MHC genes showed on average at least a 2-fold
up-regulation (log2-fold change $1) or 50% reduction (log2-fold
change #21) of mRNA levels (Fig. 2A, Table S1c). This
amplitude of change is conventionally considered to be biologically
relevant. Of these genes one was down-regulated (Ly6g6e) while 10
were up-regulated (Fig. 2A). Fourteen further MHC genes were
regulated significantly (p,0.05) but with smaller amplitude
(Table S1c). The regulation of 17 MHC genes appeared to be
more doubtful because less than 50% of the probes for that gene
indicated a significant regulation. Thus, we considered 25 MHC
genes to be significantly regulated in the expression profiling
Figure 2. Expression profiling of BN skin explant samples exposed to allogeneic (PVG) lymphocytes in comparison to those
exposed to syngeneic (BN) lymphocytes. (A) The log2-fold changes in gene expression of significantly regulated MHC genes (p,0.05) are
shown. (B) The log2-fold changes in gene expression of significantly regulated NKC genes (p,0.05) are shown. (C) The log2-fold changes in gene
expression of 168 significantly (p,0.05) and strongly (log2-fold change $1 or #21) regulated non-MHC and non-NKC genes indicate the range of
observed alterations in gene expression levels among the 6342 tested genes. In panels A and B, black bars indicate a strong change (log2-fold change
$1 or #21), dotted bars alterations below this amplitude, and white bars expression changes that were not detected at a significant level with all,
but at least with 50% of the probes present on the array for that gene. When more than one probe indicated a significant change of gene expression
the means and standard deviations of the log2-fold changes are shown (see Tables S1, S2, and S3 for further details).
doi:10.1371/journal.pone.0016582.g002
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experiment (Fig. 2A). These included the classical class Ia genes
RT1-A1 and RT1-A2, 8 non-classical class Ib genes (RT1-CE2,
RT1-CE3, RT1-CE5, RT1-CE8, RT1-CE10, RT1-CE16, RT1-
T24-4, RT-BM1) and 3 genes involved in antigen presentation
(RT1-DMb, Tap1, Psmb8).
Furthermore, 43 genes of the NKC region, as a second
important immune gene cluster, were represented on the array
including all Ly49 genes in this region (Table S2a). For 8 of the 43
NKC genes represented on the array, a probe indicated a
significant regulation (p,0.05) in the allogeneic skin explant assays
compared to the syngeneic controls (Table S2b, S2c). In addition
to the Olr1 gene, 6 Ly49 genes appeared to be up-regulated in the
allogeneic skin explant assays (Fig. 2B). Not all probes for the
Ly49i3 gene indicated a significant up-regulation. However, all
significant results for this gene indicated a strong regulation (log2-
fold change .2). A statistically significant (p,0.05) but only
moderate up-regulation (log2-fold change,1) was detected for the
Ly49i7 gene.
Probes for 6342 additional genes from all chromosomes were
included mainly to allow for data normalization. For 168 of the non-
MHC/non-NKC genes, a probe on the array indicated a significant
(p,0.05) and strong (log2-fold change $1 or #21) regulation in
the allogeneic skin explant assays compared to the syngeneic
controls (Fig. 3C, Table S3). The 20 genes showing the strongest
change in expression levels are shown inTable 1. All 20 genes were
up-regulated and they included several genes with functions clearly
associated with the immune response such as genes encoding
chemokines (Ccl9, Ccl6), Fc receptors (Fcgr3a, Fcgr2b), the proteases
cathepsin S (Ctss) and granzyme C (Gzmc), and the inflammatory
triggering receptor on myeloid cells 2 (Trem2).
The percentage of significantly (p,0.05) and strongly (log2-fold
change $1 or #21) up- or down-regulated genes was higher in
the NKC region (14.0%) compared to MHC region (4.9%) and
the genes encoded in other regions of the genome (2.6%). This
difference was even more pronounced for up-regulated genes.
14.0% of the NKC, but only 4.5% of the MHC and 1.5% of the
other genes were up-regulated (Table 2).
For a general analysis of the gene expression data the PANTHER
system [23] was used. With this tool we found a significant up-
regulation of genes taking part in ‘‘immunity and defence’’
(p,0.0001, binominal test). More specifically, genes involved in
‘‘T cell-mediated immunity’’ (p,0.0001), ‘‘NK cell-mediated
immunity’’ (p,0.0001), ‘‘cytokine and chemokine-mediated signal-
ing’’ (p= 0.0032), and ‘‘B cell and antibody-mediated immunity’’
(p= 0.0235) were up-regulated. Genes involved in ‘‘complement-
mediated immunity’’ (p= 0.0336) and ‘‘cell adhesion‘‘ (p= 0.0003)
were down-regulated (data not shown).
Confirmation of microarray results by quantitative real-
time polymerase chain reaction (qRT-PCR)
To determine the reliability of the microarray results, we
analyzed the expression of 13 selected genes from the MHC and
NKC regions by qRT-PCR experiments in 8 of the sample pairs
that had been used for the microarrays (see Fig. 1). For 12 genes
the regulation that was observed in the microarray experiment was
confirmed by qRT-PCR as indicated by a regulation into the same
direction when the allogeneic and syngeneic skin explant assays
were compared using the DD cycle threshold (ct) method for
relative quantification of gene expression (Fig. 3). Only one gene,
RT1-CE10, was found to be strongly up-regulated in allogeneic
skin explants in the microarray experiment but slightly down-
regulated in qRT-PCR. In the qRT-PCR experiments, we also
included parallel skin explants that were cultured in medium only.
Eight genes (RT1-DMb, Aif1, Lst1, RT1-CE3, Ubd, Olr1, Ly49si1,
Figure 3. Verification of the regulation in gene expression observed in the microarray experiment by qRT-PCR. A subgroup of 8
samples used for the microarray experiment (see Fig. 1) was analyzed by qRT-PCR for the expression of 10 MHC and 3 NKC genes. The DDct value
was calculated, i.e. the Dct (Gapdh – gene of interest) of the allogeneic skin explant samples minus Dct (Gapdh – gene of interest) of the
corresponding control sample. The control sample was either a parallel skin explant exposed to syngeneic lymphocytes as in the microarray
experiment (syngeneic control, black bars) or a parallel skin explant sample cultured in medium only (medium control, white bars). The means of the
DDct values plus standard errors of the mean (SEM) are shown. A positive value indicates an up-regulation of gene expression in the allogeneic
samples.
doi:10.1371/journal.pone.0016582.g003
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and Ly49i9) showed an up-regulation in the allogeneic skin explant
assay also in this comparison (Fig. 3). Six of these genes (Aif1, Lst1,
Ubd, Olr1, Ly49si1, and Ly49i9) were clearly found to be up-
regulated in both comparisons.
The up-regulation of genes in skin explants could be due to the
change of gene expression in cells of the skin or due to infiltration of
donor lymphocytes. Non-infiltrating or non-attaching donor
lymphocytes were washed off before freezing of the skin explants
and therefore would not contribute significantly to the results.
Infiltrating lymphocytes were rarely seen in skin explants by
histological analysis (data not shown). To further determine T cell
infiltration at the RNA level, we analyzed the expression of the CD3
zeta chain in qRT-PCR. Cd3z expression was found to be up-
regulated in comparison to syngeneic controls and medium controls
(Fig. 4A). The expression of most tested genes showed no
correlation with Cd3z mRNA levels (Fig. 4B). Only two of the
genes analyzed in qRT-PCR (Ly6g6e and Olr1) showed a moderately
positive correlation (r.0.50) with the Cd3z expression level
(Fig. 4B). Importantly, Ly6g6e was down- and not up-regulated in
allogeneic skin explants. The expression levels of three up-regulated
genes (Psmb8, Aif1, and Lst1) were even negatively associated with
Cd3z expression (Fig. 4B). Thus, of the tested genes only the
increase of Olr1 expression may be formally explained by infiltrating
T cells. However, Olr1 has not been described to be expressed in T
cells. Therefore, infiltration of skin explants with T cells is unlikely to
explain the observed gene expression changes.
Analysis of microarray results by qRT-PCR in independent
skin explant samples
Next we determined the expression of 10 selected genes in an
independent set of skin explant assays. Skin explants derived from BN
(RT1n) and LEW.1N (RT1n) rats were co-cultured with pre-stimulated
allogeneic lymphocytes from rats with minor (BN lymphocytes and
LEW.1N skin), major (LEW.1A [RT1a] or LEW.1AV1 [RT1av1]
lymphocytes and LEW.1N skin), or minor and major histoincompat-
ibility (PVG lymphocytes [RT1c] and BN skin or LOU/C [RT1u]
lymphocytes and LEW.1N skin). Skin samples cultured with syngeneic
lymphocytes (BN or LEW.1N) or cultured in medium only served as
controls. The GVHR grading obtained in these experiments is shown
in Figure 5. The general regulation of the selected genes during
GVHR was reproduced in this second experimental set when
compared to skin explants exposed to syngeneic lymphocytes and also
to samples cultured in medium only (Fig. 6). Aif1 and Lst1 were the
most consistently up-regulated genes in skin explants with minor,
major, and minor plus major histoincompatibility. The samples with
minor plus major histoincompatibility showed the highest variation in
gene regulation (Fig. 6). However, these samples were also most
heterogeneous in the GVHR grading (Fig. 5). Therefore, we analyzed
Table 1. The 20 most strongly regulated non-MHC/non-NKC genes in allogeneic skin explants compared to syngeneic controls as
revealed by the microarray experiment.
gene log2-fold change adjusted p-value gene description
LOC685020 8.18 0.0100 paired immunoglobin-like type 2 receptor alpha
Ptpns1l3 6.36 0.0100 protein tyrosine phosphatase, non-receptor type substrate 1-like 3
Fcgr3a 5.24 0.0100 Fc fragment of IgG, low affinity IIIa, receptor
Nat8 5.14 0.0100 Rattus norvegicus endogenous retrovirus mRNA, partial sequence [AY212271]
Ccl9 4.16 0.0100 chemokine (C-C motif) ligand 9
XM_226926 3.92 0.0149 Rattus norvegicus similar to protein tyrosine phosphatase, non-receptor type
substrate; brain immunological-like with tyrosine-based motifs (LOC310212)
Hck 3.87 0.0100 hemopoietic cell kinase
Trem2 3.78 0.0100 triggering receptor expressed on myeloid cells 2
Ccl6 3.71 0.0100 Rattus norvegicus chemokine (C-C motif) ligand 6
Cd36 3.57 0.0100 CD36 antigen
Igf1 3.23 0.0100 insulin-like growth factor 1
Ctss 3.15 0.0100 cathepsin S
Gzmc 3.11 0.0373 granzyme C
LOC100048479 2.97 0.0373 one cut domain, family member 1
Plscr1 2.83 0.0100 phospholipid scramblase 1
Nfe2 2.74 0.0149 nuclear factor, erythroid derived 2
Prg4 2.74 0.0149 proteoglycan 4
Spic 2.68 0.0278 Spi-C transcription factor
Fcgr2b 2.62 0.0100 Fc receptor, IgG, low affinity IIb
LOC498277 2.61 0.0100 similar to Low affinity immunoglobulin gamma Fc region receptor III precursor
doi:10.1371/journal.pone.0016582.t001
Table 2. Proportion of regulated genes as indicated by the
gene expression profiling experiment.
region
analyzed
genes regulated1 up-regulated
down-
regulated
MHC 224 11 (4.9%) 10 (4.5%) 1 (0.4%)
NKC 43 6 (14.0%) 6 (14.0%) 0 (0%)
others 6342 168 (2.6%) 93 (1.5%) 75 (1.2%)
1Only those genes that were both significantly (p,0.05) and strongly (log2-fold
change $1 or #21) regulated were taken into account for this comparison.
doi:10.1371/journal.pone.0016582.t002
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the gene regulation dependent from the GVHR grading in samples
from both experimental sets.
Regulation of selected MHC and NKC genes during GVHR
The expression of 7 MHC and 3 NKC genes was evaluated in
the skin explant samples showing grade I, II, III or IV GVHR
(Fig. 7). To provide an even more accurate comparison of the
different genes in this evaluation of the data, the relative changes
of gene expression levels were calculated using a mathematical
model for relative quantification of real-time PCR data which
takes into account variations in the amplification efficiencies of
different primer pairs [24]. When compared to skin explants
exposed to syngeneic lymphocytes or to medium controls, the
genes Aif1, Lst1, Olr1, and Ly49i9 were consistently up-regulated.
Ly6g6e was down-regulated in some but not all comparisons. The
expression of Aif1, Lst1 and Ly49i9 was found to be increased in all
GVHR grades. The extremely high up-regulation of Ly49i9
encoding an NK receptor in comparison to medium controls
might be explained by complete absence of NK cells in normal
skin biopsies and infiltration of few NK cells during GVHR. When
the gene expression was compared to freshly frozen healthy skin,
the principal findings were confirmed. Interestingly, Olr1 was up-
regulated mainly in grade II and III GVHR samples when
compared to syngeneic control skin explants and healthy skin.
Thus, this gene could be a marker of intermediate grade GVHR.
Regulation of selected MHC and NKC genes during GVHD
Next, we wanted to know whether the genes found to be
differentially expressed in GVHR in skin explant assays were also
regulated in vivo in GVHD. For this purpose we analyzed skin
samples from BN rats that were transplanted with bone marrow
from PVG rats and developed acute GVHD. The analyzed skin
samples showed in histology a grade I or grade II GVHD. The
results of qRT-PCR for 7 MHC genes and 3 NKC genes are
shown in Figure 8. The strongest up-regulation in GVHD-
affected skin was observed for RT1-DMb, Aif1, Lst1, and Olr1.
Thus, most genes that were found to be regulated in GVHR in
skin explants were also regulated in GVHD-affected skin.
However, the Ly49si1 gene that was up-regulated consistently in
allogeneic skin explants showing GVHR of grade II and above
appeared to be down-regulated in GVHD. Compared to the skin
explant samples, also the Ly49i9 gene was only moderately up-
regulated in grade II GVHD samples from transplanted rats.
Regulation of selected MHC and NKC genes during GVHR
in human skin explant assays
Finally, we explored the regulation of the identified genes
during GVHR in human skin explant assays. We determined the
expression of those genes for which human homologues exist. At 1,
2 and 3 days of co-culture with alloreactive lymphocytes skin
samples of one donor were taken and analyzed in comparison to
parallel samples cultured in medium only. At day 1 a GVHR of
grade I was observed that increased to grade II at day 2 and grade
III at day 3. We determined the expression of 15 MHC and 1
NKC gene by qRT-PCR (Table 3). Of these 16 genes 12 (75%)
were regulated at least in one skin explant sample in the way
predicted by the results of the rat expression profiling experiments
(Table 4). Three genes TAP1, PSMB8, and UBD were up-
regulated in all 3 human skin explant samples. The genes C2,
FLI13158, and OLR1 were regulated in 2 of the 3 samples as
predicted by the rat experiments. In addition, we determined the
expression of 153 non-MHC/non-NCR genes that were identified
to be regulated in rat skin explant assays. Also of these genes 105
(69%) were regulated in at least one of the human skin explant
samples in accordance with the results obtained in the rat model
(Table 4). These results suggest that the rat model of the skin
explant assay can reliably predict gene expression changes that
occur also in human skin explant assays during GVHR.
Discussion
We aimed to identify genes that are regulated during GVHR in
the skin explant assay because these genes could be involved in the
pathophysiology of GVHR and contribute to the genetic risk of
GVHD. Special attention was given to genes encoded within the
MHC region for the following reasons: Firstly, evidence has been
presented that further risk genes for GVHD in addition to MHC
class I and class II genes are present in this region [12]. Secondly,
those genes cannot easily be identified by genetic linkage analysis
alone due to the strong linkage disequilibrium with MHC class I
and class II genes so that expression profiling could be a
worthwhile alternative approach. Thirdly, we wanted to focus in
this initial study on a fully characterized genomic region of special
immunological importance rather than to follow a whole genome
expression profiling approach. Importantly, 39% of the BN rat
MHC genes (RT1n haplotype) annotated by Hurt and colleagues
[16] were at the time point of array construction not represented
Figure 4. Analysis of T cell infiltration in skin explants. (A) Analysis of Cd3z gene expression in the same samples as shown in Fig. 3. (B)
Correlation of Cd3z and other gene expression levels (DDct values for allogeneic skin explants minus syngeneic controls) in these samples. Pearson’s
correlation coefficients (r) and the p-values for the corresponding tests are given above the diagrams. In brackets Spearman’s correlation coefficients
(r) and the p-values for the corresponding tests are shown.
doi:10.1371/journal.pone.0016582.g004
Figure 5. Induction of a GVHR in a second series of BN (filled
circles) and LEW.1N (open circles) rat skin explants. Skin explants
were co-cultured with pre-stimulated allogeneic lymphocytes from rats
with a minor (BN lymphocytes and LEW.1N skin), major (LEW.1A (RT1a)
or LEW.1AV1 (RT1av1) lymphocytes and LEW.1N skin), or a minor and
major histoincompatibility (PVG lymphocytes (RT1c) and BN skin or
LOU/C (RT1u) lymphocytes and LEW.1N skin). A summary of the
histological GVHR grading of skin samples cultured in medium alone,
together with syngeneic BN or LEW.1N lymphocytes, and together with
allogeneic lymphocytes is given.
doi:10.1371/journal.pone.0016582.g005
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Figure 6. Verification of gene regulations observed in the microarray experiment by qRT-PCR in an independent set of 17 skin
explant assays. Three samples were derived from skin explant assays with minor (upper panel), 5 with major (middle panel), and 9 with minor and
major histoincompatibility (lower panel). The GVHR grading for these samples is shown in Fig. 5. The expression of 7 MHC and 3 NKC was analyzed
by qRT-PCR. The DDct value, i.e. Dct (Gapdh – gene of interest) of the allogeneic skin explant samples minus mean of Dct (Gapdh – gene of interest) of
MHC Genes and Risk of Graft versus Host Disease
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in the Agilent database and therefore not represented on the
Agilent whole rat genome array. In addition to the MHC region,
genes of the NKC region were included because this region
encodes Ly49 genes and their products can function as receptors
for the numerous MHC class Ia and Ib gene products encoded in
the MHC [17].
A higher percentage of MHC genes and NKC genes than genes
in other regions of the genome were found to be regulated in the
allogeneic skin explants compared to skin samples co-cultured with
syngeneic lymphocytes. Of the 25 MHC genes found to be
significantly regulated (p,0.05), 5 are known to be involved in
antigen processing and presentation. Besides two of three MHC
class Ia genes in the BN strain (RT1-A1 and RT1-A2) that present
peptides to cytotoxic T lymphocytes (CTL), the genes Tap1 and
Psmb8, encoding a subunit of the antigen transporter and a subunit
of the immunoproteasome (also known as LMP7), were found to
be up-regulated. RT1-DMb encodes a homologue of HLA-DMB, a
chaperone in the MHC class II presentation pathway. Further-
more, non-classical MHC class Ib genes (RT1-CE2, RT1-CE3,
RT1-CE5, RT1-CE8, RT1-CE10, RT1-CE16, RT1-T24-4, RT-
BM1) were up-regulated during GVHR in the skin explants. The
function of the RT1-C/E/M class I genes is not well defined. It is
known that they can become targets of CTL [25] and function as
ligands for activating or inhibitory NK receptors [17,18]. RT1-C/
E/M incompatibility has been shown to induce skin and pancreas
graft rejection [26] and to modulate the fate of MHC class II-
mismatched heart grafts [27]. The RT1-T24-4 gene belongs to a
family of genes that was originally identified as pseudogenes in the
haplotype r21 [28]. In the RT1n haplotype all four family members
are presumably functional [16]. However, their actual function has
not been experimentally demonstrated so far. The RT-BM1 (RT1-
S3) gene is assumed to be orthologous to the mouse H2-T23 gene
[29,30], which encodes the Qa-1 molecule. This is a functional
homologue of HLA-E, which presents leader peptides of MHC
class I molecules to the inhibitory NK receptor CD94/NKG2A
[31]. Interestingly, its expression can vary substantially depending
on the RT1 haplotype [14]. It has to be noticed that no human/
rat orthology can be established for the class I genes in the various
class I clusters. Therefore, with respect to class I genes, the rat
cannot serve as a model for the HLA complex. However, the non-
class I genes are clearly orthologous [15,16].
In addition to Tap1, Psmb8, and RT1-DMb, 12 further non-class
I MHC genes were found to be regulated in the rat skin explant
assays, some of them also involved in the immune response, such
as the complement component C2, while such a role is strongly
assumed for other genes. The allograft inflammatory factor 1
(Aif1), was cloned from chronically rejecting rat cardiac allografts
[32] and it was also found in transplanted human hearts [33].
Persistent expression of AIF-1 is associated with the development
of a cardiac allograft vasculopathy [34]. The expression of AIF-1 is
mostly limited to the monocyte/macrophage lineage, and can be
augmented by interferon (IFN)-c. The specific function of the
leukocyte specific transcript 1 (Lst1) gene is not known, although its
strong expression in dendritic cells and functional data suggest an
immunomodulatory role [35]. The expression of human LST1,
specifically of splice variants encoding soluble isoforms, was
increased in rheumatoid arthritis-affected blood and synovium and
was up-regulated in response to IFN-c [36]. The immediate early
response 3 (Ier3) gene is stress-inducible and is involved in the
regulation of cell death and oncogenesis [37]. The protein (also
known as IEX-1 or IEX-1L) functions in the protection of cells
from Fas or TNF-a-induced apoptosis [38]. However, it increases
the rate of apoptosis in ultraviolet B irradiated keratinocytes [39].
Distinct domains of the proteins were described to be responsible
for pro and anti-apoptotic activities of the protein [40]. The
diubiquitin gene (Ubd) has been shown to be expressed in rat
lymphoblasts, thymus, and testis [41]. In the mouse it is expressed
in dendritic cells and B cells, is inducible by IFN-c, and can cause
apoptosis [42]. The protein (also known as FAT10) provides an
ubiquitin-independent signal for proteasomal degradation [43]. It
has been suggested to participate in antigen processing [44], but its
expression did not affect MHC class I expression or antigen
presentation [42]. In view of the reported roles of these genes in
the immune response, a direct involvement in GVHD is
conceivable.
For the other regulated MHC genes an involvement in immune
functions has not been established so far. Spr1 (or Psors1c2) is the
psoriasis susceptibility 1 candidate 2 gene and was found to be
expressed in the thymus of rats [41]. Its human homologue is
expressed in normal and psoriatic skin and has been suggested to
confer susceptibility to psoriasis [45]. The function of the gene
product is not known so far. G18 (Gpsm3) is an activator of G-
protein signaling [46]. Pbx2 encodes an ubiquitously expressed
transcriptional activator [47]. The Ly6g6e gene belongs to the
lymphocyte antigen 6 (Ly-6) superfamily that encodes proteins
attached to the cell surface by a glycosylphosphatidylinositol (GPI)
anchor that is directly involved in signal transduction [48]. Mouse
Ly6g6e was found to be highly expressed at the leading edges of
cells, on filopodia, which are normally involved in cell adhesion
and migration [49]. The mitochondrial ribosomal protein S18B
(Mrsps18b) gene encodes a 28S subunit protein that belongs to the
ribosomal protein S18P family. The functions of the HLA-B
associated transcript 5 (Bat5) and Fij13158 (or RGD1303066) genes
have not been characterized so far. Some MHC genes, such as Tnf
encoding the tumor necrosis factor alpha or the heat shock protein
70 genes Hspa1b and Hspa1a, which were expected to be up-
regulated [22,50], were actually not found to be significantly
regulated in the rat skin explants. Thus, it is possible that some
MHC genes that can be regulated during GVHR were not
identified in our microarray experiments.
Many of the up-regulated MHC genes are inducible by IFN-c a
type II cytokine that is primarily secreted by activated T and NK
cells. Several studies have demonstrated an increased level of IFN-
c in the early phase of GVHD [51,52]. Therefore, this cytokine
might be highly important for the regulation of the expression of
MHC genes during GVHR.
We also included the NKC region in the expression profiling
which harbors the Ly49 genes that encode NK receptors of the
killer cell lectin-like receptor type [19] and some of these have
been shown to interact with both MHC class Ia and Ib molecules
[17,18]. In contrast to the MHC region, no reference sequence has
been published for the NKC region of the rat. Therefore, 20 genes
that were recently assigned to this region in the assembly RGSC
v3.4 [53] were not represented on the array. However, for most of
them no function associated with the immune system has been
reported. Interestingly, only Ly49 receptor genes which have an
the corresponding control samples (BN or LEW.1N, respectively), was calculated. The control samples were either skin explant samples exposed to
syngeneic lymphocytes (syngeneic control) or skin explant samples cultured in medium only without added lymphocytes (medium control) and their
GVHR grading is also shown in Fig. 5. The means of the DDct values plus SEM are shown. A positive value indicates an up-regulation of gene
expression in the allogeneic samples.
doi:10.1371/journal.pone.0016582.g006
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Figure 7. Analysis of MHC and NKC gene regulation in skin explants exposed to pre-stimulated allogeneic lymphocytes depending
on GVHR grading. The expression of 7 MHC and 3 NKC was analyzed by qRT-PCR. The relative changes of gene expression levels were calculated
using a mathematical model for relative quantification of real-time PCR data which also takes into account variations of the amplification efficiencies
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ITIM motif in their cytoplasmic region were up-regulated in the
allogeneic skin explant assays. This includes also the LOC690045
gene which encodes an immunoreceptor similar to Ly49si1. It is
not clear whether one of these gene products interacts with the
MHC class Ib molecules that we found to be up-regulated. Ly49
receptors are normally present mainly on NK cells and the skin
explants harbored few leukocytes. However, skin resident
lymphocytes can become activated in human skin explant assays
[54]. Although few NK cells infiltrating a tissue that normally does
not contain these cells might cause a drastic relative change in the
presence of Ly49 transcripts, the possibility should not be dismissed
that other cells may express the receptors under pathological
conditions. The role of NK cells for GVHR in skin explants needs
to be further explored. In general NK cells are assumed to prevent
GVHR, improve engraftment and to exert strong graft-versus-
leukemia effects without causing GVHD [55].
In the NKC region we found one non-Ly49 gene to be
regulated. The Olr1 gene encodes a receptor protein which
belongs to the C-type lectin superfamily. The protein (also known
as LOX-1) binds, internalizes and degrades oxidized low-density
lipoprotein, which induces vascular endothelial cell activation and
dysfunction, resulting in pro-inflammatory responses, pro-oxida-
tive conditions and apoptosis [56]. In addition, it acts as a receptor
for extracellular heat shock protein 70 on dendritic cells. Binding
and internalization of heat shock protein 70/peptide complexes
channels peptides into the MHC class I presentation pathway [57].
Thus, the protein is involved in antigen cross-presentation to naive
T cells.
In addition to the MHC and NKC region genes, 168 further
genes were significantly regulated in allogeneic skin explants.
Many of them also have immunological functions and need to be
analyzed in more detail in subsequent studies.
The results obtained in the MHC and NKC gene expression
profiling experiment were confirmed in most tested cases by qRT-
PCR on the skin explant samples. Some genes, e.g. Aif1 and
Ly49i9, appeared to be up-regulated even in grade I GVHR. Olr1,
in contrast, was up-regulated predominantly in grade II and III
GVHR in all comparisons. Importantly, several of the MHC and
NKC genes that were identified to be regulated in the skin explant
assays, including Aif1, Lst1, and Olr1, were also regulated in the
GVHD affected skin of transplanted animals. Thus, the skin
explant assay can model GVHD not only histologically but also
with respect to gene regulation. However, the up-regulation of the
tested Ly49 genes (Ly49si1 and Ly49i9) that were observed in the
skin explant was not clearly confirmed in the GVHD-affected skin
of transplanted rats. Skin lesions from transplanted animals are
likely to be more heterogeneous with respect to the dynamics of
the pathophysiological process, including infiltration of NK cells,
than skin explant samples, and this may contribute to the variation
in results. In addition, variability between microarray and qRT-
PCR results might be partly attributed to the fact that in qRT-
PCR experiments the results were normalized to only one control
gene. In contrast, many genes were used in the microarray
experiments for data normalization. More control genes could be
employed for data normalization in qRT-PCR experiments in
further validation studies to reduce this source of variability [58].
In an exploratory experiment, we analyzed the expression of
169 genes with human homologues, including the respective MHC
and NKC region genes, identified in the rat in human skin explant
samples. These human skin explants were cultured for 1, 2, or 3
days resulting in GVHR of grades I, II, and III, respectively.
Notably, 69% of all tested human genes were found to be
regulated in at least one of these human samples as predicted by
the results of the rat expression profiling experiments. 21%, i. e. 36
of different primer pairs [24]. The means plus SEM are shown. A value .1 indicates an up-regulation of gene expression in the allogeneic samples.
The control samples were either skin explant samples exposed to syngeneic lymphocytes (syngeneic control, upper panel), skin explant samples
cultured in medium only (medium control, mean panel), or freshly frozen healthy skin samples (healthy skin control, lower panel).
doi:10.1371/journal.pone.0016582.g007
Figure 8. Analysis of MHC and NKC gene regulation in GVHD skin lesions from transplanted animals. BN (RT1n) rats were transplanted
with bone marrow of PVG (RT1c) rats. Rats that developed acute GVHD were scarified and skin lesions with signs of GVHD were obtained for RNA
preparation and histology. The expression of 7 MHC and 3 NKC was analyzed by qRT-PCR using the B2m gene as reference. The relative changes of
gene expression levels were calculated [24]. The means plus SEM are shown for skin lesion with grade I and grade II GVHD. A value .1 indicates an
up-regulation of gene expression in the allogeneic samples. The control samples were freshly frozen skin samples from healthy BN rats (n = 7).
doi:10.1371/journal.pone.0016582.g008
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of the tested genes, were regulated in all 3 human skin explant
samples in accordance with the rat model, but this regulation
varied depending on the GVHR grade and the time course of the
skin explant assay. Although we only validated these genes on 3
samples, the unexpectedly high concordance rate between the
results of rat and human skin explant assays strongly suggests that
the rat skin explant assay is an informative model for human
GVHR and possibly GVHD. However, the variability of results in
these few human skin explant samples also indicates that it is
unlikely to find a single gene that can serve as universal marker for
GVHR. It is more conceivable that patterns of gene expression
could contribute to an improved diagnosis and classification of
GVHR.
Interestingly, for some of the genes that we found to be
regulated in GVHR and GVHD in the rat, the human
homologues are polymorphic and disease associations of gene
polymorphisms have been described. These include HLA-DMB
[59], C2 [60], AIF1 [61], SPR1 [45], and possibly UBD [62].
Therefore, these genes are especially interesting candidates of
further non-class I/class II HLA genes that might confer an
increased genetic risk of GVHD after HSCT depending on the
genotype. In addition, the OLR1 gene in the NKC is polymorphic
and polymorphisms of this gene have been associated with
atherosclerosis, myocardial infarction [63], and Alzheimer’s
disease [64].
Table 4. Proportion of concordantly regulated in MHC, NKC, and genes encoded in other regions in human skin explant assays in
comparison to rat skin explant assays.
region
analyzed human
genes mRNA not detected
concordantly regulated in human skin explant
assays in comparison to rat skin explant assays not concordantly regulated
3/3 2/3 1/3 0/3
MHC 15 1 (7%) 3 (20%) 2 (13%) 6 (40%) 3 (20%)
NKC 1 0 (0%) 0 (0%) 1 (100%) 0 (0%) 0 (0%)
others 153 18 (12%) 33 (22%) 31 (20%) 41 (27%) 30 (20%)
doi:10.1371/journal.pone.0016582.t004
Table 3. Regulation of MHC and NCR candidate genes in human skin explants.
regulation in rat skin explant
assays (expression profiling) regulation in human skin explant assay concordance rate
day 1
(GVHR I)
day 2
(GVHR II)
day 3
(GVHR III)
MHC region
HLA-DMB q1 - q - 1/3
TAP1 (q) q q q 3/3
PSMB8 q q q q 3/3
G18 (GPSM3) q n.d. n.d. n.d.
PBX2 (q) Q n.d. q 1/3
C2 q q q Q 2/3
LY6G6E Q n.d. q n.d. 0/3
BAT5 Q - - - 0/3
AIF1 q Q q Q 1/3
LST1 q - q n.d. 1/3
SPR1 (PSORS1C2) q - - q 1/3
IER3 q Q q - 1/3
FLI13158 (Q) Q Q - 2/3
MRPS18B (q) Q Q Q 0/3
UBD q q q q 3/3
NCR region
OLR1 q q q n.d. 2/3
1Explanation of symbols:
q up-regulated mRNA expression level (log2-fold change $1).
Q down-regulated mRNA level (log2-fold change #21).
- unchanged mRNA expression level (log2-fold change .-1 and ,1).
(q) significant (p,0.05) but moderate up-regulation (log2-fold change ,1) of mRNA expression level in the rat expression profiling experiment.
(Q) significant (p,0.05) but moderate down-regulation (log2-fold change .21) of mRNA expression level.
n.d. no mRNA detected.
doi:10.1371/journal.pone.0016582.t003
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Several laboratory tests have been assessed for their ability to
predict the risk of GVHD in patients. The skin explant assay has a
predictive value of about 80% when cyclosporine alone is used for
GVHD prophylaxis [65]. A gene expression analysis of selected
genes may help to further improve the predictive value of the
assay. Pre-transplant gene expression profiling of donor peripheral
blood mononuclear cells (PBMC) has recently been shown to be a
useful tool to predict the risk of GVHD [66]. Post transplant
differences in the gene expression profile of PBMC of patients with
acute [67,68] and chronic GVHD [69] compared to non-GVHD
samples have been described. The general gene expression profile
of target tissues of GVHD has been previously analyzed only in
mouse models of cutaneous and hepatic GVHD [70,71]. Some of
the genes identified in these studies overlap with our results. In
cutaneous GVHD the MHC genes Tap1, Psmb8, and Ubd were
also found to be up-regulated [71]. In hepatic GVHD the
expression of Tap1, Psmb8 (Lmp7), H2-DMb, Aif1, and Ubd (Fat10)
was increased [70].
In conclusion, the MHC gene expression profiling approach in
the rat skin explant assay identified a number of non-class I/class
II genes that might contribute to the MHC-associated risk of
GVHD following HSCT. These genes could be directly involved
in the pathophysiology of GVHD or serve as molecular markers
for GVHD and GVHR. The possibility should not be dismissed,
however, that these marker genes could indicate that protective
pathways are induced which modulate tissue damage during
inflammation. Moreover, their human homologues may be useful
for risk assessment, diagnosis, and as potential targets for therapy
of GVHD in patients.
Materials and Methods
Rat strains
For the skin explant assays, rats of the inbred strains LEW.1N
(RT1n), LEW.1A (RT1a), LEW.1AV1 (RT1av1), LOU/C (RT1u),
and BUF (RT1b) were bred in the central animal facility of the
Medical Faculty of the University of Go¨ttingen. Rats of the strains
PVG/OlaHsd (RT1c) and BN/RijHsd (RT1n) were purchased
from Harlan Winkelmann (Borchen, Germany). Animals between
10 and 20 weeks of age were used for the experiments. For
transplantation experiments, PVG rats of the RT7.2 allotype
(allelic variant RT7b), originally obtained from Harlan OLAC,
UK), were bred at the animal facility of the University of Oslo and
BN rats were purchased from Harlan.
Rat skin explant assays
Rat skin explant assays were performed as previously described
in detail [22]. Briefly, mononuclear cells were obtained from rat
spleens. Responder and irradiated (25 Gy) stimulator splenocytes
were co-cultured in a MLR and the proliferation of responder
lymphocytes was tested by [methyl-3H]-thymidine (Amersham,
Braunschweig, Germany) incorporation. The stimulation index
was calculated as described [22]. After 7 days 106 responder
lymphocytes were added to freshly obtained skin samples from the
stimulator strain that were cultured in 200 ml NaHCO3-buffered
Dulbecco’s modified Eagle’s medium (DMEM; Biochrom) sup-
plemented with 3% normal rat serum, 2 mM L-glutamine, 1 mM
sodium pyruvate, and antibiotics in round-bottomed microtitre
plates (Sarstedt, Nu¨mbrecht, Germany). The skin samples were
excised from the paws of rats after washing with 70% ethanol. The
subcutaneous fat tissue was removed and the samples were
trimmed to a size of approximately 1.561.5 mm. Skin samples
cultured in medium only and samples co-cultured with lympho-
cytes from a ‘‘syngeneic MLR’’ were used as controls. After 3 days,
the skin explants were washed with N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonic acid (HEPES)-buffered DMEM and snap
frozen in liquid nitrogen and stored at 280uC for RNA
preparation. Parallel samples were fixed in 10% neutral-buffered
formalin, sectioned, and stained with hematoxylin and eosin
(H&E). The histological evaluation of the skin explants was
performed blind by an expert histopathologist (L.S.) based on the
grading system described by Lerner [72].
Human skin explant assays
PBMC and skin samples were obtained from healthy volunteers
or autologous HSCT patients following written informed consent
and approval from the North Tyneside Research Ethics
Committee. Buffy coat from normal blood donations were
obtained from Newcastle National Blood Service with consent.
Skin explant assays were performed as previously described with
slight variations [73]. In brief, 16107 responder PBMC from a
healthy volunteer were cultured with an equal number of
irradiated PBMC from a bone marrow transplant patient, in
10 ml complete medium (RPMI 1640 supplemented with
antibiotics, 2 mM L-glutamine and 10% heat inactivated human
AB serum) in a 25 cm2 flask. After 7 days of culture, MLR primed
lymphocytes were washed and resuspended in complete medium
supplemented with 20% heat inactivated autologous (patient)
serum and co-cultured with patient skin explants at a cell
concentration of 16106 cells/well in a volume of 200 ml/well.
Standard 4-mm punch skin biopsy specimens were obtained pre-
transplant from the patients. Under sterile conditions the skin
biopsies were trimmed of excess dermis and divided into 8 to 10
sections of equal size. Each section was cultured separately with
either MLR-primed responder cells or culture medium in 96-well
round-bottomed microtitre plates. After 1, 2 or 3 days of co-
culture skin explants were fixed in 10% buffered formalin,
sectioned and stained with H&E. The histopathological evaluation
[72] of the skin explants was performed blindly and independently
by at least 2 assessors. Grade I histopathological damage in skin
biopsies was regarded as background which would be observed in
medium control or autologous cell/autologous MLR controls. All
biopsies presenting histopathological damage of grade II or above
were regarded as positive.
Bone marrow transplantation
Transplantation experiments were approved by the Experi-
mental Animal Board under the Ministry of Agriculture of
Norway (ID 09.1514, 09.1515 and VIT 09.1512). Male PVG
(RT7b) rats served as bone marrow and lymph node donors.
Mononuclear bone marrow cells were purified by density gradient
centrifugation in Nycoprep 1.077A (Medinor ASA, Norway). The
cells were depleted of T cells by magnetic separation using anti-
CD5 (Ox19) and anti-ab T cell receptor (R73) antibodies
conjugated to pan-mouse IgG coated Dynabeads (Dynal Biotech
ASA, Norway). This procedure reduced the CD3+ T cell content
in the bone marrow from 3% to less than 0.3%. Male BN rats
were used as recipients. They were irradiated (9 Gy) and
subsequently received an i.v. injection of 306106 PVG.7b T
cell-depleted bone marrow cells. 14 days post transplantation,
1.56106 lymph node cells were injected i.v. to evoke GVHD. The
rats were regularly monitored for GVHD symptoms. Rats
suffering from irreversible GVHD were sacrificed and skin samples
were processed for RNA preparation and histology in parallel.
RNA preparation
RNA extraction was carried out using TRIZOL reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
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recommendations. Afterwards, the RNA samples were treated
with RQ1 RNase free DNase (Promega, Madison, WI, USA) for
20 min at 37uC in order to remove genomic DNA contamina-
tions. The RNA was then purified as described previously [22].
Quantity and quality of extracted RNA were controlled by
capillary electrophoresis using the Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA, USA).
Microarray experiment
For the expression profiling, a custom-designed oligo DNA
microarray (Agilent) was used. The 15K microarray covered 224
MHC genes by 649 oligonucleotide probes and 43 NKC genes by
101 probes. These probes were spotted in triplicates. Further
probes representing 6342 genes were added mainly to allow for
data normalization. A two-color 1262 paired swap design [74]
using 24 arrays was applied, comparing RNA samples from 12
independent allogeneic and 12 independent syngeneic skin explant
assays. Aliquots of total RNA (200 ng) were used as starting
material. The ‘‘Low RNA Input linear Amplification Kit Plus, two
color’’ (Agilent, 5188-5340) and the ‘‘RNA Spike-In Kit’’ (Agilent,
5188-5279) were used for cDNA synthesis and in-vitro transcription
according to the manufacturer’s recommendations. Quantity and
dye incorporation rates of the amplified cRNAs were determined
using the NanoDrop ND-1000 UV-VIS Spectrophotometer
version 3.2.1 (NanoDrop Technologies, Wilmington, DE, USA).
Afterwards, 300 ng aliquots of Cy3 and Cy5-labeled cRNAs from
syngeneic and allogeneic skin explant assays, respectively, were
mixed and hybridized to the microarrays. The hybridization was
performed for 17 hours at 10 rpm and 65uC. After washing, Cy3
and Cy5 intensities were detected by two-color scanning using a
DNA microarray scanner (Agilent, G2505B) at 5 micron
resolution. Scanned image files were visually inspected for
artifacts. The generated raw data were extracted using the Feature
Extraction 9.1 software (Agilent). The normalization of the raw
microarray data was done with a non-linear loess regression [75].
Differentially expressed genes were identified by an analysis of
variance (ANOVA) mixed effects model [74] using SAS PROC
MIXED. The resulting p-values were adjusted with the Benjamini-
Hochberg method to control the false discovery rate [76]. The
microarray data were generated conforming to the MIAME
guidelines and have been deposited in NCBI’s Gene Expression
Omnibus (accessible through GEO series accession number
GSE17928). For a general analysis of the gene expression data
the PANTHER (Protein ANalysis THrough Evolutionary Rela-
tionships) system [23] was used, which classifies genes by their
functions (www.pantherdb.org/tools/genexAnalysis.jsp). The mi-
croarray data were mapped to PANTHER molecular function
and biological process categories, as well as to biological pathways
[77].
Validation of rat candidate genes by quantitative real-
time PCR
To validate the expression change of candidate genes, qRT-
PCR assays were used. Specific primers for 10 MHC and 3 NKC
genes were designed (Table S4). To generate external standard
curves and to calculate the amplification efficiency of each primer
pair, a pool of 20 random cDNAs was amplified in serial 10-fold
dilutions [24]. The amplification reactions were carried out as
described previously [22] using an ABI 7500 Real-Time PCR
System. The data were analyzed with the ABI 7500 SDS software
(Applied Biosystems). As internal control, mRNA expression of
housekeeping genes Gapdh (Rn_Gapd_1_SG QuantiTect Primer
Assay QT00199633, Qiagen, Hilden, Germany) or B2m (Table
S4) were monitored. To normalize variations in the RNA
concentration in different samples, the ct values obtained in real-
time PCR for the genes were corrected by the ct-value obtained
for the housekeeping gene in the same sample (Dct = ct
housekeeping gene - ct gene of interest). For direct comparison
with microarray data, the relative changes of mRNA expression
were calculated using the DDct method (DDct = Dct sample of
interest – Dct control sample) [78]. For additional analyses, the
relative changes of gene expression levels were calculated using a
mathematical model for relative quantification of real-time PCR
data which takes into account variations of the amplification
efficiencies of different primer pairs [24].
Validation candidate genes in human skin explant assays
by quantitative real-time PCR
Validation of the rat candidate genes with human homologues
in the human skin explant assay was also done by qRT-PCR. For
this we used relative quantification using custom designed
Taqman low density array (TLDA) cards (Applied Biosystems),
each card contained 4 replicates of 95 unique genes and a control
gene, 18S. The qRT-PCR reactions were set up using Taqman x2
gene expression mastermix (Applied Biosystems), 50 ng RNA
equivalent of cDNA and the total volume adjusted to 200 ml with
nuclease free water (Quiagen). The TLDA cards were run on a
7900 qRT-PCR system (Applied Biosystems) using the TLDA
block and analysed using the RQ manager 1.2 software (Applied
Biosystems). The relative changes in RNA expression were also
calculated using the DDct method described above.
Statistical analyses not related to microarray experiments
Paired comparisons between experimental groups were per-
formed using the nonparametric Mann-Whitney U test. Pearson’s
and Spearman’s correlation coefficients were calculated to
determine the correlation between mRNA expression levels of
two genes. The statistical analyses were performed using
WinSTATH software.[79]
Supporting Information
Table S1 Expression profiling results of MHC genes. In
Table S1a, results for all 224 MHC genes are shown in their
chromosomal order [16]. The expression profiling results of BN
skin explant samples exposed to pre-stimulated allogeneic (PVG)
lymphocytes in comparison to those exposed to syngeneic (BN)
lymphocytes are given. The log2-fold changes and the fold
changes in gene expression are shown for every oligonucleotide
probe used. The adjusted p-values are indicated. Significant
(p,0.05) and strong (log2-fold change $1 or #21; i.e. fold
change $2 or #0.5) results are indicated in bold font. In addition,
the identification numbers of the probes on the arrays are given
(probe ID) together with the information whether these probes
were taken from the Agilent database or custom designed. Table
S1b contains the same information for all MHC genes for which
at least one probe indicated a significant alteration of gene
expression. In Table S1c, the data for those genes are
summarized that are considered to be regulated significantly
because either at least a single probe indicated a significant
(p,0.05) and strong (log2-fold change $1 or #21) regulation or
at least 50% of the gene probes indicated a significant (p,0.05)
regulation of gene expression.
(XLS)
Table S2 Expression profiling results of NKC genes. In
Table S2a, results for all 43 NKC genes investigated are
indicated in their chromosomal order (Klrg; Pzp to Csda). The
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expression profiling results of BN skin explant samples exposed to
pre-stimulated allogeneic (PVG) lymphocytes in comparison to
those exposed to syngeneic (BN) lymphocytes are given. The log2-
fold changes and the fold changes in gene expression are shown for
every oligonucleotide probe used. The adjusted p-values are
indicated. Significant (p,0.05) and strong (log2-fold change $1 or
#21; i.e. fold change $2 or #0.5) results are indicated in bold
font. In addition, the identification numbers of the probes on the
arrays are given (probe ID) together with the information whether
these probes were taken from the Agilent database or custom
designed. Table S2b contains the information for all NKC genes
for which at least one probe indicted a significant alteration of
gene expression. In Table S2c, the data for those genes are
summarized that are considered to be regulated significantly
because either at least a single probe indicated a significant
(p,0.05) and strong (log2-fold change $1 or #21) regulation or
at least 50% of the probes indicated a significant (p,0.05)
regulation of gene expression.
(XLS)
Table S3 Regulated non-MHC non-NKC genes. The
expression profiling results of non-MHC non-NKC genes are
given for those genes that were both significantly (p,0.05) and
strongly (log2-fold change $1 or #21; i.e. fold change $2 or
#0.5) regulated. The log2-fold changes and the fold changes in
gene expression are shown. The adjusted p-values are indicated.
For 20 of these genes at least two different probes were present on
the array. In 8 cases (indicated by gene symbols in bold) the second
probe indicated the same strong and significant regulation and in 7
further cases (indicated by gene symbols in italics) the second
probe indicated a regulation with borderline amplitude or
significance. In 5 cases (indicated by gene symbols in blue font)
the results of the two probes for a gene did not confirm each other.
Furthermore, the identification numbers of the probes on the
arrays are given (probe ID) together with the information whether
these probes were taken from the Agilent database or custom
designed.
(XLS)
Table S4 Primer sequences used for mRNA expression
analysis.
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Table S4. Primer sequences used for mRNA expression analysis 
Primer sequence 5`- 3`1 Amplicon
(bp)
Proximity 
to poly-A (bp)
Efficiency 
coefficient (E)2
RT1-A2 F: TCCCTCCCTGCTACCCTGAG
R: GCCATCCACACTTGGGTCAA
103 105 1.93
RT1-DMb F: TCAAATCTGCCTCGGGTGTTT
R: GACAAGGTGGGGCTTTCAGG
80 53 1.87
Psmb8 F: CACTGCTGGGCAGACATCCT
R: GCTTTGTCTCCAGCCCAGGT
109 91 1.92
Ly6g6e F: CCCAGGCAAAGGGACAGAAG
R: TGAGACCCTCAGGCACCAAG
87 151 1.97
Aif1 F: TCCCCCAGCCAAGAAAGCTA
R: TCTTTTCCCATGCTGCTGTCA
99 51 1.86
Lst1 F: GGGCAGGAGCTCCACTACG
R: CGATGCAGGCATAGTCAGTGC
118 20 1.89
RT1-CE3 F: TGTCGTCCTTGGAGCCATCT
R : TCCTCACAACAGGCACCAGA
62 106 1.91
RT1-CE10 F: ACACAGGTGGGGAAGGAGGA
R : CAATCTGGGAGGGACACATCAG
82 10 1.94
RT-BM1
(RT1-S3)
F: GCAGCTATGCTCATGTTCTAGGC
R: TGCCTTCTGAGGCCAGTCAG
62 7 1.89
Ubd F: TGGGGTGATGAGAAGCTCAAAA
R: CCCCACCTCAAATCTTTATTTCATTC
105 7 1.92
Olr1 F: GGAAGTCAGAAGAGGGCATGG
R: TCCTGGGTTCAATTTCCAGAGT
89 271 1.90
Ly49si1 F: TGGCCAATCTGAATTTTCCTTG
R : ACATGGGAAGGGGTTCATGC
115 36 1.84
Ly49i9 F: GGGACTTGGCAACCTCAGGA
R: TTGGAACATCTGCACAATGGAA
110 179 1.88
Cd3z F: AGTGCCTGCTGGGATTTAGC
R: CATCCATGGTCACAGGCACTT
118 50 1.93
B2m F: GAGCAGGTTGCTCCACAGGT
R: CAAGCTTTGAGTGCAAGAGATTGA
128 246 1.94
1 F: forward primer, R: reverse primer
2 The real-time PCR efficiency coefficient (E) of one cycle in the exponential phase was 
calculated according to the equation: E = 10[–1/slope of standard curve] 
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Abstract
Background: Mesenchymal stromal cells (MSC) have important immunomodulatory effects that can be exploited in the
clinical setting, e.g. in patients suffering from graft-versus-host disease after allogeneic stem cell transplantation. In an
experimental animal model, cultures of rat T lymphocytes were stimulated in vitro either with the mitogen Concanavalin A
or with irradiated allogeneic cells in mixed lymphocyte reactions, the latter to simulate allo-immunogenic activation of
transplanted T cells in vivo. This study investigated the inhibitory effects of rat bone marrow-derived MSC subsequently
found to be infected with a common mycoplasma species (Mycoplasma hyorhinis) on T cell activation in vitro and
experimental graft-versus-host disease in vivo.
Principal Findings: We found that M. hyorhinis infection increased the anti-proliferative effect of MSC dramatically, as
measured by both radiometric and fluorimetric methods. Inhibition could not be explained solely by the well-known ability
of mycoplasmas to degrade tritiated thymidine, but likely was the result of rapid dissemination of M. hyorhinis in the
lymphocyte culture.
Conclusions: This study demonstrates the potent inhibitory effect exerted by M. hyorhinis in standard lymphocyte
proliferation assays in vitro. MSC are efficient vectors of mycoplasma infection, emphasizing the importance of monitoring
cell cultures for contamination.
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Introduction
Mesenchymal stromal cells (MSC) comprise a heterogeneous
population of progenitor cells that can differentiate alongmesodermal
lineages [1]. As characteristic markers are lacking, MSC are currently
defined by a set of minimal criteria based on their morphology,
phenotype andmultipotency [2].Multipotent stromal progenitor cells
were originally isolated from the bone marrow (BM) [3], but are
readily available from many adult and fetal tissues [4–7]. In recent
years, a number of studies have shown that MSC have important
immunomodulatory potential [8–12]. MSC can suppress the
activation and proliferation of T and B cells, inhibit proliferation
and cytotoxicity of NK cells, block the activation and maturation of
dendritic cells, and induce expansion of regulatory T cells [13].
Although a variety of soluble mediator molecules have been
implicated [14], the molecular mechanisms by which MSC exert
their immunomodulatory effects are presently not well understood.
Graft-versus-host disease (GvHD) is caused by activation of
donor T cells due to disparities of major histocompatibility
complex (MHC) and minor histocompatibility antigens with the
recipient. MSC have emerged as a promising treatment modality
for GvHD after allogeneic stem cell transplantation [15,16]. A
clinical phase II study showed that a majority of patients suffering
from acute, steroid-refractory GvHD responded to treatment with
one or several MSC transfusions [17]. This effect was independent
of the MHC constitution of the MSC donor. Conversely, results
from experimental animal models have been conflicting. While
some attempts to treat GvHD with MSC have been successful in
murine models of allogeneic BM transplantation (BMT) [18,19],
other studies have failed to show a protective effect [20–22]. The
influence of source of MSC, experimental protocols and treatment
strategies on the efficiency of MSC remain unclear.
Mycoplasmas are parasitic bacteria that lack a cell wall and
colonize animals and plants. In humans and other mammals, they
have been associated with a variety of maladies in the respiratory
tract and the genito-urinary tract. Interactions of mycoplasma with
the host immune system are currently not fully understood. Efforts
to prevent mycoplasma infection have proven difficult, partly due
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to the lack of successful vaccination strategies [23]. Several strains
of mycoplasma frequently occur as latent contaminants of human
and animal cell lines in research laboratories [24]. Mycoplasma
hyorhinis is a pathogen of the porcine respiratory system and one of
the most common cell culture contaminants [24]. Infections can
remain undetected unless methods such as polymerase chain
reaction (PCR) using mycoplasma-specific primer sequences are
employed. Recently, M. hyorhinis has been implicated in the
transformation of human prostate cells [25] and thus may pose a
significant health risk related to carcinogenesis.
The aim of this work was to evaluate the immunosuppressive
effects of rat MSC on mixed lymphocyte reactions (MLR) in vitro
and GvHD in vivo using an experimental animal model of MHC-
mismatched BMT. In the course of this work, we noted that our
MSC lines were unusually potent inhibitors of MLR in vitro and
discovered that this was caused by accidental contamination of the
primary MSC cultures with M. hyorhinis.
Results
Mycoplasma-infected MSC strongly inhibit MLR and
mitogen-induced T cell proliferation in vitro
A MSC line generated from the BM of PVG strain rats
(expressing the RT1c MHC haplotype) exhibited a potent
inhibitory effect on lymphocyte proliferation in vitro (Figure 1).
Tenfold dilutions of MSC were added to a MLR of PVG.7B (RT1 c;
used interchangeably with PVG) lymph node cells (LNC) and
allogeneic irradiated BN (RT1n) stimulator cells. Incorporation of
tritiated thymidine ([3H]TTP) was inhibited at ratios up to 1 MSC
per 10 000 responder cells (1024) (Figure 1A). MSC were equally
effective inhibitors of proliferation induced by Concanavalin A (Con
A; data not shown). Irradiation of MSC (20 Gy) did not change
their inhibitory capacity (data not shown). MSC showed a marked
inhibitory effect when introduced at delayed time points during
MLR or mitogen-induced stimulation, but required at least 3 d of
co-incubation with the responder cells (Figure 1B and data not
shown).
MSC exerted a potent inhibitory effect in transwell co-cultures
with LNC using 0.4 mm pore size membranes (data not shown).
Addition of cell-free MSC culture medium also resulted in strong
inhibition of MLR, but this effect was reversed by filtering through
0.22 mm membranes or repeated centrifugation at 100 000 g
(Figure 2A,B). Inhibition was furthermore mediated by the pellet
fraction sedimented at 100 000 g, but reversed by heat-inactivation
for 30 min at 60uC (Figure 2B,C). These inhibitory effects were
striking compared with several previous reports of MSC from
different species [8,9,11,12,20,21], and it was therefore with some
disappointment that we discovered that the cells were infected with
M. hyorhinis, a common cell culture contaminant (cf. Materials and
Methods).
A single mycoplasma-infected MSC can inhibit allogeneic
MLR
A second MSC line derived from another MHC-congenic strain
on the PVG background (PVG.1U expressing the RT1u MHC
haplotype), which was also subsequently found to be infected with
M. hyorhinis, displayed an even stronger inhibition of lymphocyte
proliferation (Figure 3). [3H]TTP incorporation was fully
abrogated (less than 15% of the positive control) by addition of
only 2 MSC per 200 000 LNC responder cells (1025) at the start of
the MLR culture. At even lower MSC:LNC ratios (1026), we
observed an ‘‘all-or-none’’ phenomenon, with either full inhibition
or normal proliferation in individual wells. To evaluate whether
inhibition was mediated by single infected cells, we added serial
threefold dilutions in replicate wells as depicted schematically in
Figure 3A. Complete block of proliferation was observed in
mycoplasma-contaminated wells as detected by PCR, while
normal responses were recorded in mycoplasma-negative wells
(Figure 3B,C). Analogous results were obtained for MSC/LNC co-
cultures stimulated with Con A (data not shown). These data
Figure 1. Mycoplasma-infected MSC effectively inhibit MLR. (A) MSC generated from the BM of PVG rats, subsequently found to be infected
with M. hyorhinis, were added in tenfold dilutions at the start of co-cultures of 26105 PVG.7B LNC and 26105 irradiated BN LNC (gray bars). No MSC
were added to the positive control (MLR, black bar). The basal proliferation of PVG.7B LNC in the absence of stimulus is also shown as negative
control (neg ctrl, white bar). Values on the x-axis denote the common logarithm (log) of MSC:LNC ratios, i.e. 1:10 (21) through 1:100 000 (25). [3H]TTP
incorporation was abrogated depending on the number of mycoplasma-infected MSC added. (B) MSC were added either at the start of MLR (dark
gray bars), after 24 h (light gray) or 48 h (white), respectively, at 1:100 (22) or 1:10 000 (24) MSC:LNC ratios, and co-cultured for a total of 4 d. No
MSC were added to the positive control (MLR). Mycoplasma-infected MSC fully inhibited the assay with at least 3 d of co-incubation at the 1:100
MSC:LNC ratio. Representative data from at least three independent experiments are shown as the mean plus the standard error of the mean of
triplicates. Statistical difference to the respective positive controls, N P,.05, NN P,.01.
doi:10.1371/journal.pone.0016005.g001
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suggest that M. hyorhinis has an extremely potent inhibitory effect
on lymphocyte proliferation in vitro.
The suppressive effect of mycoplasma infection is
removed by anti-mycoplasma treatment and restored by
re-infection
The PVG.1U MSC line was treated with Mynox (cf. Materials
and Methods) to resolve the mycoplasma infection. As a result of
the treatment, the cells were consistently free from mycoplasma as
confirmed by PCR, and most of the observed inhibitory capacity
was concomitantly lost (Figure 4A). MLR stimulation was
prevented only at a relatively high MSC:LNC cell ratio of 1:10,
in line with several previous MSC studies [9,20,21]. Similar results
were obtained with Con A-induced proliferation (unpublished
observations). Intentional contamination of a previously uninfect-
ed MSC line with mycoplasma-containing supernatant increased
its suppressive potential dramatically (Figure 4B), showing the
same phenomenon of either full inhibition or a normal
proliferative response in individual wells at limiting dilutions.
Figure 2. MLR is inhibited by MSC culture supernatant.
Inhibition of lymphocyte proliferation was reversed either by (A)
filtration at 0.22 mm, (B) serial centrifugation at 100 000 g, or (C) heat-
treatment at 60uC. (A) MSC-conditioned supernatant (MSC-sn; gray
bars) was added at 1:10 (v/v) dilution (22 mL added to 200 mL per well)
at the start of mitogenic stimulation of 26105 PVG.7B LNC with Con A
(positive control with no MSC-sn added, black bar). MSC-sn was added
either unfiltered or filtered with the indicated cut-off sizes. (B) MSC-sn
was sedimented with the indicated centrifugal forces and durations
(min) and added at 1:10 (v/v) dilution at the start of allogeneic MLR
(cf. Figure 1). The pellet fraction (MSC-pt) was obtained after
centrifugation twice for 60 min at 100 000 g, resuspended and added
at 1:10 (v/v) dilution to the MLR. (C) Unprocessed MSC-sn or the
resuspended pellet fraction described in panel B were treated at 30uC
(light gray bars) and 60uC (dark gray) for 30 min, respectively, before
adding to MLR (dilution 1:10). Representative data of at least two
independent experiments are shown as mean values plus the standard
error of the mean of quadruplicates. Statistical difference to the
respective positive controls, NN P,.01, NNN P,.001.
doi:10.1371/journal.pone.0016005.g002
Figure 3. A single mycoplasma-infected MSC can completely
block the MLR. (A) Mycoplasma-infected MSC were added at limiting
dilution conditions at the start of MLR cultures with 26105 responder
cells. Proliferation was assessed in 9 replicate wells for each dilution.
Wells with more than 70% or less than 15% of the [3H]TTP incorporation
observed in the positive control (MLR without MSC) are shown as open
(#) and filled circles (N), respectively. The log of MSC:LNC ratios are
denoted. (B) Mycoplasma was detected in the supernatant of seven out
of nine wells at the 26.5 dilution shown in panel A, and in the same
wells (C) complete inhibition of MLR was observed. Positive (MLR) and
negative (neg ctrl) controls are also shown (mean of triplicates). Results
are representative of three independent experiments.
doi:10.1371/journal.pone.0016005.g003
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Similar inhibitory potential was observed after deliberate infection
of a rat colon carcinoma (CC531s) cell line (Figure 4C). These data
were firm evidence that the strong inhibitory effect was mediated
by the contaminant and was not dependent on a specific cellular
vehicle.
M. hyorhinis effectively inhibits T cell proliferation as
evaluated by Carboxyfluorescein diacetate succinimidyl
ester (CFSE) dilution assay
Mycoplasmas are known to interfere with the read-out of
[3H]TTP incorporation assays commonly used to measure DNA
synthesis during lymphocyte proliferation, due to their endogenous
pyrimidine-nucleosidase activity [26]. We therefore opted to use
the CFSE dilution assay as an alternative method to measure cell
division and cell proliferation [27]. Infected and mycoplasma-
treated MSC were added to Con A cultures of CFSE-labeled LNC
(Figure 5). The presence of mycoplasma-infected MSC led to
increased cell division arrest of both CD4+ and CD8+ T cells
compared to mycoplasma-free MSC. The levels of inhibition of
cell division correlated with [3H]TTP incorporation of LNC
performed in parallel, and similar results were obtained for
allogeneic MLR (data not shown).
We also determined the relative numbers of natural T regulatory
(Treg) cells in our assays. The frequency of CD4
+CD25hiFoxP3+Treg
cells markedly decreased as a result of addition of MSC to Con A
cultures (Figure S1A), indicating that inhibition was not mediated
by Treg cells. In line with this observation, cell death was increased
in mycoplasma-contaminated LNC cultures (Figure S1B). Taken
together, these data show that M. hyorhinis has a high capacity to
arrest lymphocyte proliferation in vitro. The extent to which M.
hyorhinis interfered with the [3H]TTP incorporation assay by
substrate degradation is not known, however, the results from
CFSE dilution assays suggest that this effect is of less importance.
Mycoplasma is rapidly disseminated in lymphocyte
cultures
Because cultivation of M. hyorhinis in cell-free anaerobic agar
medium for microbiological assays is rarely feasible [24], we
performed semi-quantitative measurements of bacterial load by
PCR analysis of sequentially collected culture supernatants
(Figure 6). Initially, mycoplasma was detected only at high
MSC:LNC ratios, but bacterial titers increased more rapidly in
co-culture with LNC as compared to cultures of MSC alone, and
mycoplasma infection manifested even in the highest dilutions
where only single infected MSC were added to the MLR. Similar
results were obtained for PCR-testing of supernatants from Con A-
stimulated LNC co-cultures with MSC (data not shown).
Mycoplasma-infected MSC retain their cell phenotype,
differentiation potential and cytokine expression profile
in mixed lymphocyte cultures
Mycoplasma-contaminated MSC adhered to plastic surface in
vitro and had the cell morphology of spindle-shaped colony-
forming unit fibroblasts (Figure S2A). The infection did not seem
to inhibit in vitro growth or the differentiation potential of MSC
(Figure S2B,C,E-H and unpublished observations). MSC ex-
pressed surface markers CD59, CD71, CD90, and CXCR4, but
Figure 4. Mycoplasma-treated or previously uninfected MSC
show a markedly reduced ability to inhibit lymphocyte
proliferation. (A) Infected PVG.1U MSC were treated with Mynox
reagent to eradicate the mycoplasma infection. Tenfold dilutions of
untreated (dark gray bars) and treated MSC (light gray) were tested in
allogeneic MLR. Mycoplasma-treated MSC, which tested negative for
mycoplasma by PCR, inhibited MLR at 1:10 (21) but not at higher
dilutions. Mycoplasma-infected MSC, on the other hand, effectively
inhibited up to a cell ratio of 1:106 (26). Previously uninfected PVG.7B
MSC (B) or the rat colon carcinoma cell line CC531s (C) were
intentionally infected with M. hyorhinis by transfer of cell culture
supernatant from the infected PVG.1U MSC line shown in panel A.
Infection was verified by PCR after passage. MSC were added at the
start of MLR, and CC531s cells were irradiated to prevent spontaneous
proliferation and added at the start of lymphocyte culture with Con A.
Proliferation was effectively inhibited by addition of M. hyorhinis-
infected cells, but not by uninfected CC531s cells. Values on the x-axis
denote the log of MSC:LNC and CC531s:LNC ratios, respectively. When
infected cells were added at the highest dilutions, individual wells
showed either full inhibition or a normal proliferative response (cf.
Figure 3); e.g. when infected CC531s cells were added to the Con A
culture, proliferation was detected in one of three (log dilution 25) and
two of three (26) replicates. Representative data from at least three
independent experiments are shown as the mean plus the standard
error of the mean of (A, B) quadruplicates or (C) triplicates.
doi:10.1371/journal.pone.0016005.g004
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lacked CD31 and CD45 (Figure S2D). Class I MHC molecules
(RT1-A) were also expressed while class II MHC molecules (RT1-
B/D) were not detected by flow cytometric staining. Based on
these parameters, the cells are in accordance with the current
definition of MSC [2].
Culture supernatants from mycoplasma-positive MSC alone
contained considerable amounts of interleukin (IL)-6, but not other
cytokines tested (Figure S3A), in agreement with previous
observations of uninfected MSC [28]. Adding increasing numbers
of mycoplasma-positive MSC to MLR resulted in no significant
changes of the concentrations of IL-1b, IL-2 and IL-10. The levels
of IL-1a, IL-6, and granulocyte macrophage colony-stimulating
factor, however, were markedly increased, while IL-4, interferon-c
(IFNc) and tumor necrosis factor-a were clearly diminished after
6 d of co-incubation (Figure 7A and data not shown). These results
were in agreement with several previous observations on the effects
of murine and human MSC on cytokine secretion by stimulated
lymphocytes [29–31], but failed to reproduce an increase of IL-10
in co-cultures with human MSC [29,32].
Next, we studied the capacity of M. hyorhinis to suppress the
production of IFNc as an important function of activated T cells.
A significant fraction of T cells produce intracellular IFNc after
24 h of Con A stimulation (Figure 7B,C). Addition of mycoplas-
ma-infected MSC at ratios up to 1:1000 reduced the relative
frequency of IFNc+ T cells. This effect can explain the
concentration-dependent decrease of IFNc observed in MLR/
MSC co-cultures (Figure 7A).
Blocking the IL-6 signal by addition of IL-6 specific antibody
did not counteract the suppressive effect of infected MSC. Also,
addition of recombinant IFNc, either alone or in combination
with anti-IL-6, was without effect (Figure S3B). These data suggest
that the changes in IL-6 or IFNc were not important for the
suppressive effect mediated by mycoplasma-infected MSC.
Intravenous injections of mycoplasma-positive MSC fail
to reduce GvHD severity in BM-transplanted rats
In a model of experimental allogeneic BMT, we used the same
combination of PVG.7B donor rats and fully MHC-mismatched
BN recipient rats as for MLR in vitro experiments. Lethally
irradiated (9.0 Gy total body irradiation) BN rats were injected
with 306106 T cell-depleted PVG.7B BM cells. Two weeks later,
at a time point when the transplanted recipients had regained their
initial body weight, donor lymphocyte infusions (DLI) of graded
minimal doses of 1.5–2.56106 CD3+ T cells from PVG.7B lymph
node donors reproducibly invoked lethal GvHD in 90% of the
recipients. Two groups were treated with intravenous injections of
high doses of MSC that later proved to be infected with M.
hyorhinis.
Transplanted rats received either single or repeated injections of
16106 MSC 14 d after DLI before or after rats had developed
symptoms of ongoing acute GvHD, but with no improvements of
GvHD morbidity and mortality. All recipients were moribund
between 14 and 26 d after DLI regardless of either repeated
prophylactic (36MSC) or acutely curative (16MSC) cell therapy
(for details refer to Figure S4).
Discussion
We here report a potent inhibitory effect of M. hyorhinis infection
of MSC on in vitro lymphocyte proliferation assays based on
[3H]TTP incorporation and CFSE dilution. Addition of single
infected MSC led to rapid dissemination of mycoplasma in mixed
lymphocyte cultures. Mycoplasma spp. have been shown to reach
titers in cell cultures sufficient to degrade pyrimidine substrates with
more than 90% efficiency within 3–5 d [34]. In our study, high
titers of mycoplasma were reached already after 2 d which may
explain the observed potent inhibition of lymphocyte proliferation
as a result of direct cytopathic/cytolytic effects. Studies testing for
proliferative responses should therefore rigorously control their cell
cultures for mycoplasma contamination.
Many mycoplasma strains, including M. hyorhinis, produce
nucleoside phosphorylases which rapidly convert [3H]TTP to its
thymine-derivative in vitro [26,35]. Caution has therefore been
advised in the interpretation of in vitro proliferation assays based on
quantification of such compounds [26,34]. Due to its potent
enzymatic activity, it has been suggested that [3H]TTP degradation
can be utilized as a sensitive detection method for mycoplasma
infection [36], however, specific PCR and other readily available
Figure 5. Mycoplasma-infected MSC inhibit T lymphocyte proliferation in vitro as measured by CFSE dilution. Previously uninfected
(light gray histograms) and intentionally infected PVG.7B MSC (dark gray; cf. Figure 4B) were added to CFSE-labeled, Con A-stimulated PVG.7B LNC
(values to the left denote the log of MSC:LNC ratios). LNC alone were cultured either with (black histogram) or without (white) Con A as positive and
negative controls, respectively. CFSE dilution indicating cell divisions was measured by flow cytometry after 3 d of incubation. Histogram plots
(percent of maximum count) are representative of triplicates and show the fluorescence intensity of lymphocyte populations gated on
CD3+CD4+CD82 (CD4 T cells) and CD3+CD42CD8+ (CD8 T cells). The potent inhibition of lymphocyte proliferation by infected MSC measured by CFSE
dilution cannot be explained by degradation of [3H]TTP. For the highest dilution (26) of mycoplasma-infected MSC, individual cultures displayed
either full inhibition or full proliferation (cf. Figure 3); one replicate in which full lymphocyte proliferation was detected is shown. Data are
representative of three independent experiments.
doi:10.1371/journal.pone.0016005.g005
Figure 6. Mycoplasma infection spreads rapidly in MLR cultures. Mycoplasma-positive MSC were cultured either alone (right panel) or
together with PVG responder cells and irradiated BN cells (left panel) for 3 d. Supernatants were collected at the indicated time points and tested by
PCR. The log dilutions of MSC are denoted; ctrl, no MSC added. Mycoplasma was detectable at considerably lower MSC concentrations when co-
cultured with lymphocytes.
doi:10.1371/journal.pone.0016005.g006
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detection methods today have advantages of ease of use and
relatively low cost. We did not directly assess to which extent our
results reflect degradation of pyrimidine substrate, but this
mechanism could not explain the observed effect as proliferation
was similarly inhibited when measured by CFSE dilution.
These experiments also showed that proliferation of both CD4+
and CD8+ T cells was equally abrogated, and were in agreement
with the finding that ovine Con A-activated lymphoblast cultures
were inhibited by a different mycoplasma species (M. ovipneumoniae)
in a recent study [37]. CD4+ T cells are critically involved in
clearing persisting bacterial infection. We speculate that the ability
to directly infect proliferating T lymphocytes inducing cell cycle
arrest and cell death can be an important mechanism for
mycoplasmas to evade and counteract an immune response.
Other plausible mechanisms such as inhibition through mycoplas-
ma membrane proteins have been suggested [38,39].
The inhibitory properties of rat MSC were dramatically
reduced by removal of M. hyorhinis by anti-mycoplasma treatment.
Mycoplasma-negative MSC had a weaker, but significant
inhibitory effect on T cell proliferation. Their suppressive potential
is in agreement with several previous findings where MSC
inhibition of responder cells were measured at ratios of 1:1 to
1:100 [8,9,11,12,20,21], while some studies have reported
exceptionally high immunosuppressive potential of MSC
[10,40,41].
In contrast to their substantial suppressive effects on lympho-
cytes in vitro, mycoplasma-infected MSC did not have a beneficial
effect upon preemptive or curative treatment of BM-transplanted
rats suffering from acute GvHD. The applied dosage of
1–26106 MSC (approximately 4–106106 per kg body weight) is
comparable to what is typically administered in patients [16,17].
Increasing the dose above 26106 MSC per injection was
associated with a high risk of pulmonary embolism and sudden
death of the animals (unpublished observations). Injected MSC
may be susceptible to immune responses in the host against
mycoplasma infection, which could explain their lack of efficiency
in alleviating GvHD. We cannot rule out, however, that the MSC
lines applied in the present study are ineffective in suppressing
alloreactive donor lymphocytes in vivo, as has been reported for
other animal studies [20–22,42]. The extent to which M. hyorhinis
infection can affect the inhibitory properties of MSC in vivo is
therefore not clear.
In our hands, mycoplasma infection did not deprive MSC of
their characteristic differentiation potential, nor their capacity to
proliferate or to secrete cytokines. Infection did not result in an
upregulation of class I or class II MHC surface expression. Thus,
M. hyorhinis infection of MSC may pass unnoticed. The host-
pathogen relationship between M. hyorhinis and MSC remains
elusive. The two important pro-inflammatory cytokines IFNc and
tumor necrosis factor-a were strongly reduced by the addition of
infected MSC to mixed lymphocyte cultures [29–31]. It is
conceivable that M. hyorhinis can alter the inherent immunosup-
pressive potential of MSC [43], e.g. by changing the expression of
cytokines and other important secreted proteins [44,45]. In order
Figure 7. Mycoplasma-infected MSC alter the cytokine profile of MLR and inhibit IFNc production by T cells. (A) Mycoplasma-positive
MSC (PVG) were added at the start of MLR of PVG.7B and irradiated BN LNC (16106 cells each) at the indicated dilutions (log [MSC:LNC]). The
concentration of various cytokines was determined in the supernatant at the end of 6 d co-culture. IL-6 was markedly increased, while interferon-c
(IFNc) and tumor necrosis factor-a (TNFa) were reduced by addition of MSC compared to the control MLR. Representative data from three
independent experiments are shown as the average of duplicates. (B) Mycoplasma-infected MSC (PVG.7B) were added at the start of Con
A-stimulated culture of PVG.7B LNC at the indicated tenfold dilutions. The fraction of IFNc-expressing CD3+ T cells was determined after 24 h by
intracellular staining (triplicates were pooled) and flow cytometry, as shown in (C). Cells were gated on CD3+ lymphocytes, numbers represent the
percentage of gated cells. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016005.g007
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to dissect such mechanisms, it will be necessary to gain a better
understanding of the immunomodulatory properties of BM
stromal progenitor cells as well as the pathobiology of mycoplasma
infection on MSC and immune cells. This research may have
important implications for the design of vaccination strategies
against mycoplasma species which continue to cause disease
requiring extensive use of antibiotics in veterinary and human
medicine.
Materials and Methods
Ethics statement
Our Department of Comparative Medicine at the Institute of
Basic Medical Sciences led by our institutional veterinarian has
established the rules for feeding, monitoring and handling of
laboratory animals in compliance with regulations set by the
Ministry of Agriculture of Norway. The institutional veterinarian
has delegated authority from the Norwegian Animal Research
Authority (NARA) and approved the protocols (license numbers:
VIT02.02, VIT09.1512, 05.07), which were conducted in
compliance with ‘‘The Norwegian Regulations on Animal
Experimentation’’ and ‘‘The European Convention for the
Protection of Vertebrate Animals used for Experimental and
other Scientific Purposes’’. Intravenous injections were performed
under neuroleptanalgesia with fentanyl citrate and fluanisone
(HypnormH; VetaPharma, UK). All animals used in this study
were euthanized with CO2, and every effort was made to minimize
their suffering.
Animals
The PVG-RT7b (PVG.7B) strain expresses an allotype of rat
CD45 (RT7.2) and was used interchangeably with the standard
PVG strain (RT7.1) as both strains express the RT1c haplotype of
the rat MHC. PVG.7B and PVG-RT1u (PVG.1U; RT1u) rats were
bred at the Institute of Basic Medical Sciences, University of Oslo.
PVG and BN (RT1n) rats were purchased from Harlan, The
Netherlands. The animals were housed on location under a
12:12 h light/dark cycle with access to food and filtered drinking
water ad libitum, and were routinely screened for common
pathogens following FELASA recommendations [46].
MSC isolation, ex vivo culture and differentiation assays
MSC lines were obtained from 8–11 w-old PVG, PVG.7B and
PVG.1U strain rats as previously described [47]. In short, BM cells
were aspirated from femurs and tibias, filtered through nylon cell
strainers (70 mm mesh; BD Biosciences, MA), and cultured in
MSC medium comprising a-modified minimal essential medium
supplemented with 20% fetal bovine serum and 100 U mL21
penicillin, 100 mg mL21 streptomycin, 250 ng mL21 amphotericin
B (all from Invitrogen, UK) and 2 mM L-glutamine (Millipore,
MA) in 175 cm2 culture flasks (Nunc, Denmark) at 37uC in a
humidified atmosphere of 5% CO2. Non-adherent cells were
removed after approximately 24 h by replacement of the MSC
medium. Adherent cells were allowed to expand to near
confluence, detached using 500 mg mL21 trypsin and 200 mg
mL21 EDTAN4Na (Invitrogen) and reseeded at a density of
approximately 500 cells per cm2. Cells were used in experiments
after the third passage.
The differentiation potential of MSC was tested using
adipogenic and osteogenic assays. MSC were cultured for 3 w in
MSC medium supplemented with adipogenic (StemCell Technol-
ogies, BC) or osteogenic (10 nM dexamethasone, 50 mg mL21
ascorbic acid, and 5 mM b-glycerophosphate; StemCell Technol-
ogies) stimulatory supplements. Neutral lipids in fat vacuoles were
visualized by staining with Oil Red O (Sigma Aldrich, CO) and
mineralization by staining with 40 mM Alizarin Red (Sigma
Aldrich).
Mycoplasma detection, treatment and infection
Supernatants from confluent cultures were tested for mycoplas-
mas by nested PCR [48] using the following primer sequences:
Mike-O-Plasma-F1 59-ACACCATGGGAGCTGCTAAT-39; Mike
-O-Plasma-R1 59-CTTCWTCGACTTYCAGACCCAAGGCAT-
39; Mike-O-Plasma-F2 59-GTTCTTTGAAAACTGAAT-39; Mike-
O-Plasma-R2 59-GCATCCACCAWAWACTCT-39. Mycoplasma-
positive PCR test results were confirmed using a detection kit
(MycoAlertH; Lonza Rockland, ME) based on enzymatic ATP-
conversion combined with luminescence measurement. MSC that
tested positive for mycoplasma were cultured in a quarantine
laboratory using MSC medium without antibiotics.
The mycoplasma strain was detected and identified as M.
hyorhinis from cell cultures by means of 16S ribosomal DNA PCR
and sequencing. DNA extracted from the cell cultures was
amplified and sequenced (ABI Prism 3730 DNA analyzer; Applied
Biosystems, CA) using two primers within the 16S rRNA gene.
The obtained sequences were compared to sequences in the NCBI
database using BLAST version 2.210.
In some experiments, non-infected MSC lines (PVG.1U or
PVG.7B) and a rat colon carcinoma cell line (CC531s, a kind gift
from Peter Kuppen, Leiden, The Netherlands) were deliberately
infected with M. hyorhinis by transferring membrane-filtered
(0.45 mm Filtropur S; Sarstedt, Germany) culture supernatant
from nearly confluent cultures of mycoplasma-positive MSC and
incubated for 1–2 d before replacement of fresh culture medium.
Infected cells were confirmed as mycoplasma-positive by PCR.
CC531s cells were maintained in culture medium comprising
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented
with 20% fetal bovine serum (Invitrogen) without antibiotics in a
quarantine laboratory. In another experiment, the original
infected MSC line was cleared of mycoplasma using MynoxH
reagent (Minerva Biolabs, Germany) according to the manufac-
turer’s protocol, and was confirmed negative by PCR. The treated
cell line continued to grow normally and no recurrence of
mycoplasma was observed in several passages after the treatment.
Mixed lymphocyte cultures and radionucleotide
incorporation assays
Mononuclear cells from mesenteric and cervical lymph nodes of
8–14 w-old PVG, PVG.7B and BN rats were obtained by filtering
through nylon cell strainers (BD Biosciences) and density gradient
centrifugation (LymphoprepTM; Medinor, Norway) following the
manufacturer’s protocol. Stimulator cells were irradiated with a
dose of 20.0 Gy using a 137Cs source (GammacellH 3000; MDS
Nordion, Canada). MLR were performed in RPMI medium 1640
supplemented with 10% heat-inactivated fetal bovine serum,
100 U mL21 penicillin, 100 mg mL21 streptomycin, 2 mM L-
glutamine and 25 mM 2-mercaptoethanol (MLR medium; all from
Invitrogen) with responder (PVG or PVG.7B) and stimulator cells
(BN; each 26105 unless otherwise specified) in 200 mL per well
using round-bottom, 96-well cell culture clusters (Corning, NY). In
the same format, Con A (Sigma Aldrich, MO) was used at a final
concentration of 5 mg mL21 for mitogenic stimulation of
responder cells. Polyclonal rabbit anti-rat IL-6 antibody (Pepro-
Tech, UK) at 2 mg mL21 or recombinant rat IFNc at 500 U
mL21 was added where specified.
CC531s and MSC were harvested using trypsin and EDTA
(Invitrogen), washed twice, diluted in MLR medium, and in some
experiments irradiated (20 Gy) to inhibit mitosis, before adding to
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MLR cultures at the indicated cell ratios. Medium supernatants
were removed from MSC cultures prior to cell harvest and
sedimented at 400 g for 10 min before adding to MLR cultures at
the indicated dilutions. They were further processed using syringe
filter units (Millipore, Ireland) of different mesh size (indicated) or
serial sedimentation applying increasing centrifugal force and
durations (indicated). The pellet fraction of 100 000 g sedimen-
tation (OptimaTM LE-80K Ultracentrifuge; Beckman Coulter
Inc., CA) was resuspended in a volume of MLR medium equal to
the original amount of supernatant.
DNA synthesis was assessed after 3 d of mitogen stimulation or
4 d of mixed lymphocyte culture by pulsing with 1 mCi of [3H]TTP
(diluted in 20 mL MLR medium; Hartmann Analytic, Germany)
18–20 h before the termination of the culture. Cells were then
harvested on glass fiber filters using a cell harvester (Filtermate 196;
Packard Bioscience Co., CT) and radioactivity was measured with
MicroScintTM O solution (PerkinElmer, MA) using a Top CountH
NXTTM (Packard Bioscience) or Wallac 1450 MicroBetaH TriLux
(PerkinElmer) microplate scintillation counter.
CFSE dilution assays
In some experiments, responder cells were stained with CFSE
(Sigma Aldrich) prior to in vitro culture. Briefly, cells were resuspended
in OPTI-MEM (Invitrogen) at a concentration of 26106 mL21 and
incubated with 500 nM CFSE for 10 min at 37uC before adding
MLR medium. The cells were then washed in MLR medium twice,
incubated for 5 min at 37uC, washed again and resuspended inMLR
medium. At the termination of MLR and Con A cultures, cells were
harvested and washed in phosphate buffered saline before labeling
with monoclonal antibodies (mAb) and flow cytometric analysis.
Intracellular staining and flow cytometry
The following mouse anti-rat mAb (conjugated in our own lab
unless stated otherwise; W3/25 and OX antibodies were a kind
gift from A. Neil Barclay, Oxford, UK) were used for flow
cytometric analysis: FITC-conjugated W3/25 (anti-CD4), PE-
conjugated G4.18 (anti-CD3; BD Biosciences), Alexa FluorH 647-
conjugated OX-38 (anti-CD4), biotin-conjugated OX-8 (anti-
CD8) or OX-39 (anti-CD25) followed by secondary staining with
PerCP-conjugated Streptavidin (BD Biosciences). In some exper-
iments, 50 mM propidium iodide (Sigma Aldrich) was added to
stained cells before analysis.
For intracellular FoxP3 staining, stimulated LNC were
harvested after 3 d of culture, stained with mAb, fixed with
fixation/permeabilization buffers (eBioscience, CA) and stained
with APC-conjugated rat anti-mouse/rat FJK-16s mAb (anti-
FoxP3; eBioscience) according to the manufacturer’s guidelines.
For intracellular IFNc staining, LNC were stimulated with Con A
(5 mg mL21; Sigma Aldrich) for 24 h, and Brefeldin A (10 mg
mL21; Sigma Aldrich) was added 4 h before termination of the
culture. Triplicate wells were pooled and cells stained with FITC-
conjugated G4.18 (anti-CD3; BD Biosciences), fixed with 4%
paraformaldehyde, permeabilized with 0.5% saponin, and stained
with PE-conjugated mouse anti-rat IFNc mAb (BD Biosciences).
For phenotypic characterization of MSC, cells were labeled with
the following conjugated mouse anti-rat mAb: PE-conjugated TLD-
3A12 (anti-CD31) or OX-7 (anti-CD90); FITC-conjugated TH9
(anti-CD59); PE-Cy5 conjugated OX-1 (anti-CD45; all from BD
Biosciences). For two-step immunostaining, cells were first incubat-
ed with supernatant of OX-26 (anti-CD71), or purified OX-18
(anti-RT1-A, pan-MHC class I) or OX-6 (anti-RT1-B/D, pan-
MHC class II; all our own), followed by secondary PE-conjugated
donkey anti-mouse IgG (Jackson ImmunoResearch, UK); or with
TP-503 (polyclonal rabbit anti-rat CXCR4; Torrey Pines Biolabs,
NJ) followed by secondary FITC-conjugated anti-rabbit IgG (BD
Biosciences). PE-conjugated mouse IgG1 (BD Biosciences) and
FITC-conjugated mouse IgG2a (DAKO, Denmark) were used as
isotype controls. Cells were analyzed on a FACSCaliburTM or
FACSCantoTM flow cytometer (BD Biosciences) using CellQuestTM
software (BD Biosciences). FACS data were further analyzed using
FlowJoTM software (TreeStar Inc., OR).
Cytokine assays
For cytokine measurements, 106106 responder and 106106
stimulator cells were co-cultured for 6–7 d in MLR medium
together with specified numbers of MSC in upright 25 cm2 culture
flasks (Nunc). Cytokine levels were analyzed using the Bio-PlexTM
Rat Cytokine 9-Plex A Panel (Bio-Rad, CA) according to the
manufacturer’s protocol. Concentrations were determined on the
basis of a standard curve using defined reference samples which
were assayed (Luminex xMAPH Technology; Bio-Rad) in parallel.
Experimental BMT and GvHD monitoring
Allogeneic stem cell transplantations were adapted from a
previously described protocol [49]. BM cells were aspirated from
femurs and tibias of 8-12 w-old male and female PVG.7B rats, filtered
through cell strainers (BD Biosciences) and purified by density
gradient centrifugation (NycoprepTM 1.077A; Medinor). T cells were
removed using magnetic pan-mouse IgG-coated DynabeadsH
(Invitrogen Dynal, Norway) coated with OX-19 (anti-CD5) and
R73 (anti-ab T cell receptor) mAb. The number of CD3+ cells was
thus reduced at least fivefold to less than 0.25% of total BM cells (data
not shown). For DLI, LNC (of which approximately 60%were CD3+
T cells, data not shown) were obtained from mesenteric and cervical
lymph nodes of 10-12 w-old male and female PVG.7B rats by
filtering through cell strainers (BD Biosciences). The CD3+ T cell
contents of the BM graft and DLI were controlled by flow cytometric
analysis (not shown) after staining with PE-conjugated G4.18 (anti-
CD3; BD Biosciences) mAb.
Male BN rats were transplanted at 9 w of age with 306106 T
cell-depleted PVG.7B BM cells by intravenous injection shortly
after receiving 9.0 Gy total body irradiation (GammacellH 3000;
MDS Nordion) under anesthesia. 14 days post transplantation,
GvHD was invoked by DLI of the specified doses of PVG.7B
LNC. MSC were harvested, washed and resuspended in
phosphate buffered saline at a cell density of 1–26106 per mL
for injection at the specified time points. Transplanted animals
were frequently and carefully monitored, and were scored weekly
for disease symptoms using a protocol by Cooke et alia [33]. In this
model, cachexia, severe kyphosis, ruffled fur, skin flaking and
lesions and alopecia were predictive of GvHD. Rats suffering from
lethal GvHD were euthanized with CO2 at defined humane end
points (GvHD score exceeding 8; body weight below 150 g).
Donor BM engraftment was evaluated both by clinical observation
(weight gain, anemia) and flow cytometry using HIS41 (anti-rat
CD45) mAb (a kind gift from Jaap Kampinga, Groningen, The
Netherlands) specific for the RT7.2 allele to identify PVG.7B
donor leukocytes. 7 rats (8.9%) of a total of 79 recipients failed to
engraft and were excluded from the analysis.
Statistical analysis
Normal distribution of data was assumed and tested using
Shapiro-Wilk’s test. Student’s t test (paired, two-tailed) was used to
evaluate the probability of differences between samples. For in vivo
experiments, overall survival was compared by the log-rank test and
GvHD scores by Student’s t test (unpaired, two-tailed) for group
differences. Analysis was performed using SPSSH software version
17.0 (SPSS Inc., IL) with a P value below 0.05 deemed as significant.
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Supporting Information
Figure S1 Mycoplasma-infected MSC reduce the num-
bers of T regulatory and live cells in mitogen-stimulated
lymphocyte cultures. Mycoplasma-infected MSC (PVG.7B;
gray bars) were added at the start of a Con A stimulated culture of
PVG.7B LNC at the indicated dilutions (log [MSC:LNC]). The
relative frequency of (A) CD4+CD25hiFoxP3+ T regulatory (Treg)
cells and (B) live cells (propidium iodidelow) were determined by flow
cytometry after 3 d of co-culture. Cell death was increased when
mycoplasma-infected MSC were present. In panel A, the mean
values plus the standard error of the mean of triplicates as well as the
test statistics for cell frequencies compared to the positive control are
shown. Data are representative of three independent experiments.
(TIF)
Figure S2 Morphology, differentiation potential and
phenotype of mycoplasma-infected rat BM-derived
MSC. Light microscopy of cell culture, differentiation assays
and flow cytometric staining of MSC infected with M. hyorhinis. (A)
MSC from PVG BM appear as fibroblast-like spindle-shaped cells
that adhere to plastic in vitro (third passage). MSC have the
capacity to differentiate into adipocytes (B) as shown by staining of
neutral lipids in fat vacuoles with Oil Red O and osteocytes (C) by
staining areas of calcification with Alizarin Red. (D) Surface
expression of CD31 (PECAM-1), CD45 (CLA), CD59 (MAC
inhibitor), CD71 (transferrin receptor), CD90 (Thy-1) and
CXCR4 as well as MHC-I (RT1-A) and MHC-II (RT1-B/D)
on MSC. Histograms show the relative intensity of surface antigen
(solid lines) compared to isotype controls (filled) by flow cytometric
staining. Mycoplasma-infected PVG.1U MSC form adipocytes (E)
and osteocytes (F) under culture conditions inducing differentia-
tion (cf. Materials and Methods) and remain multipotent (G, H)
after clearing the infection with Mynox reagent. (A) Original
magnification 1006, (B, C) 406, (E–H) 2006.
(TIF)
Figure S3 MSC inhibition of MLR is not reversed by
addition of exogenous IFNc nor by anti-IL-6 antibody. (A)
A panel of cytokines was measured in the medium supernatant of a
confluent culture of infected MSC (PVG) 20–24 h after medium
was replaced. MSC constitutively secrete IL-6, while other
cytokines were not detectable. (B) Inhibition of proliferation in
allogeneic MLR at 1:1000 MSC:LNC ratio could not be reverted
by addition of anti-rat IL-6 mAb (aIL-6; 2 mg mL21) or recom-
binant rat IFNc (500 U mL21) at the start of co-culture.
Representative data from two independent experiments are shown
as mean values plus one standard error of the mean of (A) triplicate
and (B) quadruplicates tests.
(TIF)
Figure S4 Rats suffering from GvHD are not rescued by
repeated injections of mycoplasma-infected MSC. MSC
from two different cell lines subsequently found to be infected with
M. hyorhinis were injected in rats suffering from experimental acute
GvHD. Irradiated BN recipients were transplanted with
306106 T cell-depleted donor PVG.7B BM cells (n) and received
a DLI 14 d later (m) of graded doses of either (A, B) 2.56106 or
(C, D) 1.56106 donor PVG.7B LNC. Two rats that received BM
cells only (no DLI) and did not develop GvHD are also shown in
panel C. 0.5–16106 MSC from PVG.1U (A, B) or 1–26106 MSC
from PVG (C, D) were injected either repeatedly on 0, 7, and 14 d
(bold line, 36MSC) or once on 14 d (solid line, 16MSC) after
DLI. Control rats received no MSC (dashed line, no MSC). (A, C)
Cumulative survival is depicted as Kaplan-Meier plots. (B, D)
GvHD symptoms, including relative change in body weight, were
assigned discrete values using a semi-quantitative scoring table
adapted from Cooke et alia [33]. GvHD scores are shown together
with the median (horizontal line) at 7 d and 14 d after DLI,
respectively. The respective MSC treatment protocols had no
statistically significant effect on overall survival nor the GvHD
score of rats treated with 36MSC (N) or 16MSC (N) compared
to the controls (u). Data were pooled from (A, B) two and (C, D)
four individual experiments.
(TIF)
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